10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________________ 

FORM 10-K

________________________________ 

CHECK ONE:

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             .

Commission file No.: 1-12996

________________________________ 

Diversicare Healthcare Services, Inc.

(exact name of registrant as specified in its charter)

 ________________________________

Delaware	62-1559667
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

1621 Galleria Boulevard Brentwood, TN	37027
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (615) 771-7575

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Name of each Exchange on which registered
Common Stock, $0.01 par value per share	OTCQX

Securities registered pursuant to Section 12(g) of the Act:

None.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No ☑

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes ☐ No ☑

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☑ Smaller reporting company ☑

                                         Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No þ

The aggregate market value of Common Stock held by non-affiliates on June 30, 2020 (based on the closing price of such shares on the Nasdaq Capital Market) was approximately $7,441,000. For purposes of the foregoing calculation only, all directors, named executive officers and persons known to the registrant to be holders of 5% or more of the registrant's Common Stock have been deemed affiliates of the registrant.

On March 1, 2021, 6,847,305 shares of the registrant's $0.01 par value Common Stock were outstanding.

Documents Incorporated by Reference

Registrant's definitive proxy materials for its 2021 annual meeting of shareholders are incorporated by reference into Part III, Items 10, 11, 12, 13 and 14 of this Form 10-K.

Table of Contents
		Page
Part I
Item 1.	Business	1
Item 1A.	Risk Factors	13
Item 1B.	Unresolved Staff Comments	28
Item 2.	Properties	29
Item 3.	Legal Proceedings	29
Item 4.	Mine Safety Disclosures	30
Part II
Item 5.	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	30
Item 6.	Selected Consolidated Financial Data	31
Item 7.	Management's Discussion and Analysis of Financial Condition and Results of Operations	32
Item 7A.	Quantitative and Qualitative Disclosures about Market Risk	47
Item 8.	Financial Statements and Supplementary Data	47
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	47
Item 9A.	Controls and Procedures	47
Item 9B.	Other Information	48
Part III
Item 10.	Directors, Executive Officers and Corporate Governance	48
Item 11.	Executive Compensation	48
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	48
Item 13.	Certain Relationships and Related Transactions, and Director Independence	48
Item 14.	Principal Accountant Fees and Services	48
Part IV
Item 15.	Exhibits and Financial Statement Schedules	48
Item 16.	Form 10-K Summary	48

PART 1

ITEM 1. BUSINESS

Introductory Summary.

Diversicare Healthcare Services, Inc. provides post-acute care services to skilled nursing facilities, referred to as "skilled nursing centers," "nursing centers," or "centers," patients and residents in eight states, primarily in the Southeast, Midwest, and Southwest United States. Unless the context indicates otherwise, references herein to “Diversicare,” “the Company,” “we,” “us” and “our” include Diversicare Healthcare Services, Inc. and all of our consolidated subsidiaries. Diversicare Healthcare Services, Inc. was incorporated as a Delaware corporation in 1994.

The post-acute care profession encompasses a broad range of non-institutional and institutional services. For those among the aging, infirmed, or disabled requiring temporary or limited special services, a variety of home care options exist. As the need for assistance with activities of daily living develop, assisted living centers become the most viable and cost effective option. For those amongst the aging, disabled, or infirmed requiring more extensive assistance and intensive care, skilled nursing center care may become the only viable option. We have chosen to focus our business primarily on the skilled nursing centers sector and to specialize in this aspect of the post-acute care continuum.

Principal Address and Website.

Our principal executive offices are located at 1621 Galleria Boulevard, Brentwood, Tennessee 37027. Our telephone number at that address is 615.771.7575, and our facsimile number is 615.771.7409. Our website is located at www.dvcr.com. The information on our website does not constitute part of this Annual Report on Form 10-K.

Operating and Growth Strategy.

Our operating objective is to optimize market position in the delivery of health care and related services to the patients and residents in need of post-acute care in the communities in which we operate. Our strategic operations development plan focuses on (i) providing a broad range of high quality, cost-effective post-acute care services; (ii) improving skilled mix in our nursing centers via enhanced capabilities for rehabilitation and transitional care; (iii) building clinical competencies and programs consistent with marketplace needs; and (iv) clustering our operations on a regional basis. Interwoven into our objectives and operating strategy is our mission:

        • Improve Every Life We Touch

        • Provide Exceptional Healthcare

        • Exceed Expectations

• Increase Shareholder Value

Strategic operating initiatives. Our key strategic operating initiatives include improving skilled mix in our nursing centers by enhancing our staffing complement to address the increased medical complexity of certain patients, increasing clinical competencies, and adding clinical programs. Our investments in nursing and clinical care and nursing center-based sales representatives to cultivate referral and Managed Care relationships have positioned us to admit higher acuity patients.

To achieve our objectives, we:

Provide a broad range of quality cost-effective services. Our objective is to provide a variety of services to meet the needs of the increasing post-acute care population requiring skilled nursing and rehabilitation care. Our service offerings currently include skilled nursing, comprehensive rehabilitation services, programming for Memory Care units (described below) and other specialty programming. By addressing varying levels of acuity, we work to meet the needs of the population we serve. We seek to establish a reputation as the provider of choice in each of our markets. Furthermore, we believe we are able to deliver quality services cost-effectively, compared to other healthcare providers along the spectrum of care, thereby expanding the population base that can benefit from our services.

Improve skilled mix in our nursing centers. By enhancing our registered nurse coverage and adding specialized clinical care, we believe we can admit patients with more medically complex conditions, thereby improving skilled mix and reimbursement. The investments in nursing and clinical care are being conducted in concert with additional investments in nursing center-based sales representatives to develop referral and Managed Care relationships. These investments will better attract quality payor sources for patients covered by Medicare, Managed Care and Medicare replacement payors as well as certain private pay individuals. We will also continue our program for the renovation and improvement of our nursing centers to attract and retain patients and residents.

1

Cluster operations on a regional basis. We have developed regional concentrations of operations in order to achieve operating efficiencies, generate economies of scale and capitalize on marketing opportunities created by having multiple operations in a regional market area.

Key elements of our strategy are to:

Increase revenues and profitability at existing nursing centers. Our strategy includes increasing center revenues and profitability through improving payor mix, providing an increasing level of higher acuity care, obtaining appropriate reimbursement for the care we provide, and providing high quality patient care. Ongoing investments are being made in expanded nursing and clinical care. We continue to enhance center-based marketing initiatives to promote higher occupancy levels and improved skilled mix at our nursing centers.

Development of additional specialty services. Our strategy includes the development of additional specialty units and programming in nursing centers that could benefit from these services. The specialty programming will vary depending on the needs of the specific market, and may include complex medical and rehabilitation services, as well as memory care units and other specialty programming. These services allow our centers to meet market needs while improving census and payor mix. A center specific assessment of the market and the current programming being offered is conducted related to specialty programming to determine if unmet needs exist as a predictor of the success of particular niche offerings and services.

Strategic management of our portfolio of centers. We continue to pursue and investigate opportunities to acquire and lease new centers, focusing primarily on opportunities that can leverage our existing infrastructure. We routinely evaluate the performance of our existing centers within the markets in which we operate in order to determine whether continuing operations within certain centers or markets aligns with our strategic objectives.

Nursing Centers and Services.

Diversicare provides a broad range of post-acute care services to patients and residents including skilled nursing, ancillary health care services, and assisted living. In addition to the nursing and social services usually provided in long-term care centers, we offer a variety of rehabilitative, nutritional, respiratory, and other specialized ancillary services. As of December 31, 2020, our continuing operations consist of 61 nursing centers with 7,250 licensed skilled nursing beds. Our nursing centers range in size from 50 to 320 licensed nursing beds. The licensed nursing bed count does not include 397 licensed assisted living beds. Our continuing operations include centers in Alabama, Indiana, Kansas, Mississippi, Missouri, Ohio, Tennessee, and Texas.

2

The following table summarizes certain information with respect to the nursing centers we own or lease as of December 31, 2020:

	Number of Centers	Licensed Nursing Beds (1)	Available Nursing Beds (1)
Operating Locations:
Alabama	20	2,385	2,318
Indiana	1	158	158
Kansas	6	464	464
Mississippi	9	1,039	1,004
Missouri	3	339	339
Ohio	4	403	393
Tennessee	5	617	551
Texas	13	1,845	1,662
	61	7,250	6,889
Classification:
Owned	15	1,365	1,250
Leased	46	5,885	5,639
Total	61	7,250	6,889

____________

(1)The number of Licensed Nursing Beds is based on the regulatory licenses for the nursing center. The Company reports its occupancy based on licensed nursing beds. The number of Available Nursing Beds represents Licensed Nursing Beds reduced by beds removed from service. Available Nursing Beds is subject to change based upon the needs of the centers, including configuration of patient rooms, common usage areas and offices, status of beds (private, semi-private, ward, etc.) and renovations. The number of Licensed and Available Nursing Beds does not include 397 Licensed Assisted Living/Residential Beds, all of which are also available. These beds are excluded from the bed counts as our operating statistics such as occupancy are calculated using Nursing Beds only.

Our nursing centers provide skilled nursing health care services, including nutrition services, recreational therapy, social services, housekeeping, and laundry services. Skilled nursing care is provided for post-acute patients and residents with comorbidities. This care includes assessment using evidence based tools, individualized care plan development based on identified areas of risk and care needs, and skilled interventions such as IV services. We also provide for the delivery of ancillary medical services at the nursing centers we operate. These specialty services include rehabilitation therapy services, such as audiology, speech, occupational, and physical therapies, which are provided through licensed therapists and registered nurses, and the provision of medical supplies, nutritional support, infusion therapies and related clinical services. The majority of these services are provided using our internal resources and clinicians.

Within the framework of a nursing center, we may provide other specialty care, including:

Transitional Care Unit. Many of our nursing centers have units designated as transitional care units, our designation for patients requiring transitional care following an acute stay in the hospital. These units specialize in short-term nursing and rehabilitation with the goal of returning the patient to their highest potential level of functionality. These units provide enhanced services with emphasis on upgraded amenities. The design and programming of the units generally appeal to the clinical and hospitality needs of individuals as they progress to the next appropriate level of care. Specialized therapeutic treatment regimens include orthopedic rehabilitation, neurological rehabilitation, and complex medical rehabilitation. While these patients generally have a shorter length of stay, the intensive level of nursing and rehabilitation required by these patients typically results in higher levels of reimbursement.

Memory Care Unit. Like our transitional care units, many of our nursing centers have memory care units, our designation for advanced care for dementia-related disorders including Alzheimer's disease. The goal of the units is to provide a safe, homelike and supportive environment for cognitively impaired patients, utilizing an interdisciplinary team approach. Family and community involvement complement structured programming in the secure environment, which is instrumental in fostering as much resident independence and purposeful quality of life as long as possible despite diminished capacity.

Enhanced Therapy Services. We have complemented our traditional therapy services with programs that provide electrotherapy, vital stimulation, ultrasound, and shortwave diathermy therapy treatments that promote pain management, wound healing, muscle strengthening, and/or contractures management, improving outcomes for our patients and residents receiving therapy treatments.

3

Other Specialty Programming. We implement other specialty programming based on a center's specific needs. We have developed specialty programming for bariatric patients (generally, patients weighing more than 350 pounds) as these individuals have unique psychosocial and equipment needs.

Quality Assurance and Performance Improvement. We have in place a Quality Assurance and Performance Improvement (“QAPI”) program, which is focused on monitoring and improving all aspects of the care provided in a center by identifying outcomes and acting on areas of improvement. The QAPI program in our centers addresses all systems of care and management practices. Key quality indicators are determined and performance goals and benchmarks are established based on industry research standards via a Balanced Scorecard. Gaps and opportunities in performance versus benchmarks are addressed with analysis and performance improvement plans. Outcomes from each center in the areas of quality, employee workplace, customer satisfaction, and stewardship are collected monthly and overseen by regional and company quality committees.

Utilization of Electronic Medical Records. Electronic Medical Records (“EMR”) improves our ability to accurately record the care provided to our patients and quickly respond to areas of need. All of our nursing centers utilize EMR to improve Medicaid acuity capture, primarily in our states where the Medicaid payments are acuity based. By using EMR, we have increased our average Medicaid rate despite rate cuts in certain acuity based states by accurate and timely capture of care delivery. We believe the EMR system provides better support, efficiency, and improves the quality of care for our patients.

Organization. Our nursing centers are currently organized into seven regions, each of which is supervised by a regional vice president. The regional vice president is generally supported by specialists in several functions, including clinical, human resources, marketing, revenue cycle management and administration, all of whom are employed by us. The day-to-day operations of each of our nursing centers are led by an on-site, licensed administrator. The administrator of each nursing center is supported by other professional personnel, including a medical director, who assists in the medical management of the nursing center, and a director of nursing, who supervises a team of registered nurses, licensed practical nurses and nurse aides. Other personnel include those providing therapy, dietary, activities and social service, housekeeping, laundry, maintenance, and office services. The majority of personnel at our nursing centers, including the administrators, are our employees.

Marketing.

We believe that skilled nursing care is fundamentally a local business in which both patients and their referral sources are typically based in the immediate geographic area in which the nursing center is located. Our marketing plan and related support activities emphasize the role and contributions of the administrators, admissions coordinators, and clinical liaisons of each nursing center, all of whom are responsible for developing relationships with various referral sources such as doctors, hospitals, hospital case managers and discharge planners, and various healthcare and community organizations. Training, sales tools and job aids are provided for the sales and marketing teams for the product knowledge, market knowledge, and selling skills necessary to support their efforts in the field. As part of our business strategy, we have dedicated sales and marketing personnel who develop strong partnerships with physicians and hospital executives as well as Accountable Care Organizations ("ACO"), Bundled Payments for Care Improvement ("BPCI") providers, and Managed Care organizations. We believe these relationships will be mutually beneficial, providing the community with high quality healthcare while helping customers to navigate choices, manage transitions, and control costs.

At the local level, our sales and marketing efforts are designed to:

•Identify and develop strong healthcare partnerships

•Help facilitate smooth transitions between care settings

•Promote collaboration with ACOs, BPCIs providers, and other healthcare organizations

•Educate referral sources and community on our key differentiators and capabilities

•Position ourselves as a valuable resource and healthcare partner

•Enhance the customer experience

•Contribute to a strong community presence

•Promote higher occupancy levels

•Foster optimal payor mix

In addition to soliciting admissions from current and potential referral sources, we emphasize involvement in community and healthcare events and opportunities to promote a public awareness of our nursing centers and services. Activities include ongoing family councils and community based “family night” functions, providing the opportunity to educate the public on various topics such as Medicare benefits, powers of attorney, and other topics of interest. We also promote a positive customer experience, best practices, strong surveys, and a high star rating; we seek feedback through third-party resident and family surveys. We host tours and “open house” opportunities, where members of the local community are invited to visit the center to

4

see any improvements or to better understand our environment and services. We look for ways to offer increased clinical capabilities and services to better meet the needs of the community and referral sources. In addition, we have regional oversight to support the overall marketing strategies in each local center, in order to promote higher occupancy levels and improved payor and case mixes at our nursing centers. We offer the resources and metrics for strong healthcare partnerships with our referral sources, including ACOs and other Managed Care partners. Our support center marketing personnel support regional and local marketing personnel and efforts.

We have monthly marketing programs and ongoing marketing initiatives, developed internally, that focus on educating and meeting the needs of our customers while growing our business. Resources are also available to assist each nursing center administrator in analysis of local demographics and competition with a view toward complementary service development. We consider the primary referral area in long-term care to generally lie within a five-to-fifteen-mile radius of each nursing center depending on population density; consequently, we focus on local marketing efforts rather than broad-based advertising.

Therapy Services

Effective November 1, 2020, the Company entered into agreements with a third party therapy company to outsource the therapy services that were previously provided by the Company through its wholly owned subsidiary Diversicare Therapy Services. The outsourced services include all physical, occupational, and speech therapy provided to patients of the Company’s facilities. The contracts are for a three-year term, absent termination for cause by either party. The third party provider has extensive expertise in providing therapy, and the Company believes that the therapy company's expertise in this area will benefit our patients and result in an overall operational cost savings for the Company.

Texas Quality Incentive Program

During 2019, the Company expanded its participation in the Texas Quality Incentive Program ("QIPP") as administered by the Texas Health and Human Services Commission. QIPP provides supplemental Medicaid payments for skilled nursing centers that achieve certain quality measures. Eleven of the Company’s Texas centers currently participate in the QIPP. To allow four of these centers to meet the QIPP participation requirements, the Company entered into a transaction with a Texas medical district already participating in the QIPP, providing for the transfer of the related provider licenses from the Company to the medical district. The Company’s operating subsidiary retained the management of the centers on behalf of the medical district. In response to the COVID-19 pandemic, the Texas Health and Human Services Commission waived some of the performance and reporting requirements for QIPP effective March 1, 2020 through the remainder of the state's 2021 fiscal year.

Disposals

On December 1, 2018, the Company completed the sale of the assets and transfer of the operations of Diversicare of Fulton, LLC, Diversicare of Clinton, LLC and Diversicare of Glasgow, LLC (the “Kentucky Properties”) to Fulton Nursing and Rehabilitation LLC, Holiday Fulton Propco LLC, Birchwood Nursing and Rehabilitation LLC, Padgett Clinton Propco LLC, Westwood Nursing and Rehabilitation LLC, and Westwood Glasgow Propco for a purchase price of $18.7 million, On August 30, 2019, the Company terminated operations of ten centers in Kentucky and concurrently transferred operations to a new operator. These ten centers are collectively referred to as the "Kentucky Centers." The sale of the Kentucky Properties and the termination of operations at the Kentucky Centers are referred to collectively as the "Kentucky Exit." As a result of the Kentucky Exit, the Company no longer operates any skilled nursing centers in the State of Kentucky. The Kentucky Exit represented a strategic shift that had a major effect on the Company's operations and financial results. In accordance with Accounting Standards Codification ("ASC") 205-20, Presentation of Financial Statements- Discontinued Operations, the Company's discontinued operating results have been reclassified on the face of the income statement and the footnotes to reflect the discontinued status of these operations. Refer to Note 4, "Discontinued Operations" to the consolidated financial statements.

Lease Agreements

On October 1, 2018, the Company entered into a new Master Lease Agreement (the "Omega Master Lease") with Omega Healthcare Investors (the "Lessor") to lease 34 centers currently owned by Omega and operated by Diversicare. The old Master Lease with Omega provided for its operation of 23 skilled nursing centers in Texas, Kentucky, Alabama, Tennessee, Florida, and Ohio. Additionally, Diversicare operated 11 centers owned by Omega under separate leases in Missouri, Kentucky, Indiana, and Ohio. The Lease entered into by Diversicare and Omega consolidated the leases for all 34 centers under one new Maser Lease. The Lease was subsequently amended on August 30, 2019 when the Company terminated operations of the Kentucky Centers and concurrently transferred operations to a new operator. The agreement effectively amended the Lease with the Lessor to remove the ten Kentucky facilities, reduce the annual rent expense, and release the Company from any further obligations arising under the Master Lease Agreement with respect to the Kentucky facilities. The remaining Lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15% which began on October 1, 2019.

On December 1, 2020, the Company entered into an agreement with Omega to transfer operations of a facility located in Florida to another operator. The agreement effectively amended the Master Lease to remove the center, reduced the annual rent

5

expense, and released the Company from any further obligations arising under the Master Lease with respect to the Florida facility. The remaining Lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15%.

Nursing Center Industry.

We believe there are a number of significant trends within the post-acute care industry that will support the continued growth of the nursing center profession. These trends are also likely to impact our business. These factors include:

Demographic trends. The primary market for our post-acute health care services is comprised of persons aged 75 and older. This age group is one of the fastest growing segments of the United States population. As the number of persons aged 75 and over continues to grow, we believe that there will be corresponding increases in the number of persons who need skilled nursing care.

Cost containment pressures. In response to rapidly rising health care costs, governmental and other third-party payors have adopted cost-containment measures to reduce admissions and encourage reduced lengths of stays in hospitals and other acute care settings. As a result, hospitals are discharging patients earlier and referring elderly patients, who may be too sick or frail to manage their lives without assistance, to nursing centers where the cost of providing care is typically lower than hospital care.

Limited supply of centers. As the nation's population of seniors continues to grow and life expectancy continues to expand, we believe that there will be continued demand for skilled nursing beds in the markets in which we operate. However, there continues to be limitations on opening new skilled nursing centers in most states, such as Certificate of Need (“CON”) laws. CON laws generally require a state agency to determine public need for any construction or expansion of healthcare facilities. We believe that CON requirements tend to restrict the supply and availability of licensed skilled nursing center beds. High construction costs, limitations on state and federal government reimbursement for the full costs of construction, and start-up expenses also act to restrict growth in the supply for such centers.

Reduced reliance on family care. Historically, the family has been the primary provider of care for seniors. We believe that the increase in the percentage of dual income families, the reduction of average family size and the increased mobility in society will reduce the role of the family as the traditional care-giver for aging parents. We believe that this trend will make it necessary for many seniors to look outside the family for assistance as they age.

Competition.

The post-acute care business is highly competitive. We face direct competition for additional centers, and our centers face competition for employees and patients. Some of our present and potential competitors for acquisitions are significantly larger and have or may obtain greater financial and marketing resources. Competing companies may offer new or more modern centers or new or different services that may be more attractive to patients than some of the services we offer.

The nursing centers operated by us compete with other centers in their respective markets, including rehabilitation hospitals and other skilled and personal care residential centers. In the few urban markets in which we operate, some of the long-term care providers with which our centers compete are significantly larger and have or may obtain greater financial and marketing resources than our centers. Some of these providers are not-for-profit organizations with access to sources of funds not available to our centers. Construction of new long-term care centers near our existing centers could adversely affect our business. We believe that the most important competitive factors in the long-term care business are: a nursing center's local reputation with referral sources, such as acute care hospitals, physicians, religious groups, other community organizations, Managed Care organizations, and a patient's family and friends; physical plant condition; the ability to identify and meet particular care needs in the community; the availability of qualified personnel to provide the requisite care; and the rates charged for services. There is limited, if any, price competition with respect to Medicaid and Medicare patients, since revenues for services to such patients are strictly controlled and are based on fixed rates and cost reimbursement principles. Although the degree of success with which our centers compete varies from location to location, we believe that our centers generally compete effectively with respect to these factors.

Revenue Sources.

We classify our revenues earned from patients and residents into four major categories: Medicaid, Medicare, Managed Care, and Private Pay and Other. Medicaid revenues are those received under the traditional Medicaid program, which provides benefits to those in need of financial assistance in the securing of medical services. Medicare revenues include revenues received under both Part A and Part B. Managed Care revenues are received from insurance entities, including third-party plans that administer Medicare benefits, known as Medicare Advantage plans. Private Pay and Other revenues are composed primarily of individuals or parties who directly pay for their services. Included in the Private Pay and Other category are patients who are hospice beneficiaries as well as the recipients of Veterans Administration benefits. Veterans Administration payments are made pursuant to renewable contracts negotiated with these payors.

6

The Company recognized $17.0 million of Medicaid and Hospice stimulus dollars for the year ended December 31, 2020 that are reflected as patient revenues from Medicaid and Private Pay and Other in the Company's results of operations as included in the amounts presented in the table below. Refer to Note 2, "COVID-19 Pandemic" to the consolidated financial statements included in this report for more information. The following table set forth net patient revenues related to our continuing operations by payor source for the periods presented (dollar amounts in thousands): Refer to Note 5, "Revenue Recognition and Receivables" to the consolidated financial statements.

	Year Ended December 31,
	2020				2019
Medicaid	$	217,147	45.6	%	$	222,560	46.9	%
Medicare	94,375		19.8	%	80,798		17.0	%
Managed Care	49,708		10.4	%	50,323		10.6	%
Private Pay and Other	114,488		24.2	%	121,339		25.5	%
Total	$	475,718	100.0	%	$	475,020	100.0	%

The following table sets forth average daily skilled nursing census, or average number of patients per day, by payor source for our continuing operations for the periods presented:

	Year Ended December 31,
	2020			2019
Medicaid	3,451	66.9	%	3,912	68.9	%
Medicare	565	10.9	%	529	9.3	%
Managed Care	253	5.0	%	264	4.6	%
Private Pay and Other	892	17.2	%	973	17.2	%
Total	5,161	100.0	%	5,678	100.0	%

Consistent with the nursing center industry in general, changes in the mix of a center's patient population among Medicaid, Medicare, Managed Care, and Private Pay and Other can significantly affect the profitability of the center's operations. However, private payors, including managed care payors, are increasingly demanding that providers accept discounted fees or assume all or a portion of the financial risk for the delivery of health care services. Such measures may include capitated payments, which can result in significant losses to health care providers if patients require expensive treatment not adequately covered by the capitated rate.

Medicare and Medicaid Reimbursement

A significant portion of our revenues are derived from government-sponsored health insurance programs, primarily Medicare and Medicaid. We employ third-party specialists in reimbursement and also use these services to monitor regulatory developments to comply with reporting requirements and to ensure that proper payments are made to our nursing centers.

Medicare

Medicare is a federally-funded and administered health insurance program for the aged and for certain chronically disabled individuals. Part A of the Medicare program covers certain services furnished by skilled nursing centers and other institutional providers and inpatient hospital services. Part B covers physician services, durable medical equipment, various outpatient services and certain ancillary services. Under the Managed Medicare program, also known as Medicare Part C or Medicare Advantage, the federal government contracts with private health insurers to provide members with Medicare benefits. The plans may choose to offer supplemental benefits and impose higher premiums and cost-sharing obligations. An executive order issued in October 2019 seeks to accelerate the shift away from traditional fee-for-service Medicare to Managed Medicare plans. It is unclear whether the Biden administration will continue these efforts.

Skilled nursing facilities. Medicare generally covers skilled nursing center services for beneficiaries who require nursing care or rehabilitation services after a qualifying hospital stay. Medicare pays a per diem rate for each beneficiary, adjusted for patient acuity and additional factors such as geographic differences in wage rates. The payment rates are set forth under a prospective payment system that uses nursing and therapy indexes to assign a payment rate to each beneficiary. The Centers for Medicare & Medicaid Services (“CMS”) updates the rates annually. The payment rates cover all services to be provided to a beneficiary, including room and board, skilled nursing care, therapy, and medications.

In a final rule issued in July 2019, CMS set forth Medicare payment rates for skilled nursing facilities (“SNFs”) for federal fiscal year 2020, estimating a 2.4% increase in overall payments. This is based on a SNF market basket percentage increase of 2.8% with a negative 0.4 percentage point productivity adjustment. Effective October 1, 2019, CMS replaced the Resource

7

Utilization Group (“RUG-IV”) case-mix classification system with the Patient-Driven Payment Model (“PDPM”). The PDPM classifies residents in Medicare Part A-covered stays into payment groups based on clinically relevant factors using diagnosis codes, rather than by the volume of services. CMS has stated that it does not intend for the new model to change the aggregate amount of Medicare payments to SNFs. Rather, it intends the new model to more accurately reflect resource utilization.

On July 31, 2020, CMS issued a final rule outlining Medicare payment rates for skilled nursing facilities for federal fiscal year 2021. Effective October 1, 2020, payments to SNFs are estimated to increase by 2.2% based on a market basket percentage update of 2.2%, adjusted by a 0.0 percentage point multifactor productivity adjustment.

The payment rates described above are reduced pursuant to ongoing sequestration. The Budget Control Act of 2011 (“BCA”) requires automatic spending reductions to reduce the federal deficit, including Medicare spending reductions of up to 2% per fiscal year, with a uniform percentage reduction across all Medicare programs. CMS began imposing a 2% reduction on Medicare claims in April 2013. The Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and related legislation suspends the Medicare sequestration payment adjustment from May 1, 2020 through March 31, 2021 (but extend sequestration through 2030).

CMS has implemented policies intended to shift Medicare to value-based payment methodologies, tying reimbursement to quality of care rather than quantity. For example, under the Quality Reporting Program ("QRP"), SNFs are required to report quality data to CMS or be subject to a 2% reduction to the annual market basket update. In response to the COVID-19 pandemic, CMS granted an exception to all SNFs, relieving them from data reporting requirements from October 1, 2019 to June 30, 2020. In federal fiscal year 2019, the Skilled Nursing Facility Value-Based Purchasing (“SNF VBP”) Program began making incentive payments available to skilled nursing centers based on their past performance on a specified quality measure related to hospital readmissions. CMS funds the SNF VPB Program incentive payment pool by withholding 2% of SNF payments and then redistributing some of the withheld payments. Data collected from each performance period affects Medicare payments two years later. CMS announced it would exclude certain measures from SNF VBP performance calculations from January 1, 2020 to June 30, 2020 due to the COVID-19 pandemic. CMS also finalized the SNF VBP's Extraordinary Circumstances Exception Policy, which may relieve facilities from program requirements due to natural disasters or other circumstances beyond the facility's control that may affect the facility's ability to provide quality care. Facilities must apply for the exception and demonstrate that an extraordinary circumstance affected the care provided to their patients. If CMS approves a facility's request, it will exclude the calendar months affected by the extraordinary circumstances from the facility's performance calculations.

CMS publishes rankings based on performance scores on the Care Compare website. Care Compare is a streamlined redesign of eight existing CMS healthcare compare tools, including Nursing Home Compare, which is intended to assist the public in finding and comparing skilled care or other providers. The Care Compare website also publishes for each nursing home a rating between 1 and 5 stars as part of CMS’s Five-Star Quality Rating System. An overall star rating is determined based on three components (information from the last three years of health inspections, staffing information, and quality measures), each of which also has its own five-star rating. The ratings are based, in part, on the quality data nursing centers are required to report. For example, nursing centers must report the rate of short-stay residents who are successfully discharged into the community and the percentage who had an outpatient emergency department visit. As a result of the COVID-19 pandemic, CMS issued temporary waivers and flexibilities that impact the information posted on the Care Compare website and used in the Five-Star Quality Rating System. For example, CMS temporarily waived the requirement to submit staffing data and issued guidance prioritizing or suspending certain nursing home surveys. Some of these measures have been lifted, while some are subject to phased re-opening criteria. However, due to these changes and their impact on data, CMS adjusted some ratings (e.g., by holding specific quality measures constant) and did not report on certain data to the Quality Rating System, but resumed updating the quality measure data on the Care Compare website and Five-Star Quality Rating System on January 27, 2021. In addition to the standard Nursing Home Compare data, CMS is reporting COVID-19 data submitted by nursing homes to the Centers for Disease Control and Prevention's ("CDC") National Healthcare Safety Network and linking to this information from the Care Compare website. The information reported includes the number of confirmed and suspected cases of COVID-19 in each facility, resident deaths related to COVID-19, availability of personal protective equipment and COVID-19 testing, and potential staffing shortages.

We remain diligent in continuing to provide outstanding patient care to achieve high rankings for our centers as well as assuring that our rankings are correct and appropriately reflect our quality results. Our focus has been and continues to be on the delivery of quality care to our patients and residents.

Therapy Services. Reimbursement for physical therapy, occupational therapy, and speech-language pathology services covered under Medicare Part B is determined according to the Medicare Physician Fee Schedule (“MPFS”), which is updated annually. For 2021, CMS updated the conversion factor based on a budget neutrality adjustment of negative 10.20%. However, the Consolidated Appropriations Act, 2021 ("CAA") provides for a 3.75% payment increase under the MPFS, which will partially offset this reduction. If a beneficiary receives multiple therapy treatments in one day, Medicare Part B pays the full rate for the therapy unit of service that has the highest Practice Expense (“PE”) component. A multiple procedure payment reduction is

8

applied to the second and subsequent therapy units, reducing reimbursement to 50% of the applicable PE component. Targeted medical reviews are performed when expenses for a beneficiary exceed a threshold of $3,000 for physical and speech therapy services combined or $3,000 for occupational therapy services alone. Deductible and coinsurance amounts paid by the beneficiary for therapy services count toward the amount applied to the limit. Claims above the threshold may be subject to post-payment review of medical necessity documentation by Supplemental Medical Review Contractors.

CMS has implemented value-based programs that affect Medicare payments for physician and other clinician services. Under the Quality Payment Program (“QPP”), a payment methodology intended to reward high-quality patient care, physicians and certain other clinicians, including therapists, are required to participate in one of two QPP tracks. Under both tracks, performance data collected in each performance year affects Medicare payments two years later. The Advanced Alternative Payment Model (“Advanced APM”) track makes incentive payments available for participation in specific innovative payment models approved by CMS. A provider with sufficient participation in an Advanced APM is exempt from the reporting requirements and payment adjustments imposed under the second track, the Merit-Based Incentive Payment System (“MIPS”). Providers electing to participate in MIPS receive either payment incentives or are subject to payment reductions based on their performance with respect to clinical quality, resource use, clinical improvement activities, and meaningful use of electronic health records. For performance data collected in 2021, CMS will continue to offer the Extreme and Uncontrollable Circumstances Policy. This policy is an exception providers must apply for, which allows reweighting for any or all MIPS performance categories for providers impacted by the COVID-19 pandemic. MIPS consolidates components of previously established incentive programs, including the Value-Based Payment Modifier program and the Physician Quality Reporting System.

Medicaid

Medicaid is a medical assistance program for the indigent that is funded jointly by the federal and state governments and administered by the states. Federal law requires states to cover certain nursing center services for Medicaid-eligible individuals when other payment options are unavailable. However, Medicaid eligibility requirements and benefits vary by state, and states may impose limitations on nursing services. States may also establish levels of service or payment methodologies by acuity or specialization of a nursing center.

The Affordable Care Act requires states to expand Medicaid coverage by adjusting eligibility requirements such as income thresholds. However, certain members of Congress continue to attempt to repeal or significantly modify the Affordable Care Act, which may result in changes to Medicaid. Further, states may opt out of the Medicaid expansion. Some states use or have applied to use waivers granted by CMS to implement expansion, impose different eligibility or enrollment restrictions, or otherwise implement programs that vary from federal standards. CMS administrators have indicated that they intend to increase state flexibility in the administration of Medicaid programs. However, President Biden has issued an executive order directing agencies to re-examine measures that reduce coverage or undermine Medicaid programs, including work requirements.

Medicaid reimbursement is often less than a skilled nursing center’s cost of caring for patients. Some states make supplemental payments to Medicaid providers beyond the base payment for specific claims. Upper payment level (“UPL”) supplemental payments are intended to address the difference between Medicaid fee-for-service payments and Medicare reimbursement rates. The CAA requires the Department of Health and Human Services ("HHS") to develop a system for states to report supplemental payments data by October 2021 and publish such data on CMS's website. CMS is also considering making additional changes affecting supplemental payments. The Company receives supplemental payments, including through Indiana's UPL program, which provides supplemental Medicaid payments for skilled nursing centers that are licensed to non-state government entities such as county hospital districts. One skilled nursing center previously operated by the Company entered into a transaction with one such hospital district participating in the UPL program, providing for the transfer of the license from the Company to the hospital district. The Company’s operating subsidiary retained the management of the center on behalf of the hospital district. The agreement between the hospital district and the Company is terminable by either party.

We receive the majority of our annual Medicaid rate increases during the third quarter of each year. The rate changes received in 2020 and 2019, along with increased Medicaid acuity in our acuity based states, were the primary contributor to our 1.7% increase in average rate per day for Medicaid patients in 2020 compared to 2019. Based on the rate changes received during the third quarter of 2020, we expect a favorable impact to our rate per day for Medicaid patients as we move into 2021 due to modest rate increases in many of the states in which we operate.

Several states in which we operate face budget shortfalls, which could result in reductions in Medicaid funding for nursing centers. Pressures on state budgets are expected to continue in the future. Certain of the states in which we operate are actively seeking ways to reduce Medicaid spending for nursing center care by such methods as capitated payments and substantial reductions in reimbursement rates. In addition, enrollment in managed Medicaid plans has increased in recent years as states seek to manage costs, utilization, and quality. Managed Medicaid programs enable states to contract with private entities for the delivery of Medicaid health benefits and to handle program responsibilities like care management and claims adjudication.

9

Some states and managed care plans are promoting alternatives to nursing center care, such as community and home-based services.

Legislation and administrative actions at the federal and state levels may significantly alter the funding for, or structure of, Medicaid programs. CMS administrators have also signaled interest in changing Medicaid payment models, including through increased use of value-based care models. We are unable to predict what, if any, reform proposals or reimbursement limitations will be implemented in the future, or the effect such changes would have on our operations. For the year ended December 31, 2020, we derived 19.8% and 45.6% of our total patient revenues related to continuing operations from the Medicare and Medicaid programs, respectively.  Any health care reforms that significantly limit rates of reimbursement under these programs could, therefore, have a material adverse effect on our financial position and profitability. 

Employees.

As of March 1, 2021, we employed approximately 4,800 employees, referred to as "team members," in connection with our continuing operations, approximately 2,700 of which are considered full-time team members. Approximately 600 of our team members are represented by a labor union. We believe that we staff appropriately, focusing primarily on the acuity level and day-to-day needs of our patients and residents. In most states where we operate, our skilled nursing facilities are subject to state mandated minimum staffing ratios, so our ability to reduce costs by decreasing staffing, notwithstanding decreases in acuity or need, is limited and subject to government audits and penalties in some states. We seek to manage our labor costs by improving team member retention, improving operating efficiencies, maintaining competitive benefits and reducing reliance on overtime compensation and temporary nursing agency services. We believe that our ability to attract and retain qualified professional team members stems from our ability to offer attractive benefit packages, a high level of employee training, and a culture that provides incentives for a quality work environment.

Although we believe we are able to employ sufficient clinical personnel to provide our services, a shortage of health care professional personnel in any of the geographic areas in which we operate could affect our ability to recruit and retain qualified team members and could increase our operating costs. Such shortages may be exacerbated by the COVID-19 pandemic. We compete with other health care providers for both professional and non-professional team members and with non-health care providers for non-professional team members. This competition continues to contribute to a consistent increase in the salaries that we have to pay to hire and retain these team members. As is common in the health care industry, we expect the salary and wage increases for our skilled healthcare providers will continue to be higher than average salary and wage increases nationally.

Supplies and Equipment.

We purchase drugs, solutions and other materials and lease certain equipment required in connection with our business from many suppliers. We may experience supply chain disruptions, including delays and price increases in equipment, pharmaceuticals, and medical supplies. We have incurred additional expenditures preparing our centers for potential outbreaks of COVID-19 and providing care to our residents during required or recommended periods of isolation as a result of increased demand and supply chain constraints. National purchasing contracts are in place for all major supplies, such as food, linens and medical supplies. These contracts assist in maintaining quality, consistency and efficient pricing. Based on contract pricing for food and other supplies, we expect cost increases in 2021 to be relatively the same as we experienced in 2020.

Government Regulation.

The health care industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services, quality of patient care and Medicare and Medicaid fraud and abuse. Over the last several years, government activity has increased with respect to investigations and allegations concerning possible violations by health care providers of a number of statutes and regulations, including those regulating fraud and abuse, false claims, patient privacy and quality of care issues. Violations of these laws and regulations could result in exclusion from government health care programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Compliance with such laws and regulations is subject to ongoing government review and interpretation, as well as regulatory actions in which government agencies seek to impose fines and penalties. The Company is involved in regulatory actions of this type from time to time.

Licensure and Certification.

All our nursing centers must be licensed by the state in which they are located in order to accept patients, regardless of payor source. In most states, nursing centers are subject to CON laws, which require us to obtain government approval for the construction of new nursing centers or the addition of new licensed beds to existing centers. Our nursing centers must comply with detailed statutory and regulatory requirements on an ongoing basis in order to qualify for licensure, as well as for certification as a provider eligible to receive payments from the Medicare and Medicaid programs. Generally, the requirements for licensure and Medicare/Medicaid certification are similar and relate to quality and adequacy of personnel, quality and necessity of medical care, record keeping, dietary services, patient rights, the physical condition of the nursing center, and the

10

adequacy of equipment used in the nursing center. In response to COVID-19, CMS has issued additional requirements for long-term care facilities, including requirements to test facility staff and residents for COVID-19 and report COVID-19 data to the CDC. Failure to comply with applicable laws and regulations could result in exclusion from the Medicare and Medicaid programs, which could have an adverse impact on our business, financial condition, or results of operations.

In 2016, CMS published a comprehensive update to the health and safety standards applicable to long-term care facilities participating in the Medicare or Medicaid programs. These revisions are aimed at improving quality of life, care, and services in long-term care facilities, optimizing resident safety, and reflecting current professional standards. For example, CMS added requirements related to infection prevention and control, compliance and ethics programs, staff training, and QAPI. We believe we have achieved substantial compliance with these requirements. In April 2019, CMS announced a comprehensive overview of regulations, guidelines, and processes related to safety and quality in nursing homes, including plans to enhance enforcement efforts and increase transparency through the Nursing Home Compare website, which transitioned to the new Care Compare website in September 2020. It is unclear how related initiatives will affect our operations.

Each of our centers is subject to periodic inspections, known as “surveys” by health care regulators, to determine compliance with all applicable licensure and certification standards. Such requirements are both subjective and subject to change. If a survey concludes that there are deficiencies in compliance, the center will be subject to various sanctions, including but not limited to monetary fines and penalties, suspension of new admissions, non-payment for new admissions and loss of licensure or certification. Generally, however, once a center receives written notice of any compliance deficiencies, it may submit a written plan of correction and is given a reasonable opportunity to correct the deficiencies. In March 2020, certain nursing home surveys were suspended due to the COVID-19 pandemic. CMS issued guidance instructing state survey agencies to resume survey activities as soon as they have resources to do so. There can be no assurance that we will be able to maintain such licenses and certifications for our centers in the future or that we will not be required to expend significant sums in order to comply with regulatory requirements.

Health care and health insurance reform.

In recent years, the U.S. Congress and some state legislatures have considered and enacted significant legislation concerning health care and health insurance. The most prominent of these efforts, the Affordable Care Act, affects how health care services are covered, delivered and reimbursed. The Affordable Care Act expands coverage through a combination of public program expansion and private sector reforms, provides for reduced growth in Medicare program spending, and promotes initiatives that tie reimbursement to quality and care coordination. Some of the provisions, such as the requirement that large employers provide health insurance benefits to full-time employees, have increased our operating expenses. The Affordable Care Act expands the role of home-based and community services, which may place downward pressure on our sustaining population of Medicaid patients. Reforms that we believe have had, or may have in the future, a material impact on the long-term care industry and on our business include, among others, bundling of payments to cover both acute and post-acute care and the imposition of enrollment limitations on new providers. However, significant regulatory and statutory changes have been made to the statute, and there is considerable uncertainty regarding the future of the Affordable Care Act. For example, final rules issued in 2018 expand the availability of association health plans and allow the sale of short-term, limited-duration health plans, neither of which are required to cover all of the essential health benefits mandated by the Affordable Care Act. Certain members of Congress have stated their desire to repeal or make additional significant changes to the Affordable Care Act, its implementation or interpretation. Effective January 1, 2019, Congress eliminated the financial penalty associated with the individual mandate. As a result of this change, a federal judge in Texas ruled in December 2018 that the individual mandate was unconstitutional and determined that the rest of the Affordable Care Act was, therefore, invalid. In December 2019, the Fifth Circuit Court of Appeals upheld this decision with respect to the individual mandate, but remanded for further consideration of how this affects the rest of the law. On November 10, 2020, the Supreme Court heard oral arguments regarding this case, and the law remains in place pending the appeals process. The impact of the 2020 federal election on health reform is not yet known, although President Biden has indicated through executive orders that his administration intends to protect and strengthen the Affordable Care Act and Medicaid programs.

Skilled nursing centers are required to bill Medicare on a consolidated basis for certain items and services that they furnish to patients, regardless of the cost to deliver these services. This consolidated billing requirement essentially makes the skilled nursing center responsible for billing Medicare for all care services delivered to the patient during the length of stay. CMS has instituted a number of test programs designed to extend the reimbursement and financial responsibilities under consolidated billing beyond the traditional discharge date to include a broader set of bundled services. Such examples may include, but are not exclusive to, home health, durable medical equipment, home and community based services, and the cost of re-hospitalizations during a specified bundled period. Currently, these test programs for bundled reimbursement are confined to a small set of clinical conditions, but CMS has indicated that it is developing additional bundled payment models. This bundled form of reimbursement could be extended to a broader range of diagnosis related conditions in the future. The potential impact on skilled nursing center utilization and reimbursement is currently unknown. The process for defining bundled services has not

11

been fully determined by CMS and, therefore, is subject to change during the rule making process. CMS has indicated that it is working toward a unified payment system for post-acute care services, including those provided by skilled nursing centers.

Health Insurance Portability and Accountability Act of 1996, and other Privacy and Security Requirements and Data Exchange Requirements.

The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) has mandated an extensive set of regulations to standardize electronic patient health, administrative and financial data transactions and to protect the privacy and security of individually identifiable health information (“protected health information”). We have a HIPAA compliance committee and designated privacy and security officers.

The HIPAA transaction standards are intended to simplify the electronic claims process and other healthcare transactions by encouraging electronic transmission rather than paper submission. These regulations provide for uniform standards for data reporting, formatting and coding that we must use in certain transactions with health plans. The HIPAA security regulations establish requirements for safeguarding protected health information that is electronically transmitted or electronically stored. Some of the security regulations are technical in nature, while others are addressed through policies and procedures.

The HIPAA privacy regulations establish limits on the use and disclosure of protected health information, provide for patients' rights, including rights to access, to request amendment of, and to receive an accounting of certain disclosures of protected health information, and require certain safeguards for protected health information. In addition, each covered entity must contractually bind individuals and entities that furnish services to the covered entity or perform a function on its behalf, and to which the covered entity discloses protected health information, to restrictions on the use and disclosure of that protected health information. Covered entities must report breaches of unsecured protected health information to affected individuals without unreasonable delay, but not to exceed 60 calendar days from the discovery of the breach. Notification must also be made to the Department of Health and Human Services and, in certain cases involving large breaches, to the media.

There are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns. We are subject to any federal and state laws that are more stringent or grant greater privacy rights to individuals. These laws vary and could impose additional penalties. For example, the Federal Trade Commission uses its consumer protection authority to initiate enforcement actions in response to data breaches.

Health care providers and industry participants are also subject to a growing number of requirements intended to promote the interoperability and exchange of patient health information. For example, beginning April 5, 2021, health care providers and certain other entities will be subject to information blocking restrictions pursuant to the 21st Century Cures Act that prohibit practices that are likely to interfere with the access, exchange or use of electronic health information, except as required by law or specified by HHS as a reasonable and necessary activity. Violations may result in penalties or other disincentives.

Although we believe that we are in material compliance with the HIPAA regulations and other federal and state laws and regulations related to privacy and security, inadvertent violations may occur in the course of our business. For this and other reasons, the HIPAA regulations and other federal and state laws are expected to continue to impact us operationally and financially and may pose increased regulatory risk.

Self-Referral and Anti-Kickback Requirements.

The health care industry is subject to state and federal laws that regulate the relationships of providers of health care services, physicians and other clinicians. These restrictions include self-referral laws that impose restrictions on physician referrals to any entity with which they have a financial relationship, which is a broadly defined term. We believe our relationships with physicians comply with the self-referral laws. Failure to comply with self-referral laws could subject us to a range of sanctions, including civil monetary penalties and possible exclusion from government reimbursement programs. There are also federal and state laws making it illegal to offer anyone anything of value in return for referral of patients. These laws, generally known as “anti-kickback” laws, are broad and subject to interpretations that are highly fact dependent. Given the lack of clarity of these laws, there can be no absolute assurance that any health care provider, including us, will not be found in violation of the anti-kickback laws in any given factual situation. Strict sanctions, including fines and penalties, exclusion from the Medicare and Medicaid programs and criminal penalties, may be imposed for violation of the anti-kickback laws. From time to time, the government issues regulations and guidance that interpret these laws, including final rules issued in November 2020, that are intended to modernize and clarify the federal self-referral and anti-kickback statutes.

False Claims Act and Billing Compliance.

There are a number of laws and regulations that govern the submission of claims for reimbursement from Medicare or Medicaid that, if not followed, can result in payment denials, significant fines, or criminal liability. Among the more serious of these laws, is the federal False Claims Act (“FCA”), pursuant to which actions may be brought against a provider by the federal government or by a private party on behalf of the federal government, known as a “qui tam relators” or “relators,” for the submission of false claims for reimbursement by Medicare or Medicaid. These actions can lead to significant civil monetary

12

penalties, significant criminal fines and imprisonment, and/or exclusion from participation in state and federally-funded healthcare programs. Relators are entitled to share in any amounts recovered by the government under the FCA. Both direct enforcement activity by the government and qui tam relator actions have increased significantly in recent years.

The basis of an FCA violation can include issues such as coding errors, billing for services not provided, billing for unnecessary services, or submitting false cost reports. Liability also arises for the known failure to report and refund an overpayment received from the government within 60 days of identifying such overpayment. An overpayment is deemed to be identified when a person has, or should have through reasonable diligence, determined that an overpayment was received and quantified the overpayment. Some courts have held that providers who allegedly have violated other statutes, such as self-referral or kickback laws, have thereby submitted false claims under the FCA. Allegations of poor quality of care can also lead to FCA actions under a theory of worthless services, which contends that care provided was so deficient that it was tantamount to no service at all.

A violation of the FCA also occurs when a provider’s request for payment falsely certifies compliance with the applicable statutes (including self-referral or kickback laws), regulations or contract provisions that are preconditions to payment. The recognition of this theory has increased the risk that a healthcare company will have to defend an FCA action, pay fines and treble damages or settlement amounts or be excluded from federal and state healthcare programs as a result of an investigation arising out of the FCA.

Secondary Coverage Reporting Obligations.

As required by the Medicare Secondary Reporting Act and related laws and regulations, we report to CMS specific information regarding all claimants and claim settlements involving Medicare participants so CMS can recover Medicare funds expended to provide healthcare treatment to the claimant. The requirements are to ensure that CMS is notified so that it may recoup the amounts paid for services from the settlement proceeds. The requirements do not result in us making additional payments to CMS for these services provided and does not result in an incremental cost to us. Strict sanctions, including fines and penalties, exclusion from the Medicare and Medicaid programs and criminal penalties, may be imposed for non-compliance with these reporting obligations.

Available Information.

We file reports with the Securities and Exchange Commission (“SEC”), including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. The SEC maintains electronic versions of the Company's reports on its website at www.sec.gov. We also make available, free of charge through our website, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and other materials filed with the SEC as soon as reasonably practical after such material is electronically filed with or furnished to the SEC via a link to the SEC's EDGAR system. Our website address is www.dvcr.com. The information provided on our website is not part of this report, and is therefore not incorporated by reference unless such information is otherwise specifically referenced elsewhere in this report.

In addition, copies of the Company's annual report will be made available, free of charge, upon written request.

Corporate Governance Principles.

The Company has adopted Corporate Governance Principles relating to the conduct and operations of the Board of Directors. The Corporate Governance Principles are posted on the Company's website (www.dvcr.com) and are available in print to any stockholder who requests a copy.

Committee Charters.

The Board of Directors has an Audit Committee, Compensation Committee, Corporate Governance Committee, Risk Management Committee, and Executive Committee. The Board of Directors has adopted written charters for each committee, except for the Executive Committee, which are posted on the Company's website (www.dvcr.com) and are available in print to any stockholder who requests a copy.

13

ITEM 1A. RISK FACTORS

There have been a number of material developments both within the Company and the long-term care industry. These developments have had and are likely to continue to have a material impact on us. This section summarizes these developments, as well as other risks that should be considered by our shareholders and prospective investors.

Risks Related to our Operations

We are substantially self-insured and have significant potential professional liability exposure.

The provision of health care services entails an inherent risk of liability. Participants in the health care industry are subject to an increasing number of lawsuits alleging malpractice, negligence, product liability or related legal theories, many of which involve large claims and significant defense costs. Like many other companies engaged in the long-term care profession in the United States, we have numerous pending liability claims, disputes and legal actions for professional liability and other related issues. We expect to continue to be subject to such suits as a result of the nature of our business. We have professional liability insurance coverage for our nursing centers that, based on historical claims experience, is likely to be substantially less than the amount required to satisfy claims that are expected to be incurred. See “Item 3. Legal Proceedings” for further descriptions of pending claims and see “Item 7. Management's Discussion and Analysis of Financial Condition - Accounting Policies and Judgments - Professional Liability and Other Self-Insurance Reserves” for discussion of our reserve for self-insured claims and of our ability to meet our anticipated cash needs.

We may have substantial adjustments to our accrual for professional liability claims which could cause significant changes in our net earnings.

Each year, we record adjustments to our accrual for self-insured risks associated with professional liability claims. While these adjustments to the accrual result in changes to reported expenses and income, they are not directly related to changes in cash because the accrual is not funded. These self-insurance reserves are assessed on a quarterly basis, with changes in estimated losses being recorded in the consolidated statements of operations in the period identified. Any increase in the accrual decreases income in the period, and any reduction in the accrual increases income during the period. Our actual professional liabilities may vary significantly from the accrual due to an increase in the number of claims asserted or claim costs in excess of estimates, and the amount of the accrual has and may continue to fluctuate by a material amount in any given quarter. For the years ended December 31, 2020 and 2019, we recorded professional liability expense from continuing operations of $8.3 million and $7.0 million, respectively.

We face numerous risks related to the recent outbreak of COVID-19, which have had and could continue to have a material adverse effect on our business, financial condition, liquidity, results of operations and prospects and other pandemics, epidemics, or outbreaks of a contagious illness may have a similar impact on us.

The COVID-19 pandemic, declared as a national public health emergency by the Secretary of the HHS and renewed as recently as January 2021, has disrupted many aspects of the economy and our industry and it is unclear what the ultimate impact on our business will be. Federal, state and local governments and health departments have taken a number of unprecedented actions as precautionary measures to avoid the spread of COVID-19 and may take additional steps. Governments have implemented social distancing measures which have caused, and may continue to cause patients to postpone or refuse necessary care in an attempt to avoid possible exposure to COVID-19. Restrictions or limitations on admissions to our centers may have a negative impact on us. Although social contact restrictions have eased across the U.S., some restrictions remain in place, and some states are re-imposing or may re-impose these and other restrictions due to increasing rates of COVID-19 cases. Measures we are taking to limit the spread of the virus include implementing screening protocols for staff, residents, and visitors. CMS requires nursing homes in states with positive testing rates above a certain threshold to test all staff on a weekly basis.

Although we have implemented considerable safety measures, caring for COVID-19 patients has associated risks. In addition, we have experienced reduced occupancy in our centers, in part due to perceived risks by patients and family members of residential care and their perception of restrictions such as limited visitation policies, a reduction in patients released to nursing homes from hospitals and other healthcare facilities, and a general reluctance to seek medical care or interface with the healthcare system during the pandemic or for an undetermined period of time. Occupancy may also be affected by the data each nursing home is required to report, including the number of confirmed and suspected cases of COVID-19 and resident deaths related to COVID-19, which is made publicly available through the CDC National Healthcare Safety Network.

We have incurred, and may continue to incur, increased expenses arising from the COVID-19 pandemic. Residents in our centers that have tested positive for COVID-19 have caused an increase in the costs of caring for the residents in that center and may also cause a reduced occupancy at those centers. We have also incurred additional expenditures preparing our centers for potential outbreaks and providing care to our residents during required or recommended

14

periods of isolation. In addition, we have experienced and may continue to experience supply chain disruptions, including delays and price increases in equipment, pharmaceuticals, and medical supplies. Staffing, equipment, and pharmaceutical and medical supplies and vaccine shortages may impact our ability to admit and treat patients. The COVID-19 outbreak has caused our centers and our management to spend considerable time planning- for and responding to the impacts of COVID-19, which diverts their attention from other business concerns.

Recently, two COVID-19 vaccines were approved for general use. While the supply of COVID-19 vaccine in the United States may be limited and subject to the direction of each state’s department of health, many states have generally prioritized residents of long-term care facilities, health care providers, and the elderly. We have worked hard to offer vaccines to our staff and residents; however, distribution of the vaccine has taken longer than expected due to logistics and scheduling issues. Availability is expected to remain scarce for the next several months, even as newer, more contagious variants of COVID-19 circulate worldwide. In addition, in our centers where we have offered the vaccine to staff and residents, the percentage of healthcare providers who have elected not to receive the vaccine has been significant. There can be no assurance that our staff and residents will choose to receive a COVID-19 vaccine or that the vaccines will prove to have long term efficacy as currently understood by the scientific community.

Our future operations, financial condition, results of operations, compliance with financial covenants and liquidity will continue to be impacted materially by developments related to the COVID-19 pandemic, including, but not limited to:

•duration and severity of the spread of COVID-19 in our core markets and among our patients and staff;

•effectiveness of measures we are taking to respond to COVID-19;

•increases in patients and/or staff infected by COVID-19 who reside or work at our centers and the resulting impact on occupancy and new admissions;

•significantly reduced occupancy as a result of local government restrictions, including shelter-in-place mandates, sweeping restrictions on travel, and substantial changes to selected protocol within the healthcare system across the United States, including cancelled or rescheduled elective procedures at referring hospitals in our markets and the resulting impact to the volume of new admissions to our centers;

•governmental and administrative regulations as well as the nature and adequacy of financial relief and other forms of support for our industry;

•the timing and impact of termination of state or federal financial relief measures or the inability of states to continue to make payments to our centers for state funded services;

•disruptions to operations due to shortages in center-based staffing needs;

•disruptions and shortages to the supply chain of critical services and supplies, including personal protective equipment and the capacity to test patients and employees for COVID-19;

•increases in expenses related to staffing, supply chain or other expenditures including additional protocols implemented in connection with CDC and related isolation procedures, including obligations to test patients and staff for COVID-19;

•the rollout and availability of effective COVID-19 medical treatments and vaccines;

•increases in workers' compensation expense, insurance premiums and potential lawsuits against the Company by patients or their families as a result of COVID-19 in our centers; and

•significant disruption of the global financial markets, which could have a negative impact on our ability to access capital in the future.

We are continuing to evaluate and consider the potential impact of the COVID-19 outbreak, which could result in these or other negative outcomes and adversely impact our business, operating results and financial condition. The extent to which COVID-19 will impact our business and our financial results will depend on future developments, which are highly uncertain and cannot be predicted. There can be no assurances that COVID-19 or another pandemic, epidemic or outbreak of a contagious illness, will not have a material and adverse impact on our business, operating results and financial condition in the future.

We continue to have significant potential professional liability exposure related to our discontinued operations.

Effective August 30, 2019, we terminated our operations in Kentucky. Even though we no longer have on-going operations in Kentucky, the Company is required to continue to defend, and make cash payments related to, professional liability claims asserted against our previously operated nursing centers for events occurring prior to August 30, 2019. The Company has approximately 35 pending law suits related to its operations in Kentucky as of

15

December 31, 2020. We also have one remaining action related to our former operations in Arkansas. Our professional liability insurance coverage for these claims is likely to be substantially less than the amount required to satisfy these claims, and the cash expenditures associated with these claims could have a material adverse effect on our on-going business, results of operations and financial condition. See “Item 3. Legal Proceedings” for further descriptions of pending claims and see “Item 7. Management's Discussion and Analysis of Financial Condition - Accounting Policies and Judgments - Professional Liability and Other Self-Insurance Reserves” for discussion of our reserve for self-insured claims and of our ability to meet our anticipated cash needs.

Our outstanding indebtedness is subject to various financial covenants and floating rates of interest which could be subject to fluctuations based on changing interest rates.

We have long-term indebtedness of $61.1 million at December 31, 2020. Certain of our debt agreements contain various financial covenants, the most restrictive of which relate to minimum cash deposits, cash flow and fixed charge coverage ratios. Our failure to comply with those covenants could result in an event of default, which, if not cured or waived, could result in the acceleration of some or all of our debts. Such non-compliance could result in a material adverse impact to our financial position, results of operations and cash flows. We are in compliance with all such covenants for the period ending December 31, 2020. See “Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources” for additional discussion of our covenants.

Changes in the method of determining LIBOR, or the replacement of LIBOR with an alternative reference rate, may adversely affect interest rates on our current or future indebtedness and may otherwise adversely affect our financial condition and results of operations.

In 2017, the United Kingdom’s Financial Conduct Authority announced that after 2021 it would no longer compel banks to submit the rates required to calculate the London Interbank Offered Rate ("LIBOR"). This announcement indicates that the continuation of LIBOR on the current basis cannot and will not be guaranteed after 2021.  We have a significant number of debt instruments with attributes that are dependent on LIBOR. The transition from LIBOR to an alternative reference rate could have a material adverse effect on our liquidity, financial condition and results of operations.

Our accrual for professional liability claims is not funded, and if a material judgment is entered against us in any lawsuit, we may lack adequate cash to pay the judgment.

As of December 31, 2020, we are engaged in 79 professional liability lawsuits, including 36 of which related to centers we no longer operate. Although we work diligently to limit the cash required to settle and defend professional liability claims, a significant judgment entered against us in one or more legal actions could have a material adverse impact on our cash flows and could result in our being unable to meet all of our cash needs as they become due.

We have entered a settlement agreement with the U.S. Department of Justice that requires substantial future payments.

In February 2020, we entered into a settlement agreement with the U.S. Department of Justice and the State of Tennessee of actions alleging violations of the federal False Claims Act in connection with our provision of therapy and the completion of certain resident admission forms. This agreement requires material annual payments for a period of five years ending in February 2025 and also requires a contingent payment in the event the Company sells any of its owned facilities during the five year payment period. Failure to make timely any of these payments could result in rescission of the settlement and result in the government having a very large claim against us, including penalties, and/or make us ineligible to participate in certain government funded healthcare programs, any of which could in turn significantly harm our business and financial condition.  See Legal Proceedings for further information regarding this investigation and the terms of the settlement.

We are subject to the terms of a Corporate Integrity Agreement.

In February 2020, in conjunction with the settlement of the government investigation related to our therapy practices, we entered into a corporate integrity agreement ("CIA") with the Office of the Inspector General of CMS. This agreement has a term of five years and imposes material burdens on the Company, its officers and directors to take actions designed to insure compliance with applicable healthcare laws, including requirements to maintain specific compliance positions within the Company, to report any non-compliance with the terms of the agreement, to return any overpayments received, to submit annual reports and for an annual audit of submitted claims by an independent review organization. The CIA sets forth penalties for non-compliance by the Company with the terms of the agreement, including possible exclusion from federally funded healthcare programs for material violations of the agreement.

Our operational and strategic flexibility is limited due to the number of our centers that are leased from third parties.

16

A substantial majority of our centers are leased from third parties including 23 centers leased from Omega and 20 centers leased from Golden Living. The loss or deterioration of our relationship with either of these landlords may adversely affect our business. The terms of such leases generally require us to operate such centers as skilled nursing centers, and generally do not allow us to assign the lease to a third party without the applicable landlord’s consent. Therefore, our ability to divest such leased properties is limited, and we may be forced to continue operating such centers as skilled nursing centers even if doing so becomes unprofitable.

While we expect to renew or extend our leases in the normal course of business, there can be no assurance that these rights will be exercised in the future or that we will be able to satisfy the conditions precedent to exercising any such renewal or extension, to the extent that such provisions exist in our leases. In addition, if we are unable to renew or extend any of our master leases, we may lose all of the facilities subject to that master lease agreement. If we are not able to renew or extend our leases at or prior to the end of the existing lease terms, or if the terms of such options are unfavorable or unacceptable to us, our business, financial condition and results of operation could be adversely affected.

Our failure to pay rent or otherwise comply with the provisions of any of our Master Lease Agreements could materially adversely affect our business, financial position, results of operations, and liquidity.

Many of our facilities are under a Master Lease Agreement. Our failure to pay the rent or otherwise comply with the provisions of any of our lease agreements could result in an “event of default” under such lease agreement and also could result in a cross default under other master lease agreements and the agreements for our indebtedness. Upon an event of default, remedies available to our landlords generally include, without limitation, terminating such lease agreement, repossessing and reletting the leased properties and requiring us to remain liable for all obligations under such lease agreement, including the difference between the rent under such lease agreement and the rent payable as a result of reletting the leased properties, or requiring us to pay the net present value of the rent due for the balance of the term of such lease agreement. The exercise of such remedies would have a material adverse effect on our business, financial position, results of operations and liquidity. An event of default under any of our Master Lease Agreements could result in a default under the Credit Facilities and, if repayment of the borrowings under the Credit Facilities were accelerated, the payments under the indentures governing our outstanding notes could also be accelerated. The exercise of remedies by any of our landlords could have a material adverse effect on our business, financial position, results of operations, and liquidity.

We are highly dependent on reimbursement by third-party payors, and we may be negatively impacted by changes to third-party payor programs and any delays in reimbursement.

Substantially all of our nursing center revenues are directly or indirectly dependent upon reimbursement from third-party payors, including the Medicare and Medicaid programs and private insurers. For the year ended December 31, 2020, our patient revenues from continuing operations derived from Medicaid, Medicare, Managed Care and private pay (including private insurers) sources were approximately 45.6%, 19.8%, 10.4%, and 24.2%, respectively. Changes in the mix of our patients among Medicare, Medicaid, Managed Care and private pay categories and among different types of private pay sources may affect our net revenues and profitability. For example, we may be adversely affected by increasing enrollment in Managed Medicare and Managed Medicaid programs. Our net revenues and profitability are also affected by the continuing efforts of all payors to contain or reduce the costs of health care. Efforts to impose reduced payments, greater discounts and more stringent cost controls by government and other payors are expected to continue.

The federal government makes frequent changes to the reimbursement provided under the Medicare program. Effective October 2019, CMS changed the case-mix model used under the SNF prospective payment system. The new model, known as the Patient-Driven Payment Model, shifts the focus to the patient’s condition and resulting care needs rather than the amount of care provided in order to determine Medicare reimbursement. Future changes to payment rates or methodology could significantly reduce the reimbursement we receive. For example, CMS has indicated that it is working toward a unified payment system for post-acute care services, including those provided by SNFs, home health agencies, and other long-term care providers.

In addition, there may be changes to Medicaid reimbursement rates and methodologies, supplemental payment programs, or provider assessment programs. For example, the CAA requires HHS to develop a system for states to report supplemental payments data by October 2021 and publish such data on CMS's website. Further, a number of state governments, including several of the states in which we operate, face projected budget shortfalls and/or deficit spending situations. Because Medicaid is typically a substantial part of a state’s budget, many states are considering or have implemented strategies to reduce Medicaid spending or decrease spending growth. Some states are exploring or implementing alternatives to traditional long-term care, including community and home-based nursing services.

17

Any changes in reimbursement levels or in the timing of payments under Medicare, Medicaid, or private pay programs and any changes in applicable government regulations could have a material adverse effect on our net revenues, net income (loss) and cash flows. We are limited in our ability to reduce the direct costs of providing care. We are unable to predict the nature and success of future financial or delivery system reforms or the effect such changes will have on our operations. No assurance can be given that such reforms will not have a material adverse effect on us. See “Item 1. Business - Government Regulation and Reimbursement.”

If we have problems with our information systems that affect payment or if other issues arise with Medicare, Medicaid, or other payors that affect the amount or timeliness of reimbursements, we may encounter delays in our payment cycle. Any significant payment timing delay could cause us to experience working capital shortages. Working capital management, including prompt and diligent billing and collection, is an important factor in our consolidated results of operations and liquidity. Our working capital management procedures may not successfully mitigate the effects of any delays in our receipt of payments or reimbursements. Accordingly, such delays could have an adverse effect on our liquidity and financial condition.

We operate in an industry that is highly competitive.

The long-term care industry generally, and the nursing home business particularly, is highly competitive. We face direct competition for the acquisition of centers, and our centers face competition for patients. Our ability to compete is based on several factors including, but not limited to, building age and appearance, reputation, relationships with referral sources, availability of patients, survey history and CMS rankings. Some of our present and potential competitors are significantly larger and have or may obtain greater financial and marketing resources than we can. In addition, some competitors are implementing vertical alignment strategies. For example, some hospitals provide long-term care services and some providers are aligned or are pursuing alignment strategies with payors. Certain of our competitors are operated by not-for-profit, non-taxpaying or governmental agencies that can finance capital expenditures on a tax exempt basis and receive funds and charitable contributions unavailable to us. In addition, we may encounter substantial competition from new market entrants. The prevalence and severity of COVID-19 outbreaks in long-term care facilities may also affect our ability to attract patients or compete for business if our facilities experience an outbreak or are perceived to be affected by COVID-19. Consequently, there can be no assurance that we will not encounter increased competition in the future, which could limit our ability to attract patients or expand our business, and could materially and adversely affect our business or decrease our market share.

We may have difficulty attracting and retaining qualified nurses, therapists, healthcare professionals, and other key personnel, which, along with a growing number of minimum wage and compensation related regulations, may increase our costs related to these employees.

Our team members are essential to our business. We rely on our ability to attract and retain qualified nurses, therapists, and other healthcare professionals. The market for these key personnel is highly competitive, and we could experience significant increases in our operating costs due to shortages in their availability, which could be exacerbated by the COVID-19 pandemic. Like other healthcare providers, we have at times experienced difficulties in attracting and retaining qualified personnel. We may continue to experience increases in our labor costs, primarily due to higher wages and greater benefits required to attract and retain qualified healthcare personnel, and such increases may adversely affect our profitability. Furthermore, while we attempt to manage overall labor costs in the most efficient way, our efforts to manage them through wage freezes and similar means may have limited effectiveness and may lead to increased turnover and other challenges.

Tight labor markets and high demand for such team members can contribute to high turnover among clinical professional staff. A shortage of qualified personnel at a facility could result in significant increases in labor costs and increased reliance on overtime and expensive temporary staffing agencies, and could otherwise adversely affect operations at the affected centers. If we are unable to attract and retain qualified professionals, our ability to adequately provide services to our residents and patients may decline and our ability to grow may be constrained.

Our cost of labor may be influenced by unanticipated factors in certain markets or, with respect to collective bargaining agreements that we are a party to, we may experience above-market increases. A substantial number of our team members are hourly team members whose wage rates are affected by increases in the federal or state minimum wage rate. As collective bargaining agreements are renegotiated or minimum wage rates increase we may need to increase the wages paid to team members. This may be applicable to not only minimum wage team members but also to team members at wage rates which are currently above the minimum wage. The new Presidential administration has recently proposed an increase in the federal minimum wage over a four year phase-in period starting at $9.50 an hour and increasing annually over the next 4 years to $15 an hour. While we do not know what, if any, increase in the minimum wage may be adopted, we estimate that a phased-in minimum wage of $9.50 to $15 an hour would likely increase our labor cost materially.

18

The Department of Labor issued rule changes to the Fair Labor Standards Act that increased the minimum salary threshold for team members exempt from overtime along with an automatic annual increase to this salary threshold. The future of these rule changes, as well as other potential changes, remains uncertain given the recent change in Presidential administrations. However, these rule changes could increase our cost of services provided.

Because we are largely funded by government programs according to predetermined, nonnegotiable rates, we do not have an ability to pass such wage increases through to revenue sources. Any such mandated wage increases could have a material adverse effect on our results of operations, liquidity and financial condition.

Possible changes in the acuity of residents and patients, as well as payor mix and payment methodologies, may significantly affect our profitability.

The sources and amount of our revenues are determined by a number of factors, including the occupancy rates of our facilities, the length of stay, the payor mix of residents and patients, rates of reimbursement, and patient acuity. These factors may be impacted by continued efforts to shift patients from institutional care settings to home and community-based services. Changes in patient acuity as well as payor mix among private pay, Medicare, and Medicaid may significantly affect our profitability. In particular, any significant decrease in our population of high-acuity patients or any significant increase in our Medicaid population could have a material adverse effect on our business, financial position, results of operations, and liquidity, especially if state Medicaid programs continue to limit, or more aggressively seek limits on, reimbursement rates or service levels.

The industry trend toward value-based purchasing may negatively impact our revenues.

There is a growing trend in the healthcare industry among both government and commercial payors toward value-based purchasing of healthcare services. Value-based purchasing programs emphasize quality and efficiency of services, rather than volume of services. For example, the SNF VBP program makes incentive payments available based on past performance on specified quality measures related to hospital readmissions. Failure to report quality data or poor performance may negatively impact the amount of reimbursement received.

Other initiatives aimed at improving quality and cost of care include alternative payment models, such as ACOs and bundled payment arrangements. It is unclear whether alternative models will successfully coordinate care and reduce costs or whether they will decrease overall reimbursement. Additionally, commercial payors have expressed intent to shift toward value-based reimbursement arrangements.

We expect value-based purchasing programs, including programs that condition reimbursement on patient outcome measures, to become more common and to involve a higher percentage of reimbursement amounts. While we believe we are adapting our business strategies to compete in a value-based reimbursement environment, we are unable at this time to predict how this trend will affect our results of operations. If we are unable to meet or exceed quality performance standards under any applicable value-based purchasing program, perform at a level below the outcomes demonstrated by our competitors, or otherwise fail to effectively provide or coordinate the efficient delivery of quality healthcare services, our reputation in the industry may be negatively impacted, we may receive reduced reimbursement amounts, and we may owe repayments to payors, causing our revenues to decline.

Our systems are subject to security breaches and other cybersecurity incidents.

While we maintain information technology security and safeguards, complex medical systems have been and may continue to be targeted for cyber-attacks, which may result in unauthorized parties obtaining access to our computer systems and networks. Cyber-attacks could result in the misappropriation of our patient information that is protected by law, private employee information, proprietary business information and technology or result in interruptions to our business. The reliability and security of our information technology infrastructure is critical to our business. To the extent that any disruptions or security breaches result in significant loss or damage to our data, or inappropriate use or disclosure of patient, employee or proprietary information, we could be required to notify affected individuals, state and federal agencies and the media of the breach, could experience damage to our reputation and patient relationships and be subject to civil and/or criminal fines and penalties or related class action litigation, any of which could have a material adverse effect on our business, results of operations and financial condition. In addition, we may be at increased risk because we outsource certain services or functions to, or have systems that interface with, third parties. Some of these third parties may store or have access to our data and may not have effective controls, processes, or practices to protect our information from attack, damage, or unauthorized access. A breach or attack affecting any of these third parties could harm our business.

The success of previous and future acquisitions cannot be guaranteed and such acquisitions may consume substantial capital and other resources and could expose us to unforeseen liabilities and integration risks.

19

We have in the past and plan to in the future make investments in additional centers, whether by opening new centers or acquiring existing centers. Such acquisitions may involve significant cash expenditures, debt incurrence, operating losses and additional expenses that could have a material adverse effect on our financial position, results of operations and liquidity. Acquisitions involve numerous risks, including:

•difficulties integrating acquired operations, personnel and accounting and information systems, or in realizing projected efficiencies and cost savings;

•diversion of management's attention from other business concerns;

•potential loss of key team members or customers of acquired companies;

•entry into markets in which we may have limited or no experience;

•increased indebtedness and reduced ability to access additional capital when needed;

•assumption of unknown liabilities or regulatory issues of acquired companies, including failure to comply with healthcare regulations or to establish internal financial controls; and

•straining of our resources, including internal controls relating to information and accounting systems, regulatory compliance, logistics and others.

Furthermore, certain of the foregoing risks could be exacerbated when combined with other growth measures that we may pursue.

Investing in our business initiatives and development could adversely impact our results of operations and financial condition.

We plan to invest in business initiatives and development that could increase our operating expenses. These initiatives may or may not be successful in growing our census or revenues. A part of our business initiative is to emphasize our skilled nursing facilities' care on patients with shorter stays but higher acuities. Shorter stays may result in decreased census during certain periods. In addition, there is typically a time delay between incurring such expenses and the attaining of revenues and cash flows expected from these initiatives and development. As a result, our revenue and operating cash flow may not increase enough during a reporting period to cover these increased expenses. Such additional revenues may not materialize to the level we anticipate, if at all.

We may be unable to reduce costs to offset decreases in our patient census levels or other expenses completely.

We depend on implementing adequate cost management initiatives in response to fluctuations in levels of patient census in our centers in order to maintain our current cash flow and earnings levels. Fluctuation in our patient census levels may become more common as we continue our emphasis in our skilled nursing facilities on patients with shorter stays but higher acuities. With the average length of stay decreasing for a skilled nursing patient, as well as the increased availability of assisted living facilities and home and community-based services, the challenge of maintaining desirable patient census levels has been amplified. A decline in patient census levels would likely result in decreased revenue. If we are unable to put in place corresponding reductions in costs in response to decreases in our patient census or other revenue shortfalls, our financial condition and operating results would be adversely affected. There are limits in our ability to reduce the costs of our centers because we must maintain required staffing levels.

The geographic concentration of our affiliated facilities could leave us vulnerable to an economic downturn, regulatory changes or acts of nature in those areas.

Our affiliated facilities located in Alabama, Mississippi, and Texas account for the majority of our total revenue. As a result of this concentration, the conditions of local economies, changes in governmental rules, regulations and reimbursement rates or criteria, changes in demographics, state funding, acts of nature and other factors that may result in a decrease in demand and/or reimbursement for skilled nursing services in these states could have a disproportionately adverse effect on our revenue, costs and results of operations. Areas where we operate have been and may in the future be "hot spots" of the COVID-19 pandemic or a similar pandemic, epidemic or outbreak of disease, which could also adversely affect our revenue, costs and results of operations.

Disasters and similar events may seriously harm our business.

Natural and man-made disasters, including terrorist attacks and acts of nature such as hurricanes, tornados, earthquakes and wildfires, may cause damage or disruption to us, our employees and our centers, which could have an adverse impact on our patients and our business. Our affiliated facilities in Kansas, Missouri, Mississippi, Alabama and Texas may be more susceptible to damage caused by natural disasters including hurricanes, tornadoes and flooding. In order to provide care for our patients, we are dependent on consistent and reliable delivery of food, pharmaceuticals, utilities and other goods to our centers, and the availability of employees to provide services at our centers. If the delivery of

20

goods or the ability of employees to reach our centers were interrupted in any material respect due to a natural disaster, pandemic or other reasons, it would have a significant impact on our centers and our business. Furthermore, the impact, or impending threat, of a natural disaster has in the past and may in the future require that we evacuate one or more centers, which would be costly and would involve risks, including potentially fatal risks, for the patients. The impact of disasters, pandemics and similar events is inherently uncertain. Such events could harm our patients and employees, severely damage or destroy one or more of our centers, harm our business, reputation and financial performance, or otherwise cause our business to suffer in ways that we currently cannot predict.

Litigation and/or investigations regarding COVID-19 could materially and adversely affect our financial condition, results of operations, compliance with financial covenants and liquidity.

A growing number of professional liability and employment related claims have been filed or are threatened to be filed against us and our subsidiaries related to COVID-19. The professional liability claims relate to the death of residents of nursing centers who contracted COVID-19. Such claims may be subject to liability protection provisions within various state executive orders or legislation and/or federal legislation. The applicability of such protection has not yet been adjudicated in any pending claim against us. Employment related claims have been filed by our employees or by the Equal Employment Opportunity Commission or state agencies that primarily relate to allegations of disability or Family and Medical Leave Act discrimination or the inadequacy of the personal protective equipment made available to the employees who work in our nursing centers.

A U.S. House of Representatives subcommittee, the Select Subcommittee on the Coronavirus Crisis, announced an investigation into the ongoing COVID-19 crisis in nursing homes, demanding information from both the federal government and companies in our industry. In addition, the Attorneys General of several states have initiated inquiries into the nursing facility industry’s and/or our response to the COVID-19 pandemic and they have requested information from us. We intend to cooperate fully with these investigations.

While we deny any wrongdoing and will vigorously defend our self in these matters, managing litigation and responding to governmental investigations is costly and may involve a significant diversion of management attention. Such proceedings are unpredictable and may develop over lengthy periods of time. An adverse resolution of any of these lawsuits or investigations may involve injunctive relief and/or substantial monetary penalties, either or both of which could have a material adverse effect on our reputation, business, results of operations and cash flows.

The high levels of infected COVID-19 patients and deaths at senior living communities and resulting negative publicity may have a long-term significant detrimental impact on the senior living industry, including us, even if our senior living communities do not experience similar levels of COVID-19 infections and deaths as others in the industry.

COVID-19 has proven to be particularly harmful to seniors and persons with other pre-existing health conditions. If the senior living industry continues to experience high levels of residents infected with COVID-19 and related deaths, and news accounts emphasize these experiences, seniors may delay or forgo moving into senior living communities or using other services provided by senior living operators. These trends could be realized across the senior living industry and do not discriminate among owners and operators that have higher or lower levels of residents experiencing COVID-19 infections and related deaths. As a result, our senior living communities’ business and our results of operations may experience a long-term significant detrimental impact.

Failure to maintain effective internal control over our financial reporting could have an adverse effect on our ability to report our financial results on a timely and accurate basis.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934 (the “Exchange Act”), and is required to evaluate the effectiveness of these controls and procedures on a periodic basis and publicly disclose the results of these evaluations and related matters in accordance with the requirements of Section 404 of the Sarbanes-Oxley Act of 2002.  Effective internal control over financial reporting is necessary for us to provide reliable financial reports, to help mitigate the risk of fraud and to operate successfully. However, testing and maintaining our internal control over financial reporting can be expensive and divert our management's attention from other business matters. Any failure to implement and maintain effective internal controls could result in material weaknesses or material misstatements in our consolidated financial statements. 

If we fail to maintain effective internal control over financial reporting, we may be required to take corrective measures or restate the affected historical financial statements. In addition, we may be subjected to investigations and/or sanctions by federal and state securities regulators, and/or civil lawsuits by security holders. Any of the foregoing could also cause investors to lose confidence in our reported financial information and in our company and would likely result in a decline in the market price of our stock and in our ability to raise additional financing if needed in the future.

21

Certain events or circumstances could result in the impairment of our assets that result in material charges to earnings.

We review the carrying value of certain long-lived assets, finite-lived intangible assets and indefinite-lived intangible assets with respect to any events or circumstances that indicate an impairment or an adjustment to the amortization period may be necessary. If circumstances suggest that the recorded amounts of any of these assets cannot be recovered based upon estimated future cash flows, the carrying values of such assets are reduced to fair value. If the carrying value of any of these assets is impaired, we may incur a material charge to earnings. Any such impairment charges could have a material adverse effect on our business, financial position and results of operations.

Risks Related to Government Regulations

We are subject to significant government regulation.

The health care industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government health care program participation requirements, protection of patient health information, interoperability and the exchange of electronic health information, reimbursement for patient services, quality of patient care, Medicare and Medicaid fraud and abuse, debt collection and communications with consumers. Various federal and state laws regulate relationships among providers of services, including employment or service contracts and investment relationships. The operation of long-term care centers and the provision of services are also subject to extensive federal, state, and local laws relating to, among other things, the adequacy of medical care, distribution of pharmaceuticals, equipment, personnel, operating policies, environmental compliance, compliance with the Americans with Disabilities Act, fire prevention and compliance with building codes.

Long-term care facilities are subject to periodic inspection to assure continued compliance with various standards and licensing requirements under state law, as well as with Medicare and Medicaid conditions of participation. The failure to obtain or renew any required regulatory approvals or licenses could prevent us from offering our existing or additional services, subject us to penalties, and adversely affect our growth. In addition, health care is an area of extensive and frequent regulatory change. Changes in the laws or new interpretations of existing laws can have a significant effect on methods and costs of doing business and amounts of payments received from governmental and other payors. Our operations could be adversely affected by, among other things, regulatory developments such as mandatory increases in the scope and quality of care to be afforded patients and revisions in licensing and certification standards. We attempt at all times to comply with all applicable laws; however, there can be no assurance that we will remain in compliance at all times with all applicable laws and regulations or that new legislation or administrative or judicial interpretation of existing laws or regulations will not have a material adverse effect on our operations or financial condition. Federal or state proceedings seeking to impose fines and penalties for violations of applicable laws and regulations, as well as federal and state changes in these laws and regulations, may negatively impact us. See “Item 1. Business - Government Regulation.” See also “Item 3. Legal Proceedings.”

There is a high degree of uncertainty regarding the implementation and impact of the CARES Act, the Paycheck Protection Program and Health Care Enhancement Act ("PPPHCE Act"), the CAA and future stimulus or relief legislation, if any. There can be no assurance as to the total amount of financial assistance or types of assistance we will receive or retain, that we will be able to benefit from provisions intended to increase access to resources and ease regulatory burdens for healthcare providers or that additional stimulus legislation will be enacted.

The CARES Act is a $2 trillion economic stimulus package signed into law on March 27, 2020, in response to the COVID-19 pandemic. In an effort to stabilize the U.S. economy, the CARES Act provides for cash payments to individuals and loans and grants to small businesses, among other measures. The PPPHCE Act and the CAA, each of which include additional emergency appropriations, were signed into law on April 24, 2020 and December 27, 2020, respectively. Together, the CARES Act, the PPPHCE Act, and the CAA authorize funding to be distributed to hospitals and other healthcare providers through the Public Health and Social Services Emergency Fund ("PHSSEF"). These funds are intended to reimburse eligible providers, including public entities and Medicare- and/or Medicaid-enrolled providers and suppliers, for healthcare-related expenses or lost revenues attributable to COVID-19. As long as the recipient has sufficient COVID-19 attributable expenses and lost revenues between January 1, 2020 and June 30, 2021 and complies with certain terms and conditions, PHSSEF payments are not required to be repaid. The terms and conditions include, among other things, complying with reporting requirements, limitations on balance billing and restrictions against using PHSSEF funds to reimburse expenses or losses that other sources are obligated to reimburse. Beginning in April 2020, HHS allocated $50 billion of PHSSEF funding for "Phase 1" of general distributions to Medicare providers impacted by COVID-19, which was distributed proportional to providers' share of 2018 net patient revenue. In "Phase 2" HHS distributed $18 billion to eligible Medicaid, CHIP, dental, and assisted living providers that had not received a Phase 1 general distribution payment equal to 2% of their total patient care revenue and certain providers that had a change of ownership in 2019 or 2020. In December 2020, HHS began distributing the "Phase 3"

22

$24.5 billion general distribution for all previously eligible applicants, behavioral health providers and certain new providers that began operations in 2020. In addition to the general distributions, HHS allocated $4.9 billion in targeted distribution funding to skilled nursing facilities, with a fixed $50,000 distribution for each skilled nursing facility and variable distributions based on number of beds, and an additional $2.5 billion to skilled nursing facilities and nursing homes, with fixed a $10,000 distribution for each facility and variable distributions based on number of beds. HHS has also allocated a separate $2 billion in incentive payments to skilled nursing facilities and nursing homes based on certain performance measures tied to COVID-19 infections and mortalities. These payments are calculated based on monthly performance periods running from September through December 2020, with the total available bonus payment for each performance period determined in part based on data reported via Certification and Survey Provider Enhanced Reports ("CASPER"). The terms and conditions for this distribution limit use of payments to certain infection control expenses. HHS has also made other targeted distributions for providers in areas particularly impacted by COVID-19, providers of services with lower shares of Medicare reimbursement or who predominantly serve the Medicaid population, and providers requesting reimbursement for certain COVID-19 related testing and treatment of uninsured Americans, among others.

The CARES Act also made available or expanded other forms of financial assistance for healthcare providers, including through Medicare and Medicaid payment adjustments and an expansion of the Medicare Accelerated and Advance Payment Program, which made available accelerated payments of Medicare funds in order to increase cash flow to providers. CMS is no longer accepting applications for accelerated or advanced payments. The Company elected not to participate in this program. In addition to financial assistance, the CARES Act includes provisions intended to increase access to medical supplies and equipment and ease legal and regulatory burdens on healthcare providers. Many of these measures, such as flexibilities related to the provision of telehealth services and waiver of the requirement for a three-day prior hospitalization for Medicare coverage of a skilled nursing facility stay, are effective only for the duration of the public health emergency. The CARES Act also includes numerous income tax provisions including changes to the Net Operating Loss rules and business interest expense deduction rules.

During the year ended December 31, 2020, we received $47.2 million in payments from the PHSSEF. We are closely tracking our use of the funds received under the PHSSEF in order to demonstrate compliance with the terms and conditions, including applicable reporting requirements. Given uncertainty in HHS reporting requirements, we cannot predict with certainty whether we will have sufficient COVID-19 attributable expenses and lost revenues to retain all of the PHSSEF funds that we have received. Further, we can offer no assurance that it will be in compliance with all requirements related to retaining the payments received from the PHSSEF. If we fail to appropriately comply with all of the terms and conditions or do not have sufficient expenses and lost revenues (as defined by these programs), the Company may be required to repay some or all of these amounts, which could have a material adverse impact.

Due to the recent enactment of the CARES Act and other related legislation, there is still a high degree of uncertainty surrounding their implementation, and the COVID-19 pandemic continues to evolve. Some of the measures allowing for flexibility in delivery of care and various financial supports for health care providers are available only for the duration of the public health emergency, and it is unclear whether or for how long the public health emergency declaration will be extended. The current declaration expires April 21, 2021. The HHS Secretary may choose to renew the declaration for successive 90-day periods for as long as the emergency continues to exist and may terminate the declaration whenever he determines that the public health emergency no longer exists. The federal government may consider additional stimulus and relief efforts, but we are unable to predict whether additional stimulus measures will be enacted or their impact. There can be no assurance as to the total amount of financial and other types of assistance we will receive or retain under CARES Act, the PPPHCE Act, the CAA or future legislation, if any, and it is difficult to predict the impact of such legislation on our operations or how it will affect operations of our competitors. Moreover, we are unable to assess the extent to which anticipated negative impacts on us arising from the COVID-19 pandemic will be covered by amounts or benefits received, and which we may in the future receive, under the CARES Act, PPPHCE Act, CAA, or future legislation. There can be no assurance that the terms and conditions of provider relief funding or other relief programs will not change in ways that affect our ability to comply with such terms and conditions in the future, the amount of total stimulus funding we will receive or retain or our eligibility to participate in such stimulus funding. We continue to assess the potential impact of COVID-19 and government responses to the pandemic on our business, results of operations, financial condition and cash flows.

We are the subject of governmental audits, investigations, claims and litigation, which could have an adverse effect on our business or financial position.

Healthcare companies are subject to high levels of regulatory scrutiny. Various government agencies and their agents may conduct audits of our operations, including the Department of Health and Human Services (“HHS”) Office of Inspector General (“OIG”), which is tasked with combating fraud, waste and abuse within the Medicare and Medicaid programs. The OIG’s enforcement priorities are outlined in a work plan that is updated monthly. These priorities

23

include life safety reviews, compliant billing, quality of care, poorly performing nursing facilities, hospitalizations, criminal background checks, Medicare Part B services, accuracy of clinical data collected by nursing facilities, transparency of ownership, and civil monetary penalty funds. We cannot predict the likelihood, scope or outcome of any OIG investigations of our centers.

The costs associated with potential litigation or the public announcement that we are being investigated, even if a dispute is resolved in our favor, or any determination that we have violated laws or regulations could have an adverse effect on our business, financial position or results of operations. In particular, government investigations, as well as qui tam lawsuits, may lead to significant penalties, including fines, damages payments or exclusion from government healthcare programs. Settlements of lawsuits involving Medicare and Medicaid issues routinely involve both financial penalties and corporate integrity agreements, either of which could have an adverse effect on our business, financial position or results of operations.

Payments we receive from Medicare and Medicaid are subject to audits. Such audits could result in an obligation to refund amounts previously paid to us.

Payments we receive from Medicare and Medicaid can be retroactively adjusted after examination during the claims settlement process or as a result of post-payment audits. Private pay sources also reserve the right to conduct audits. Payors may disallow our requests for reimbursement, or recoup amounts previously reimbursed, based on determinations by the payors or their third-party audit contractors that certain costs are not reimbursable because either adequate or additional documentation was not provided or because certain services were not covered or deemed to not be medically necessary. We believe that billing and reimbursement errors and disagreements are common in our industry. Significant adjustments, recoupments or repayments of our Medicare or Medicaid revenue could adversely affect our business, financial condition or results of operations.

We are subject to claims under false claims, self-referral and anti-kickback prohibitions.

We are subject to numerous federal and state laws intended to prevent fraud, waste and abuse within the healthcare industry. Violations of these laws may result in substantial damage awards, civil or criminal penalties for individuals or entities, including large civil monetary penalties and exclusion from participation in the Medicare or Medicaid programs. Such awards, exclusion or penalties, if applied to us, could have a material adverse effect on our financial position and profitability.

In the United States, various federal laws regulate the relationships between providers of health care services, physicians, and other clinicians. These laws impose restrictions on physician referrals for designated health services to entities with which they have financial relationships. These laws also prohibit the offering, payment, solicitation or receipt of any form of remuneration in return for the referral of Medicare or Medicaid patients or patient care opportunities for the purchase, lease or order of any item or service that is covered by the Medicare and Medicaid programs. Many states in which we operate have similar anti-kickback and self-referral laws that may apply to all payors or a broader range of services. To the extent that we, any of our centers through which we do business, or any of the owners or directors have a financial relationship with each other or with other health care entities providing services to long-term care patients, such relationships could be subject to increased scrutiny.

Federal and state laws prohibit the submission of false claims for reimbursement and prohibit the making of false claims or statements. The submission of false claims or false statements may lead to the imposition of significant civil monetary penalties, significant criminal fines and imprisonment, and/or exclusion from participation in state and federally-funded healthcare programs, including the Medicare and Medicaid programs. Under the FCA, actions against a provider can be initiated by the federal government or by a private party on behalf of the federal government. These private parties, who are often referred to as “qui tam relators” or “relators,” are entitled to share in any amounts recovered by the government. Both direct enforcement activity by the government and qui tam relator actions have increased significantly in recent years.

An FCA violation occurs when a provider knowingly submits a claim for items or services not provided. Liability also arises for the known failure to report and refund an overpayment received from the government. Some courts have held that providers who allegedly have violated other statutes, such as self-referral or kickback laws, have thereby submitted false claims under the FCA. Allegations of poor quality of care can also lead to FCA actions under a theory of worthless services, which contends that care provided was so deficient that it was tantamount to no service at all.

The implied certification theory expands the scope of the FCA. Under the implied certification theory, a violation of the FCA occurs when a provider’s request for payment implies a certification of compliance with the applicable statutes, regulations or contract provisions that are preconditions to payment. The recognition of this theory has increased the risk that a healthcare company will have to defend a false claims action, pay fines and treble damages or settlement amounts or be excluded from federal and state healthcare programs as a result of an investigation arising out

24

of the FCA. Many states have enacted similar laws providing for imposition of civil and criminal penalties for the filing of fraudulent claims.

Because we submit thousands of claims to Medicare each year and there is a relatively long statute of limitations under the FCA, there is a risk that intentionally, or even negligently or recklessly submitted claims that prove to be incorrect, or billing errors, cost reporting errors or lapses in statutory or regulatory compliance with regard to the provision of healthcare services (including, without limitation the anti-kickback statues and the self-referral laws discussed above), could result in significant civil or criminal penalties against us. We recently settled one such false claims act case, and there can be no assurance that our operations will not be subject to review, scrutiny, penalties or enforcement actions under these laws, or that these laws will not change in the future. Any penalties or allegations involving false claims, whether valid or not, could have a significant impact on our business.

We are subject to laws governing the confidentiality of patient health information.

Both federal and state laws impose certain requirements regarding maintaining the confidentiality of patient health information and other personal information. In particular, HIPAA regulations require us to protect the medical records and other personal health information of our patients, limit our use of and ability to disclose such information, give patients a right to access and amend their personal health information, and notify affected patients, HHS, and, in the case of large breaches, the media of breaches involving unsecure patient health information. A violation of HIPAA or any other federal or state laws regarding the confidentiality or use of personal information could subject us to civil or criminal penalties, and could in turn damage our reputation, affect our ability to attract or retain patients, and thereby have a material adverse effect on our revenues, financial position, results of operations and cash flows.

We have significant participation in the Texas Quality Incentive Payment Program ("QIPP") and changes to the program by the state of Texas could cause changes in our net earnings.

During 2019, the Company expanded its participation in QIPP as administered by the Texas Health and Human Services Commission. QIPP provides supplemental Medicaid payments for skilled nursing centers that achieve certain quality measures.  Currently, eleven of the Company’s centers participate in the QIPP, and the Company received approximately $4.7 million in additional revenue as a result of the QIPP program in 2020. To allow four of these centers to meet the QIPP participation requirements, the Company entered into a transaction with a Texas medical district already participating in the QIPP, providing for the transfer of the provider license from the Company to the medical district. The Company's operating subsidiary retained the management of the centers on behalf of the medical district. In response to the COVID-19 pandemic, the Texas Health and Human Services Commission waived some of the performance and reporting requirements for QIPP effective March 1, 2020 and for the remainder of state fiscal year 2021. If the State of Texas should decide to terminate QIPP, reduce the payments pursuant to the program or determine that the Company can no longer participate in QIPP, such action could have a material adverse effect on our business, financial position, results of operations, and liquidity.

We cannot predict the effects that healthcare reform initiatives, including possible repeal or invalidation of or changes to the Affordable Care Act, and other changes in government programs may have on our business, financial condition or results of operations.

In recent years, there have been initiatives on the federal and state levels for comprehensive reforms affecting the availability, payment and reimbursement of healthcare services in the United States. The most prominent of these efforts is the Affordable Care Act, which affects how healthcare services are covered, delivered and reimbursed. However, there is significant uncertainty regarding the future of the Affordable Care Act. The law has been subject to legislative and regulatory changes and court challenges. Effective January 1, 2019, Congress eliminated the penalty associated with the individual mandate to maintain health insurance. As a result of this change, the United States District Court for the North District of Texas ruled in December 2018 that the individual mandate was unconstitutional and determined that the rest of the Affordable Care Act was, therefore, invalid. In December 2019, the Fifth Circuit Court of Appeals upheld this decision with respect to the individual mandate, but remanded the case for further consideration of how this affects the rest of the law. On November 10, 2020, the Supreme Court heard oral arguments regarding this case, and the law remains in place pending the appeals process. The elimination of the individual mandate penalty and other changes may impact the number of individuals that elect to obtain public or private health insurance or the scope of such coverage, if purchased.

It is difficult to predict the impact of the Affordable Care Act and related regulations or the impact of its modification on our operations in light of the uncertainty regarding whether, when or how the law will be further changed, and the ultimate impact of court challenges. There is also uncertainty regarding whether, when, and what other health reform initiatives will be adopted and the impact of such efforts on providers and other healthcare industry participants. For

25

example, some members of Congress have proposed significantly expanding the coverage of government-funded programs, including proposals to expand coverage of federally-funded insurance programs as an alternative to private insurance or establish a single-payer system (such reforms often referred to as "Medicare for All"). CMS administrators have indicated that they intend to grant states additional flexibility in the administration of state Medicaid programs, including expanding the scope of waivers under which states may impose different eligibility or enrollment restrictions or otherwise implement programs that vary from federal standards. However, President Biden has indicated through executive orders that his administration intends to protect and strengthen the Affordable Care Act and Medicaid programs, including directing agencies to re-examine measures that reduce coverage or undermine Medicaid programs, including work requirements. CMS administrators have also signaled interest in changing Medicaid payment models, including adopting value-based care models. We are unable to predict the nature and success of future financial or delivery system reforms that may be implemented by other, non-governmental industry participants, such as private payors. Healthcare reform initiatives, including changes to or repeal or invalidation of the Affordable Care Act, could materially and adversely affect our business, financial condition and results of operations.

State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of healthcare facilities could impair our ability to expand our operations, or could result in increased competition.

Some states require healthcare providers to obtain prior approval, known as a CON, for:

• the purchase, construction or expansion of healthcare facilities;

• capital expenditures exceeding a prescribed amount; or

• changes in services or bed capacity.

In addition, other states that do not require CON approval have effectively barred the expansion of existing facilities and the development of new ones by placing partial or complete moratoria on the number of new Medicaid beds they will certify in certain areas or in the entire state. Other states have established such stringent development standards and approval procedures for constructing new healthcare facilities that the construction of new facilities, or the expansion or renovation of existing facilities, may become cost prohibitive or extremely time-consuming. In addition, in some states, the acquisition of a facility being operated by a non-profit organization requires the approval of the state Attorney General.

Our ability to acquire or construct new facilities or expand or provide new services at existing facilities would be adversely affected if we are unable to obtain the necessary approvals, if there are changes in the standards applicable to those approvals, or if we experience delays and increased expenses associated with obtaining those approvals. We may not be able to obtain licensure, CON approval, Medicaid certification, Attorney General approval or other necessary approvals for future expansion projects. Conversely, the elimination or reduction of state regulations that limit the construction, expansion or renovation of new or existing facilities could result in increased competition to us or result in overbuilding of facilities in some of our markets. If overbuilding in the healthcare industry in the markets in which we operate were to occur, it could reduce the occupancy rates of existing facilities and, in some cases, might reduce the private rates that we charge for our services.

Changes to federal and state income tax laws and regulations as well as accounting guidance could adversely affect our position on income taxes, estimated income liabilities and deferred tax assets.

We are subject to both state and federal income taxes in the U.S. and our operations, plans and results are affected by tax and other initiatives. On December 22, 2017, a law commonly known as the Tax Cuts and Jobs Act (“Tax Act") was enacted in the United States. Among other things, the Tax Act reduced the U.S. corporate income tax rate to 21 percent, which resulted in changes in the valuation of our deferred tax assets and liabilities.

Accounting guidance requires that deferred tax assets be reduced by a valuation allowance, when it is more likely than not that a tax benefit will not be realized. As of December 31, 2020, we had net deferred tax assets of approximately $18.9 million, against which we have applied a full valuation allowance. We continually assess the realizability of our deferred tax assets.

Any such change in valuation could have a material impact on our income tax expense and net deferred tax assets. We are also subject to regular reviews, examinations, and audits by the Internal Revenue Service ("IRS") and other taxing authorities with respect to our taxes. There are uncertainties and ambiguities in the application of the Tax Act and it is possible that the IRS could issue subsequent guidance or take positions on audit that differ from our interpretations and assumptions. Although we believe our tax estimates are reasonable, if a taxing authority disagrees with the positions we have taken, we could face additional tax liability, including interest and penalties. Our effective tax rate could be adversely affected by changes in the mix of earnings in states with different statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in tax laws and regulations, changes in our interpretations of tax

26

laws, including the Tax Act. Unanticipated changes in our tax rates or exposure to additional income tax liabilities could affect our profitability. There can be no assurance that payment of such additional amounts upon final adjudication of any disputes will not have a material impact on our results of operations and financial position.

We may be subject to liability for environmental damages.

Under various federal, state and local environmental laws, ordinances and regulations, a current or previous owner or operator of real estate may be required to investigate and clean up hazardous or toxic substances or petroleum product releases at the property, and may be held liable to a governmental entity or to third parties for property damage and for investigation and clean-up costs incurred by those parties in connection with the contamination. These laws typically impose clean-up responsibility and liability without regard to whether the owner or operator knew of or caused the presence of the contaminants, and liability under these laws has been interpreted to be joint and several unless the harm is divisible and there is a reasonable basis for allocation of responsibility. The costs of investigation, remediation or removal of the substances may be substantial.  In addition, under our leases with Omega and Golden Living, we have agreed to indemnify the landlord for any such liabilities related to the properties that we lease from them. Persons who arrange for the disposal or treatment of hazardous or toxic substances also may be liable for the costs of removal or remediation of the substances at the disposal or treatment facility, whether or not the facility is owned or operated by the person. Finally, the owner of a site may be subject to common law claims by third parties based on damages and costs resulting from environmental contamination emanating from a site. If we become subject to any of these claims, the costs involved could be significant and could have a material adverse effect on our business, financial condition, cash flows, and results of operations.

Risks Related to our Common Stock

We do not intend to pay dividends on our common stock.

Although we paid cash dividends from the second quarter of 2009 through the third quarter of 2018, we do not anticipate paying cash dividends on our common stock in the foreseeable future. We currently anticipate that we will retain all of our available cash, if any, for use as working capital and for other general purposes, including to service or repay our debt and lease obligations as well as to fund the operations of our business. Any payment of future dividends will be at the discretion of our board of directors and will depend on, among other things, our earnings, financial condition, capital requirements, level of indebtedness, lease obligations, statutory and contractual restrictions applying to the payment of dividends and other considerations that our board of directors deems relevant.

Our common stock is no longer listed on the NASDAQ Capital Market and is quoted only in the Pink Sheets, making them subject to additional "penny stock" rules, which could negatively affect our stock price and liquidity.

On August 27, 2019, the Company was notified by Nasdaq that it denied the Company’s appeal and determined to delist the Company’s Common Stock from the Nasdaq Capital Market.  Accordingly, the trading of the Company’s Common Stock was suspended on the Nasdaq Capital Market at the opening of business on August 29, 2019. 

On October 11, 2019, Nasdaq filed a Form 25 with the Securities & Exchange Commission to effect the formal delisting of the Company’s common stock from the Nasdaq Capital Market, which became effective October 21, 2019. The Form 25 filing did not cause the removal of any shares of the Company’s common stock from registration under the Exchange Act and the Company remains subject to the periodic reporting requirements of the Exchange Act.  The Company believes that the delisting of its common stock from the Nasdaq Capital Market, as well as the related process leading up to delisting, has had a negative impact on the Company’s common stock market price as well as on the liquidity of its common stock.

Delisting from Nasdaq may adversely affect our ability to raise additional financing through the public or private sale of equity securities, may affect the ability of investors to trade our securities and may negatively affect the value and liquidity of our common stock. Delisting also could have other negative results, including the potential loss of employee confidence and the loss of institutional investor interest and business development opportunities.

Since the suspension of trading on Nasdaq on August 29, 2019, the Company's Common stock began trading on the OTCQX under the trading symbol "DVCR." However, there is no assurance that an active market will be maintained for the Company’s Common Stock. An investor would likely find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our common stock on an over-the-counter market, and many investors would likely not buy or sell our common stock due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or other reasons. In addition, as a delisted security, our common stock is subject to SEC rules as a “penny stock,” which impose additional disclosure requirements on broker-dealers. The regulations relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors such as broker commissions generally representing a higher percentage of the price of a penny

27

stock than of a higher-priced stock, would further limit the ability of investors to trade in our common stock. For these reasons and others, delisting could adversely affect the liquidity, trading volume and price of our common stock, causing the value of an investment in us to decrease and having an adverse effect on our business, financial condition and results of operations, including our ability to attract and retain qualified employees, to raise capital, and execute on a strategic alternative.

Our securities are now and have historically been thinly traded. An active trading market in our equity securities may cease to exist, which would adversely affect the market price and liquidity of our common stock, in addition our stock price has been subject to fluctuating prices.

Shares of our common stock are now and have been thinly traded, meaning that the number of persons interested in purchasing our common stock at or near ask prices at any given time may be relatively small or non-existent. As a consequence, our stock price may not reflect an actual or perceived value of the business. Also, there may be periods of several days or more when trading activity in our shares is minimal or non-existent, as compared to an issuer that has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot predict the actions of market makers, investors or other market participants, and can offer no assurances that the market for our securities will be stable. If there is no active trading market in our equity securities, the market price and liquidity of the securities will be adversely affected. The market price of our common stock could decline as a result of sales of a large number of shares of our common stock in the market or the perception that these sales could occur. Due to these conditions, you may not be able to sell your shares at or near ask prices or at all if you need money or otherwise desire to liquidate your shares. These conditions also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.

We have a number of policies in place that could be considered anti-takeover protections.

Our Certificate of Incorporation (the “Certificate”) requires the approval of the holders of two-thirds of the outstanding shares to amend certain provisions of the Certificate. Section 203 of the Delaware General Corporate Law restricts the ability of a Delaware corporation to engage in any business combination with an interested shareholder. We are also authorized to issue up to 0.8 million shares of preferred stock, the rights of which may be fixed by our Board without shareholder approval. Provisions in certain of our executive officers' employment agreements provide for post-termination compensation, including payment of amounts up to two times their annual salary, following certain changes in control (as defined in such agreements). Our stock incentive plans provide for the acceleration of the vesting of options in the event of certain changes in control (as defined in such plans). Certain changes in control also constitute an event of default under our bank credit facility. The foregoing matters may, together or separately, have the effect of discouraging or making more difficult an acquisition or change of control of the company.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

28

ITEM 2. PROPERTIES

We own 15 and lease 46 long-term care centers as discussed in “Item 1 Business - Nursing Centers and Services.” See further details below.

Our current operations include 46 nursing centers subject to operating leases, including 23 owned by Omega Health Investors ("Omega"), 20 owned by Golden Living and three owned by other parties. In our role as lessee, we are responsible for the day-to-day operations of all operated centers. These responsibilities include recruiting, hiring and training all nursing and other personnel, and providing patient care, nutrition services, marketing, quality improvement, accounting, and data processing services for each center. The lease agreements pertaining to our 46 leased centers are “triple net” leases, requiring us to maintain the premises, provide insurance, pay taxes and pay for all utilities. See the table below for a summary of owned and leased beds operated by the Company.

State	Centers	Leased Beds	Owned Beds	Total Operational Beds (1)
Alabama	20	2,079	306	2,385
Indiana	1	172	—	172
Kansas	6	—	483	483
Mississippi	9	1,039	—	1,039
Missouri	3	455	—	455
Ohio	4	651	—	651
Tennessee	5	497	120	617
Texas	13	1,370	475	1,845
Total	61	6,263	1,384	7,647

____________

(1)The number of Operational Beds includes 397 Licensed Assisted Living/Residential Beds.

Brentwood Support Center and Regional Offices

We lease approximately 29,000 square feet of office space in Brentwood, Tennessee that houses our executive offices and centralized management support functions. Regional executives for Kansas work from an office of approximately 922 square feet. Lease periods on these centers range up to three years. We believe that our leased properties are adequate for our present needs and that suitable additional or replacement space will be available as required.

ITEM 3. LEGAL PROCEEDINGS

The provision of health care services entails an inherent risk of liability. Participants in the health care industry are subject to lawsuits and administrative proceedings alleging malpractice, negligence, violations of false claims acts, violations of laws and regulations governing the operation of our business, product liability, and other related legal theories, many of which involve large claims and significant defense costs. Like most other companies engaged in the long-term care profession in the United States, we have numerous pending claims, disputes and legal actions for professional liability and other related issues that have been filed by or on behalf of current and former residents of our facilities. It is expected that we will continue to be subject to such suits as a result of the nature of our business. Further, as with all health care providers, we are periodically subject to regulatory actions seeking fines and penalties for alleged violations of health care laws and regulations, including alleged survey violations, alleged violations of elder abuse laws and other laws and regulations related to the quality of care provided to residents of our centers. Like other health care providers, in the ordinary course of our business, we are also subject to claims made by employees and other disputes and litigation arising from the conduct of our business.

As of December 31, 2020, we are engaged in 79 professional liability lawsuits, including those related centers we no longer operate. Twenty-two lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The ultimate results of any of our professional liability claims and disputes cannot be predicted. We have limited, and sometimes no, professional liability insurance with regard to most of these claims. A significant judgment entered against us in one or more of these legal actions could have a material adverse impact on our financial position and cash flows.

In February 2020, we entered into a settlement agreement with the U.S. Department of Justice and the State of Tennessee of actions alleging violations of the federal False Claims Act in connection with our provision of therapy and the completion of certain resident admission forms. This settlement resolved an investigation that had begun in 2012 and covers the time period from January 1, 2010 through December 31, 2015. This agreement requires material annual payments for a period of five years

29

ending in February 2025 and also requires a contingent payment in the event the Company sells any of its owned facilities during the five year payment period. Failure to make timely any of these payments could result in rescission of the settlement and result in the government having a very large claim against us, including penalties, and/or make us ineligible to participate in certain government funded healthcare programs, any of which could in turn significantly harm our business and financial condition.

In conjunction with the settlement of the government investigation related to our therapy practices, we entered into a corporate integrity agreement with the Office of the Inspector General of CMS. This agreement has a term of five years and imposes material burdens on the Company, its officers and directors to take actions designed to insure compliance with applicable healthcare laws, including requirements to maintain specific compliance positions within the Company, to report any non-compliance with the terms of the agreement, to return any overpayments received, to submit annual reports and for an annual audit of submitted claims by an independent review organization. The CIA sets forth penalties for non-compliance by the Company with the terms of the agreement, including possible exclusion from federally funded healthcare programs for material violations of the agreement.

In January 2009, a purported class action complaint was filed in the Circuit Court of Garland County, Arkansas against the Company and certain of its subsidiaries and Garland Nursing & Rehabilitation Center (the “Center”). The Company answered the original complaint in 2009, and there was no other activity in the case until May 2017. At that time, plaintiff filed an amended complaint asserting new causes of action. The amended complaint alleges that the defendants breached their statutory and contractual obligations to the patients of the Center over a multi-year period by failing to meet minimum staffing requirements, failing to otherwise adequately staff the Center and failing to provide a clean and safe living environment in the Center. The Company has filed an answer to the amended complaint denying plaintiffs’ allegations and has asked the Court to dismiss the new causes of action asserted in the amended complaint because the Company was prejudiced by plaintiff’s long delay in filing the amended complaint. The Court has not yet ruled on the motion to dismiss, so the lawsuit remains in its early stages and has not yet been certified by the court as a class action. The Company intends to defend the lawsuit vigorously.

We cannot currently predict with certainty the ultimate impact of any of the above cases on our financial condition, cash flows or results of operations. An unfavorable outcome in any of these lawsuits or any of our professional liability actions, any regulatory action, any investigation or lawsuit alleging violations of fraud and abuse laws or of elderly abuse laws or any state or Federal False Claims Act case could subject us to fines, penalties and damages, including exclusion from the Medicare or Medicaid programs, and could have a material adverse impact on our financial condition, cash flows or results of operations.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

30

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information. Our common stock is traded on the OTCQX Market and began trading there on August 29, 2019. The Company's OTCQX ticker symbol is “DVCR.”

Our common stock has been traded since May 10, 1994. On March 1, 2021, the closing price for our common stock was $3.50, as reported by OTCMarkets.com.

Holders. On March 1, 2021, there were approximately 270 holders of record. Most of our shareholders have their holdings in the street name of their broker/dealer.

ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA

Not applicable.

31

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

Diversicare Healthcare Services, Inc. provides long-term care services to nursing center patients in nine states, primarily in the Southeast, Midwest and Southwest. Our centers provide a range of health care services to their patients and residents. In addition to the nursing, personal care and social services usually provided in long-term care centers, we offer a variety of comprehensive rehabilitation services as well as nutritional support services. As of December 31, 2020, our continuing operations consist of 61 nursing centers with 7,250 licensed skilled nursing beds and 397 assisted-living and other residential beds. We own 15 and lease 46 of our nursing centers included in continuing operations. The Company's continuing operations include centers in Alabama, Indiana, Kansas, Mississippi, Missouri, Ohio, Tennessee, and Texas.

Key Performance Metrics

Skilled mix. Skilled mix represents the number of days our Medicare and Managed Care patients are receiving services at the skilled nursing facilities divided by the total number of days (less days from assisted living patients).

Average rate per day. Average rate per day is the revenue by payor source for a period at the skilled nursing facility divided by actual patient days for the revenue source for a given period.

Average daily skilled nursing census. Average daily skilled nursing census is the average number of patients who are receiving skilled nursing care.

COVID-19 and Federal Relief Legislation

As a result of the COVID-19 pandemic, federal and state governments have passed legislation, promulgated regulations, and taken other administrative actions intended to assist healthcare providers in providing care to COVID-19 and other patients during the public health emergency and to address public health needs. These measures include temporary relaxation of conditions of participation for healthcare providers, relaxation of licensure requirements for healthcare professionals, relaxation of privacy restrictions for telehealth remote communications, promoting use of telehealth by expanding the scope of services for which reimbursement is available, and limited waivers of fraud and abuse laws for activities related to COVID-19 during the public health emergency period. They also include requirements for skilled nursing centers to report to public health authorities, residents and their representatives when residents, and staff are confirmed as having or are being investigated for having COVID-19.

We are working with federal, state, and local health authorities to respond to the COVID-19 pandemic and are taking measures to try to limit the spread of the virus. For example, we have implemented screening protocols for staff, residents, and visitors. CMS requires nursing homes in states with positive testing rates above a certain threshold to test all staff on a weekly basis. Although we are implementing considerable safety measures, caring for COVID-19 patients has associated risks. In addition, we have experienced, and may continue to experience supply chain disruptions, including delays and price increases in equipment, pharmaceuticals, and medical supplies. Staffing, equipment, and pharmaceutical and medical supplies shortages may impact our ability to admit and treat patients. We have incurred, and may continue to incur, increased expenses arising from the COVID-19 pandemic. We have also experienced reduced occupancy in our centers, in part due to perceived risks by patients and family members of residential care and their perception of restrictions such as limited visitation policies, a reduction in patients released to nursing homes from hospitals and other healthcare facilities, and a general reluctance to seek medical care or interface with the healthcare system during the pandemic or for an undetermined period of time. Occupancy may also be affected by the data each nursing home is required to report, including the number of confirmed and suspected cases of COVID-19 and resident deaths related to COVID-19, which is made publicly available through the CDC National Healthcare Safety Network.

The Company is closely monitoring and evaluating the impact of the COVID-19 pandemic on all aspects of its business. We have identified team members and patients who have tested positive for COVID-19 at a select number of our centers, and we have incurred increases in the costs of caring for the patients and residents in those centers. The Company incurred an additional $21.2 million in labor expenses, $4.7 million of supplies expenses, $6.0 million of employee testing expenses and $0.5 million of travel expenses related to the COVID-19 pandemic for the twelve months ended December 31, 2020. The Company has also experienced reduced occupancy at its centers and has incurred additional expenditures preparing our centers for potential outbreaks. The Company has an interdisciplinary team monitoring and keeping apprised of the latest information about the virus and its prevalence. The Company has implemented precautionary measures and response protocols to minimize the spread of the virus, following guidance from the CDC, but the Company nevertheless expects additional cases of the virus will occur at these and other facilities.

One of the primary sources of relief for healthcare providers is the CARES Act, an economic stimulus package signed into law on March 27, 2020, which included, among other things, modifications to the limitation on business interest expense and net

32

operating loss provisions relative to the payment of Federal income taxes, allows an optional payment deferral of the employer's portion of Social Security taxes that are otherwise due through December 31, 2020. These provisions of the CARES Act were effective after the date of enactment and also include the appropriation of stimulus funds to healthcare providers. The PPPHCE Act and the CAA, both expansions of the CARES Act that include additional emergency appropriations, were signed into law on April 24, 2020 and December 27, 2020, respectively. In total, the CARES Act, the PPPHCE Act, and the CAA include $178 billion of funding to be distributed through the PHSSEF to eligible providers, including public entities and Medicare- and/or Medicaid-enrolled providers. PHSSEF payments are intended to financially assist healthcare providers with lost revenues and healthcare-related expenses incurred in response to the COVID-19 pandemic. As long as the recipient has sufficient COVID-19 attributable expenses and lost revenues between January 1, 2020 and June 30, 2021 and complies with certain terms and conditions, the PHSSEF payments are not required to be repaid. The terms and conditions include, among other things, complying with reporting requirements, limitations on balance billing and restrictions against using PHSSEF funds to reimburse expenses or losses that other sources are obligated to reimburse.

Recipients of more than ten thousand dollars in PHSSEF funds will be required to submit reports to HHS that include information about their expenses and lost revenues and use of the PHSSEF funds. Although registration for the reporting portal has been opened, HHS has not yet opened the portal for reporting or finalized a deadline for submission of the initial report. HHS continues to update guidance regarding post-payment reporting requirements and "frequently asked questions" that provide some additional details and examples related to how recipients should calculate their COVID-19 attributable expenses and lost revenues for purposes of PHSSEF reporting. Ultimately, to the extent that reports submitted by a recipient do not demonstrate sufficient healthcare related lost revenues and expenses attributable to COVID-19 (as those terms are defined by HHS), the recipient may have to repay any excess funds received.

During the year ended December 31, 2020, we received $47.2 million from the PHSSEF. We also applied for additional Phase 3 General Distribution PHSSEF payments; however, we do not know whether we will ultimately receive additional payments. Due to the recent enactment of the CARES Act and related legislation and evolving guidance, there is still a high degree of uncertainty surrounding their implementation. We are closely tracking our use of the funds received from PHSSEF in order to demonstrate compliance with the terms and conditions, including applicable reporting requirements. The Company is still evaluating the most recent guidance; however, the Company currently anticipates, but cannot guarantee, that it will have sufficient COVID-19 attributable expenses and lost revenues to retain the PHSSEF payments it has received to date. The Company will not be able to determine the amount of used funds until the reporting rules are finalized by the federal government, and the Company knows the full extent of its COVID-19 attributable expenses and lost revenues. The Company can offer no assurance that it will be in compliance with all requirements related to retaining the PHSSEF payments received under the CARES Act and related legislation. If we fail to appropriately comply with all of the terms and conditions or do not have sufficient expenses and lost revenues (as defined by these programs), the Company may be required to repay some or all of these amounts, which could have a material adverse impact. Infection control incentive payments may be used only for certain infection control expenses, and payments are determined based on reporting done through CASPER. However, these payments remain subject to audit by HHS and the Company cannot assure that it will not be required to repay some or all of the amounts received.

The CARES Act also made available or expanded other forms of financial assistance for healthcare providers. For example, HHS is distributing incentive payments to nursing homes and skilled nursing facilities that report infection rates lower than their respective counties as well as mortality rates lower than the nationally established performance threshold for nursing home residents infected with COVID-19. The CARES Act also provides for Medicare and Medicaid payment adjustments and an expansion of the Medicare Accelerated and Advance Payment Program, which made available accelerated payments of Medicare funds in order to increase cash flow to providers. CMS is no longer accepting application for accelerated or advanced payments. The Company has not elected to participate in this program. The CARES Act and the CAA also include other provisions offering financial relief, for example suspending the Medicare sequestration from May 1, 2020 through March 31, 2021, which would have otherwise reduced payments to Medicare providers by 2%, although the sequestration was extended through 2030.

The Company is continuing to evaluate and consider the potential impact that the COVID-19 public health emergency may have on its liquidity, financial condition and results of operations due to numerous uncertainties. We also continue to assess the potential impact of the CARES Act, the PPPHCE Act, and other stimulus measures, if any, as well as the impact of other laws, regulations, and guidance related to COVID-19 on our business, results of operations, financial condition and cash flows. Given the uncertainty as to the duration and severity of the COVID-19 pandemic, it could have a material adverse effect on the Company's future results of operations, financial condition and liquidity.

Strategic Operating Initiatives

We identified several key strategic objectives to increase shareholder value through improved operations and business development. These strategic operating initiatives include: improving our facilities’ quality metrics, improving skilled mix in our nursing centers, improving our average Medicare rate, maintaining Electronic Medical Records to improve Medicaid

33

capture, and completing strategic acquisitions and divestitures. We have experienced success in these initiatives and expect to continue to build on these improvements.

Improving skilled mix and average Medicare rate:

One of our key performance indicators is skilled mix. We believe that our skilled mix is an important indicator of our success in attracting high-acuity patients because it represents the percentage of our patients who are reimbursed by Medicare, managed care and other skilled payors, for whom we receive higher reimbursement rates. Our strategic operating initiatives of improving our skilled mix and our average Medicare rate required investing in nursing and clinical care to treat more acute patients along with nursing center-based marketing representatives to attract these patients. These initiatives developed referral and Managed Care relationships that have attracted and are expected to continue to attract payor sources for patients covered by Medicare and Managed Care. The Company's skilled mix for the years ended December 31, 2020 and 2019 was 15.9% and 13.9%, respectively. For the past several years, census and skilled mix trends have been affected by healthcare reforms resulting in lower lengths of stay among our skilled patient population and lower admissions caused by initiatives among acute care providers, managed care payors and conveners to divert certain skilled nursing referrals to home health or other community-based care settings.

Utilizing Electronic Medical Records to improve Medicaid acuity capture:

As another part of our strategic operating initiatives, all of our nursing centers utilize EMR to improve Medicaid acuity capture, primarily in our states where the Medicaid payments are acuity based. By using EMR, we have increased our average Medicaid rate despite rate cuts in certain acuity based states by accurate and timely capture of care delivery.

Completing strategic transactions:

Our strategic operating initiatives include a renewed focus on completing strategic acquisitions and divestitures. We continue to pursue and investigate opportunities to acquire or lease new centers, focusing primarily on opportunities within our existing geographic areas of operation. As part of our strategic efforts, we have also performed thorough analysis on our existing centers in order to determine whether continuing operations within certain markets or regions is in line with the short-term and long-term strategy of the business. Additionally, we have expanded our participation in certain state sponsored quality incentive programs that reward providers for achievement of certain quality measures.

On December 1, 2020, the Company entered into an agreement with Omega to transfer operations of the facility located in Florida to another operator. The agreement effectively amended the Master Lease to remove this center, reduced the annual rent expense, and released the Company from any further obligations arising under the Master Lease with respect to the Florida facility.

Effective November 1, 2020, the Company entered into agreements with a third party therapy company to outsource the therapy services that were previously provided by the Company through its wholly owned subsidiary Diversicare Therapy Services. The outsourced services include all physical, occupational, and speech therapy provided to patients of the Company's facilities. The contracts are for a three year term, absent termination for cause by either party. The third party provider has extensive expertise in providing therapy, and the Company believes that the therapy company's expertise in this area will benefit our patients and result in an overall operational cost savings for the Company.

On December 1, 2018, the Company sold three Kentucky properties for a purchase price of $18.7 million, which are collectively referred to as the "Kentucky Properties." On August 30, 2019, the Company terminated operations of ten centers in Kentucky and concurrently transferred operations to a new operator. These ten centers are collectively referred to as the "Kentucky Centers." The sale of the Kentucky Properties and the termination of operations at the Kentucky Centers are referred to collectively as the "Kentucky Exit." As a result of the Kentucky Exit, the Company no longer operates any skilled nursing centers in the State of Kentucky. The Kentucky Exit represents a strategic shift that has (or will have) a major effect on the Company's operations and financial results. In accordance with ASC 205, the Company's discontinued operating results have been reclassified on the face of the income statement and footnotes to reflect the discontinued status of these operations. Refer to Note 4, "Discontinued Operations" to the consolidated financial statements.

During 2019, the Company expanded its participation in the Texas Quality Incentive Program as administered by the Texas Health and Human Services Commission. QIPP provides supplemental Medicaid payments for skilled nursing centers that achieve certain quality measures. The Company previously had one of its Texas skilled nursing centers participating in the QIPP. During April 2019, the Company enrolled an additional eleven of its Texas skilled nursing centers in the program, such that twelve of the Company’s centers participate in the QIPP effective September 1, 2019. To allow four of these centers to meet the QIPP participation requirements, the Company entered into a transaction with a Texas medical district already participating in the QIPP, providing for the transfer of the related provider licenses from the Company to the medical district. The Company’s operating subsidiary retained the management of the centers on behalf of the medical district. In response to the

34

COVID-19 pandemic, the Texas Health and Human Services Commission waived some of the performance and reporting requirements for QIPP effective March 1, 2020 for the remainder of state fiscal year 2021.

On October 1, 2018, the Company entered into a new Master Lease Agreement (the "Omega Master Lease") with Omega Healthcare Investors ("Omega") to lease 34 centers currently owned by Omega and operated by Diversicare. The old Master Lease with Omega provided for its operation of 23 skilled nursing centers in Texas, Kentucky, Alabama, Tennessee, Florida, and Ohio. Additionally, Diversicare operated 11 centers owned by Omega under separate leases in Missouri, Kentucky, Indiana, and Ohio. The Omega Master Lease entered into by Diversicare and the Lessor consolidated the leases for all 34 centers under one new master lease. The Lease has an initial term of twelve years with two optional 10 year extensions. The Omega Master Lease has a common date of annual lease fixed escalators of 2.15% beginning on October 1, 2019. The Omega Master Lease was subsequently amended on August 30, 2019 when the Company terminated operations of ten centers in Kentucky and concurrently transferred operations to a new operator. The agreement effectively amended the Omega Master Lease to remove the ten Kentucky facilities, reduce the annual rent expense, and release the Company from any further obligations arising under the Omega Master Lease with respect to the Kentucky facilities. The remaining Omega Master Lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15% beginning on October 1, 2019.

Basis of Financial Statements.

Our patient revenues consist of the fees charged for the care of patients in the nursing centers we own and lease. Our operating expenses include the costs, other than lease, depreciation and amortization expenses, incurred in the operation of the nursing centers we own and lease. Our general and administrative expenses consist of the costs of the corporate office and regional support functions. Our interest, depreciation and amortization expenses include all such expenses across the range of our operations.

35

Selected Financial and Operating Data

The following table summarizes the Diversicare statements of continuing operations for the years ended December 31, 2020 and 2019, and sets forth this data as a percentage of "Patient revenues, net" for the same year:

	Year Ended December 31,
	(Dollars in thousands)
	2020				2019
Patient revenues, net	$	475,718	100.0	%	$	475,020	100.0	%
Other operating income	23,802		5.0	%	—		—	%
Expenses:
Operating	389,248		81.8	%	380,870		80.2	%
Lease and rent expense	54,001		11.4	%	52,990		11.2	%
Professional liability	8,310		1.7	%	6,996		1.5	%
Government settlement expense	—		—	%	3,100		0.7	%
General & administrative	27,691		5.8	%	28,009		5.9	%
Depreciation and amortization	9,069		1.9	%	9,122		1.9	%
	488,319		102.6	%	481,087		101.4	%
Operating income (loss)	11,201		2.4	%	(6,067)		(1.4)	%
Other income (expense):
Other income	53		—	%	281		0.1	%
Interest expense, net	(5,008)		(1.1)	%	(5,994)		(1.3)	%
Debt retirement costs	(247)		(0.1)	%	—		—	%
	(5,202)		(1.2)	%	(5,713)		(1.2)	%
Income (loss) from continuing operations before income taxes	5,999		1.2	%	(11,780)		(2.6)	%
Benefit (provision) for income taxes	531		0.1	%	(15,694)		(3.3)	%
Income (loss) from continuing operations	$	6,530	1.3	%	$	(27,474)	(5.9)	%

Critical Accounting Policies and Judgments

A “critical accounting policy” is one which is both important to the understanding of our financial condition and results of operations and requires management's most difficult, subjective or complex judgments, often of the need to make estimates about the effect of matters that are inherently uncertain. Actual results could differ from those estimates and cause our reported net income (loss) to vary significantly from period to period. Our accounting policies that fit this definition include the following:

Revenues

Patient Revenues, Net

The Company uses an estimate of variable considerations to arrive at the transaction price, including methods and assumptions used to determine settlements with Medicare and Medicaid payors.  See Note 5, “Revenue Recognition and Receivables.”

Recognition of CARES Act and PPPHCE Act Funds

The Company implemented certain changes to our accounting policies related to the recognition of stimulus funds through the CARES Act and the PPPHCE Act. There is no U.S. GAAP that covers accounting for government "grants" to for-profit entities with the exception of certain agricultural subsidies. In the absence of authoritative U.S. GAAP guidance, the Company considered the application of other authoritative accounting guidance by analogy and concluded that the guidance outlined in International Accounting Standard 20 - Accounting for Government Grants and Disclosures of Government Assistance ("IAS 20") was the most appropriate analogy for the purpose of recording and classifying the federal and state grant funds received by the Company. Under IAS 20, once it is reasonably assured that the entity will comply with the conditions of the grant, the grant money should be recognized on a systematic basis over the periods in which the entity recognizes the related expenses or losses for which the grant money is intended to compensate. The Company recognizes grants once both of the following conditions are met: (1) the Company is eligible to receive the grant, and (2) the Company is able to comply with the relevant conditions of the grant. In accordance with such conditions, Federal and state stimulus funds that are recognized to offset healthcare related

36

expenses and/or lost revenue, as defined in the CARES Act and PPPHCE Act, are reflected as "other operating income" on the accompanying interim consolidated statement of operations. Federal stimulus funds received and used toward capital improvements that assist with the response to and prevention and spread of COVID-19 are accounted for as a capital grant. For such an asset acquired with the use of stimulus funds, the Company will recognize the asset as a net zero asset. Refer to Note 2, "COVID-19 Pandemic" for additional information. Additionally, the Company has received Medicaid stimulus funds, which are recognized in accordance with ASC 606. Refer to Note 5, "Revenue Recognition and Receivables" for additional information.

Professional Liability and Other Self-Insurance Reserves

Accrual for Professional and General Liability Claims

The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, consolidated offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), which has issued a policy insuring claims made against all of the Company's nursing centers in Florida and Tennessee, several of the Company’s nursing centers in Alabama, Ohio, and Texas and several of the Company's prior nursing centers in Kentucky for claims prior to the transfer of such operation. The insurance coverage provided for these centers under the SHC policy include coverage limits of $1.0 million per medical incident with a sublimit per center of $3.0 million and total annual aggregate policy limits of $5.0 million. All other centers within the Company’s portfolio are covered through various commercial insurance policies which provide coverage limits of $1.0 million per claim and have sublimits of $3.0 million per center, with varying aggregate policy limits and deductibles. The deductibles for these policies vary in amount and are covered through the insurance subsidiary.

Because our actual liability for existing and anticipated professional liability and general liability claims will exceed our limited insurance coverage, we have recorded total liabilities for reported professional liability claims and estimates for incurred but unreported claims of $24.7 million and $1.0 million of estimated insurance recovery receivables as of December 31, 2020, including $3.5 million for settlements that are expected to be paid in 2021, estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, and estimates of related legal costs incurred and expected to be incurred. All losses are projected on an undiscounted basis. The payments due under the government settlement agreement are not included in this reserve.

The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, the actuary has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. The actuary primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods.

On a quarterly basis, we obtain reports of asserted claims and lawsuits from our insurers and a third party claims administrator. These reports contain information relevant to the liability actually incurred to date with that claim as well as the third-party administrator's estimate of the anticipated total cost of the claim. This information is reviewed by us quarterly and provided to the actuary semi-annually. We use this information to determine the timing of claims reporting and the development of reserves and compare the information obtained to our previously recorded estimates of liability. Based on the actual claim information obtained, on the semi-annual estimates received from the actuary and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Final determination of our actual liability for claims incurred in any given period is a process that takes years.

The Company's cash expenditures for self-insured professional liability costs from continuing operations were $5.5 million and $4.6 million for the years ended December 31, 2020 and 2019, respectively.

Although we retain a third-party actuarial firm to assist us, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of our actual liability for claims incurred in any given period is a process that takes years. As a result, our actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given quarter due to the significance of judgments and estimates.

Professional liability costs are material to our financial position, and changes in estimates, as well as differences between estimates and the ultimate amount of loss, may cause a material fluctuation in our reported results of operations. Our professional liability expense was $8.3 million and $7.0 million for the years ended December 31, 2020 and 2019, respectively. These amounts are material in relation to our reported income (loss) from continuing operations for the related periods of $6.5 million and $(27.5) million, respectively. The total liability recorded at December 31, 2020 was $24.7 million, compared to current assets of $97.3 million and total assets of $439.9 million.

37

Accrual for Other Self-Insured Claims

With respect to workers' compensation insurance, substantially all of our employees are covered under either a prefunded deductible policy or state-sponsored programs. We have been and remain a non-subscriber to the Texas workers' compensation system and are, therefore, completely self-insured for employee injuries with respect to our Texas operations. For the period from July 1, 2008 through December 31, 2020, we are covered by a prefunded deductible policy. Under this policy, we are self-insured for the first $0.5 million per claim, subject to an aggregate maximum of $3.0 million. We fund a loss fund account with the insurer to pay for claims below the deductible. We account for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred.

We are self-insured for health insurance benefits for certain employees and dependents for amounts up to $0.2 million per individual annually. We provide reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate, based on known claims and estimates of unknown claims based on historical information. The differences between actual settlements and reserves are included in expense in the period finalized. Our reserves for health insurance benefits can fluctuate materially from one year to the next depending on the number of significant health issues of our covered employees and their dependents.

Asset Impairment

We evaluate our property, equipment, right-of-use assets, and other long-lived assets on a quarterly basis to determine if facts and circumstances suggest that the assets may be impaired or that the estimated depreciable life of the asset may need to be changed for significant physical changes in the property, or significant adverse changes in general economic conditions, and significant deteriorations of the underlying cash flows or fair values of the property if impairment indicators exist. The need to recognize impairment is based on estimated undiscounted future cash flows from an asset compared to the carrying value of that asset. If recognition of impairment is necessary, it is measured as the amount by which the carrying amount of the asset exceeds the fair value of the asset.

No impairment of long lived assets was recognized during 2020 and 2019. If our estimates or assumptions with respect to an asset change in the future, we may be required to record impairment charges for our assets.

Income Taxes

Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. We generally expect to fully utilize our deferred tax assets; however, when necessary, we record a valuation allowance to reduce our net deferred tax assets to the amount that is more likely than not to be realized.

In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, we make certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with our estimates and assumptions, actual results could differ.

38

Contractual Obligations and Commercial Commitments

We have certain contractual obligations of continuing operations as of December 31, 2020, summarized by the period in which payment is due, as follows (dollar amounts in thousands):

Contractual Obligations	Total		Less than 1  year		1 to 3 Years		3 to 5 Years		After 5 Years
Long-term debt obligations (1)	$	70,277	$	5,054	$	65,203	$	20	$	—
Settlement obligations (2)	3,538		3,538		—		—		—
Settlement of civil investigative demand (3)	9,732		1,203		2,838		5,691		—
Operating leases (4)	405,287		51,165		105,262		106,985		141,875
Required capital expenditures under operating leases (5)	15,550		1,969		3,938		3,938		5,705
Total	$	504,384	$	62,929	$	177,241	$	116,634	$	147,580

(1)Long-term debt obligations include scheduled future payments of principal and interest of long-term debt and amounts outstanding on our finance lease obligations. Our long-term debt obligations decreased $11.0 million between December 31, 2019 and December 31, 2020. See Note 8, "Long-Term Debt, Interest Rate Swap and Finance Lease Obligations" to the consolidated financial statements included in this report for additional information.

(2)Settlement obligations relate to professional liability cases that are expected to be paid within the next twelve months. The professional liabilities are included in our current portion of self-insurance reserves.

(3)Settlement of civil investigative demand relates to our settlement agreement, including interest, with the U.S. Department of Justice and the State of Tennessee. See additional description of our contingencies in Note 12, "Commitments and Contingencies" to the consolidated financial statements and "Item 3. Legal Proceedings."

(4)Represents minimum annual lease payments (exclusive of taxes, insurance, and maintenance costs) under our operating lease agreements, which does not include renewals. Our operating lease obligations decreased $58.4 million between December 31, 2019 and December 31, 2020, which was due to the amendments to the Omega Master Lease relating to the transfer of operations of the Florida facility. See Note 3, "Business Developments and Other Significant Transactions" and Note 7, "Leases" to the consolidated financial statements included in this report for additional information.

(5)Includes annual expenditure requirements under operating leases. Our required capital expenditures decreased $3.1 million between December 31, 2019 and December 31, 2020. The decrease is due to the transfer of operations of the Florida facility.

Employment Agreements

We have employment agreements with certain members of management that provide for the payment to these members of amounts up to two times their annual salary in the event of a termination without cause, a constructive discharge (as defined), or upon a change of control of the Company (as defined). The maximum contingent liability under these agreements is approximately $1.5 million as of December 31, 2020. The terms of such agreements are for one year and automatically renew for one year if not terminated by us or the employee.

39

Results of Operations

As discussed in the overview at the beginning of Management's Discussion and Analysis of Financial Condition and Results of Operations, we have completed certain divestitures, acquisitions and entered several new lease agreements. We have reclassified our Consolidated Financial Statements to present certain divestitures as discontinued operations for all periods presented. The following discussion only relates to our continuing operations.

(in thousands)	Year Ended December 31,
	2020		2019		Change		%
PATIENT REVENUES, NET	$	475,718	$	475,020	$	698	0.1	%
OTHER OPERATING INCOME	23,802		—		23,802		100.0	%
EXPENSES:
Operating	389,248		380,870		8,378		2.2	%
Lease and rent expense	54,001		52,990		1,011		1.9	%
Professional liability	8,310		6,996		1,314		18.8	%
Government settlement expense	—		3,100		(3,100)		(100.0)	%
General and administrative	27,691		28,009		(318)		(1.1)	%
Depreciation and amortization	9,069		9,122		(53)		(0.6)	%
Total expenses	488,319		481,087		7,232		1.5	%
OPERATING INCOME (LOSS)	11,201		(6,067)		17,268		N/M
OTHER INCOME (EXPENSE):
Other income	53		281		(228)		N/M
Interest expense, net	(5,008)		(5,994)		986		16.4	%
Debt retirement costs	(247)		—		(247)		(100.0)	%
	(5,202)		(5,713)		511		8.9	%
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	5,999		(11,780)		17,779		N/M
BENEFIT (PROVISION) FOR INCOME TAXES	531		(15,694)		16,225		N/M
INCOME (LOSS) FROM CONTINUING OPERATIONS	$	6,530	$	(27,474)	$	34,004	N/M
NET INCOME (LOSS) PER COMMON SHARE:
Continuing operations per common share - basic	$	0.99	$	(4.25)	$	5.24	123.3	%
Continuing operations per common share - diluted	$	0.97	$	(4.25)	$	5.22	122.8	%
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	6,615		6,459
Dilutive	6,705		6,459

N/M = Not Meaningful

40

Year Ended December 31, 2020 Compared With Year Ended December 31, 2019

Patient Revenues

Patient revenues were $475.7 million in 2020 and $475.0 million in 2019, an increase of $0.7 million or 0.1%.

Our same store average Medicare, Medicaid and Managed Care rates per patient day for the twelve months ended December 31, 2020 increased compared to the year ended December 31, 2019, by 7.6%, 1.5%, and 6.0%, respectively, resulting in increases in revenue of $5.1 million, $3.8 million , and $2.2 million, respectively. Our Medicare average daily census for the year ended December 31, 2020 increased 6.9% resulting in $6.1 million in additional revenue. Conversely, our Medicaid, Private, Managed Care and Veterans average daily census for the year ended December 31, 2020 decreased 11.8%, 17.8%, 4.0% and 48.6%, respectively, resulting in revenue losses of $29.8 million, $5.9 million, $1.5 million and $1.1 million, respectively. The decline in census for the year ended December 31, 2020 was mainly due to the impact of the COVID-19 pandemic. We recognized Medicaid and Hospice state stimulus funds of $16.1 million and $0.8 million, respectively, during the year ended December 31, 2020. Additionally, the suspension of sequestration resulted in an increase in revenue of $1.8 million for the year ended December 31, 2020. The QIPP and Intergovernmental Transfer revenues ("IGT") resulted in $3.0 million of additional revenues for the year ended December 31, 2020 compared to the year ended December 31, 2019.

The following table summarizes key revenue and census statistics for continuing operations for each period:

	Year Ended December 31,
	2020			2019
Skilled nursing occupancy	70.5		%	77.5		%
As a percent of total census:
Medicaid census	66.9		%	68.9		%
Medicare census	10.9		%	9.3		%
Managed Care census	5.0		%	4.6		%
As a percent of total revenues:
Medicaid revenues	45.6		%	46.9		%
Medicare revenues	19.8		%	17.0		%
*Average rate per day:
Medicare	$	497.63		$	462.39
Medicaid	$	182.21		$	179.25
Managed Care	$	417.57		$	392.94
*Excludes COVID-19 federal and state stimulus payments

Other Operating Income

During the year ended December 31, 2020, we received $47.2 million of provider relief from the CARES Act, PPHCE Act, and the Families First Coronavirus Response Act. We recognized $19.8 million of the provider relief funds during the year ended December 31, 2020, which is classified as "Other Operating Income" in the Company's results of operations. We also recognized $4.0 million of grant funds from states, which is included in "Other Operating Income" in the Company's results of operations for the year ended December 31, 2020. The Medicare stimulus funds that we recognized during the year were used to offset healthcare-related expenses and lost revenues attributable to COVID-19. Increased healthcare related expenses included but were not limited to increased wages and increased costs of personal protective equipment, testing and other supplies. Refer to Note 2, "COVID-19 Pandemic to the consolidated financial statements for further discussion.

Operating Expense

Operating expense increased to $389.2 million in 2020 from $380.9 million in 2019. Operating expense increased to 81.8% of patient revenue in 2020, compared to 80.2% of patient revenue in 2019.

The primary driver for the increase in operating expense was incremental healthcare-related expenses attributable to COVID-19 of $32.3 million. Such expenses included increased labor expenses and increased cost for personal protective equipment, testing, food and certain other supplies. Excluding the COVID-19 related impacts, we benefited from our cost saving initiatives including decreased wages of $14.4 million. Additionally, our nursing and ancillary and health insurance costs decreased by $4.9 million, and $2.3 million, respectively.

41

Lease Expense

Lease expense increased to $54.0 million in 2020 from $53.0 million in 2019, an increase of $1.0 million, or 1.9%. The increase in lease expense was due to rent increases resulting from the amendment to the Lease with Omega Healthcare Investors in conjunction with the Kentucky Exit as well as annual rent escalation provisions.

Professional Liability

Professional liability expense was $8.3 million in 2020 compared to $7.0 million in 2019, an increase of $1.3 million, or 18.8%. Our cash expenditures for professional liability costs, including the State of Kentucky, were $5.5 million and $4.6 million for 2020 and 2019, respectively. Professional liability expense and cash expenditures fluctuate from year to year based respectively on the results of our third-party professional liability actuarial studies, the premium costs of purchased insurance, and on the costs incurred in defending and settling existing claims. See “Liquidity and Capital Resources” for further discussion of the accrual for professional liability.

Government Settlement Expense

In June 2019, the Company and the U.S. Department of Justice reached an agreement in principle on the financial terms of a settlement regarding a civil investigative demand. In anticipation of the execution of final agreements and payment of a settlement amount of $9.5 million, the Company recorded an additional contingent liability related to the DOJ investigation of $3.1 million during the twelve months ended December 31, 2019 to increase our previously estimated and recorded liability related to this investigation. Refer to Note 12, "Commitments and Contingencies" to the consolidated financial statements for further discussion.

General and Administrative Expense

General and administrative expenses were approximately $27.7 million in 2020 compared to $28.0 million in 2019, a decrease of $0.3 million, or 1.1%. The fluctuation is due to a decrease in legal fees, travel expenses, consulting fees and postage of $1.3 million, $0.6 million, $0.3 million and $0.3 million, respectively. This was slightly offset by an increase in labor expense of $1.8 million and $0.5 million of legal and consulting fees related to the Company's debt refinance in October 2020.

Depreciation and Amortization

Depreciation and amortization expense remained consistent at $9.1 million in 2020 and in 2019.

Debt retirement costs

In connection with the Company's debt refinance that took place in October 2020, the Company recorded a write off of deferred financing costs of $0.2 million in 2020. See Note 8, "Long-Term Debt, Interest Rate Swap and Finance Lease Obligations" to the consolidated financial statements included in this report for additional information.

Interest Expense, Net

Interest expense has decreased to $5.0 million in 2020 compared to $6.0 million in 2019, a decrease of $1.0 million. The decrease was due to a decrease in the outstanding borrowings on our loan facilities.

Income (loss) from Continuing Operations before Income Taxes; Income (loss) from Continuing Operations per Common Share

As a result of the above, continuing operations reported income before taxes of $6.0 million in 2020, as compared to a loss before taxes of $11.8 million in 2019. The benefit for income taxes was $0.5 million in 2020, resulting in an effective rate of 8.9%. The provision for income taxes was $15.7 million in 2019, resulting in an effective rate of 133.2%. The fluctuation is attributable to a full valuation allowance of $18.9 million in 2019. The basic and diluted income per common share from continuing operations were $0.99 and $0.97 in 2020, respectively, compared to a basic and diluted loss per common share from continuing operations of $4.25 in 2019.

COVID-19 Impact on Continuing Operations

Since the end of the year, there have been additional cases of COVID-19 at some of our centers. The Company has continued to experience reduced occupancy and increased healthcare-related expenses attributable to COVID-19 at its centers in the form of increased wages and increased cost of personal protective equipment, food and certain other supplies. The Company expects such increased expenses to continue throughout 2021.

42

Liquidity and Capital Resources

COVID-19 Impact on Liquidity

The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business. While the Company incurred significant disruptions during the twelve months ended December 31, 2020 from the COVID-19 pandemic, it is unable to fully predict the impact that the COVID-19 pandemic will have on its liquidity, financial condition and results of operations due to numerous uncertainties. As a result of the COVID-19 pandemic, we have recognized less revenue and increased healthcare-related expenses; however, we have also received additional stimulus funds through the CARES Act, PPPHCE Act, and the Families First Coronavirus Response Act during the twelve months ended December 31, 2020, which have been used and are expected to continue to be used to mitigate the impact of the reduced revenues and increased operating expenses, and any cash flow or liquidity impacts therefrom. The increased operating expenses include increased wages and the increased cost of personal protective equipment, infection control supplies, food and dietary supplies. Refer to Note 2, "COVID-19 Pandemic."

Liquidity

Our primary source of liquidity is the net cash flows provided by the operating activities of our centers in addition to provider relief funds received. These internally generated cash flows are used to service existing debt obligations, fund required capital expenditures as well as provide cash flows for investing opportunities. In determining priorities for our cash flow, we evaluate alternatives available to us and select the ones that we believe will most benefit us over the long term. Options for our cash include, but are not limited to, capital improvements, acquisitions, and payment of existing debt obligations, as well as initiatives to improve nursing center performance. We review these potential uses and align them to our cash flows with a goal of achieving long-term success.

Net cash provided by operating activities of continuing operations totaled $48.2 million and $12.3 million in 2020 and 2019, respectively. The primary drivers for the increase in cash provided by operating activities between 2020 and 2019 are income from continuing operations and federal stimulus that was received during the twelve months ended December 31, 2020 through the CARES Act and PPPHCE. As of December 31, 2020 the Company had $25.9 million remaining federal stimulus funds. These funds are required to be used to offset lost revenues and increased expenses that both resulted from the COVID-19 pandemic. Such increased expenses include but are not limited to increased costs for personal protective equipment, employee testing and other supplies. Operating activities of discontinued operations used cash of $1.4 million and $7.0 million in 2020 and 2019, respectively.

Our cash expenditures related to professional liability claims were $5.5 million and $4.6 million for 2020 and 2019, respectively. Although we work diligently to limit the cash required to settle and defend professional liability claims, a significant judgment entered against us in one or more legal actions could have a material adverse impact on our cash flows and could result in our being unable to meet all of our cash needs as they become due.

Investing activities of continuing operations used cash of $5.6 million and $5.0 million in 2020 and 2019, respectively. The cash used for investing activities represents capital expenditures for improvements to our centers and purchases of clinical equipment to assist with fighting and slowing the spread of COVID-19.

Net cash used in financing activities of continuing operations were $13.1 million and $0.3 million in 2020 and 2019, respectively. During 2020, the Company used surplus cash to repay $13.1 million net of outstanding borrowings on our loan facilities.

Professional Liability

The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, consolidated offshore limited purpose insurance subsidiary, SHC, which has issued a policy insuring claims made against all of the Company's nursing centers in Florida and Tennessee, and several of the Company’s nursing centers in Alabama, Kentucky, Ohio, and Texas. The insurance coverage provided for these centers under the SHC policy include coverage limits of $1.0 million or $3.0 million per medical incident with a sublimit per center of $3.0 million and total annual aggregate policy limits of $5.0 million. All other centers within the Company’s portfolio are covered through various commercial insurance policies which provide coverage limits of $1.0 million per claim and have sublimits of $3.0 million per center, with varying aggregate policy limits and deductibles. The deductibles for these policies are covered through the insurance subsidiary.

As of December 31, 2020, we have recorded total liabilities for reported professional liability claims and estimates for incurred, but unreported claims of $24.7 million. Our calculation of this estimated liability is based on the Company's best estimates of the likelihood of adverse judgments with respect to any asserted claim; however, a significant judgment could be entered

43

against us in one or more of these legal actions, and such a judgment could have a material adverse impact on our financial position and cash flows.

Capital Resources

The Company maintains a credit facility with a syndicate of banks. The Company originally entered into the credit facility in May 2013, and subsequently amended the facility. As of December 31, 2019, the credit facility consisted of a mortgage loan $67.5 million, an acquisition loan with a borrowing capacity of $12.5 million, a revolver with a borrowing capacity of $40.3 million and an affiliated revolver with a borrowing capacity of $2.0 million.

On October 14, 2020, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") with a syndicate of banks, which consists of a $62.0 million mortgage loan subsequently amended ("Amended Mortgage Loan"), a $36.0 million revolver subsequently amended ("Amended Revolver") and a $2.0 million affiliated revolver amended ("Amended Affiliated Revolver"). The Amended Mortgage Loan, Amended Revolver and Amended Affiliated Revolver have a 3-year maturity through September 30, 2023. The Amended Mortgage Loan has a term of 3 years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term loan facility is based on LIBOR plus 4.0% with a 1.0% floor. The Amended Mortgage Loan balance was $61.1 million as of December 31, 2020 with an interest rate of 5.0%. The Amended Mortgage Loan consolidated the mortgage and acquisition loans. The Amended Mortgage Loan is secured by 15 owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan, the Amended Revolver and the Amended Affiliated Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver and Amended Affiliated Revolver have an interest rate of LIBOR plus 4.0% and are secured by accounts receivable and are subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.

As of December 31, 2020, we had $61.6 million of outstanding long-term debt and capital lease obligations. The $61.6 million total includes $0.5 million in capital lease obligations.

As of December 31, 2020, the Company did not have any borrowings outstanding under its revolvers compared to $15.0 million outstanding as of December 31, 2019. The Company has 4 letters of credit with a total value of $12.4 million outstanding as of December 31, 2020. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolvers and the maximum loan amount of $28.8 million, the balance available for borrowing under the revolvers was $16.4 million at December 31, 2020.

Our lending agreements contain various financial covenants, the most restrictive of which relate to debt service coverage ratios. We are in compliance with all such covenants for the period ending December 31, 2020.

Our calculated compliance with financial covenants is presented below:

	Requirement	Level at December 31, 2020
Credit Facility:
Minimum fixed charge coverage ratio	1.05:1.00	1.22:1.00
Minimum adjusted EBITDA	$13.0 million	$23.4 million
Mortgaged Centers:
EBITDAR	$10.0 million	$15.7 million
Affiliated Revolver:
Minimum adjusted EBITDA	$0.8 million	$1.8 million

Exchange Listing

As previously disclosed, on June 19, 2019, the Company received written notification  from Nasdaq stating that the Company’s Common Stock was subject to delisting from Nasdaq, pending the Company’s opportunity to request a hearing before the Nasdaq Hearings Panel. The Company appealed the Notification on August 22, 2019.  On August 27, 2019, the Company was notified by the Panel that it denied the Company’s appeal and determined to delist the Company’s Common Stock from the Nasdaq Capital Market.  Accordingly, the trading of the Company’s Common Stock was suspended on the Nasdaq Capital Market at the opening of business on August 29, 2019 and the Company's Common stock began trading on the OTCQX under the trading symbol "DVCR."  On October 11, 2019 Nasdaq filed a Form 25 with the Securities & Exchange Commission to effect the formal delisting of the Company’s common stock from the Nasdaq Capital Market, which became effective October 21, 2019. The Form 25 filing did not cause the removal of any shares of the Company’s common stock from registration under

44

the Exchange Act. The Company remains subject to the periodic reporting requirements of the Exchange Act.  Delisting from Nasdaq may adversely affect our ability to raise additional financing through the public or private sale of equity securities. 

Finance Lease Obligations

Upon acquisition of certain centers, we assume certain leases, primarily related to equipment, that constitute capital leases. Additionally, the Company leases certain technology equipment that supports the clinical systems, including electronic medical records, at our nursing centers that constitute capital leases.

As a result of the lease agreements above, we have recorded the underlying lease assets and finance lease obligations of $0.5 million and $0.9 million as of December 31, 2020 and 2019, respectively. These lease agreements provide terms of three to five years.

Receivables

Our operations could be adversely affected if we experience significant delays in reimbursement from Medicare, Medicaid and other third-party revenue sources. Our future liquidity will continue to be dependent upon the relative amounts of current assets (principally cash, accounts receivable and inventories) and current liabilities (principally accounts payable and accrued expenses). In that regard, accounts receivable can have a significant impact on our liquidity. Continued efforts by governmental and third-party payors to contain or reduce the acceleration of costs by monitoring reimbursement rates, by increasing medical review of bills for services, or by negotiating reduced contract rates, as well as any delay by us in the processing of our invoices, could adversely affect our liquidity and financial position.

Net accounts receivable attributable to patient services of continuing operations totaled $53.7 million at December 31, 2020 compared to $60.5 million at December 31, 2019, representing approximately 49 days and 54 days revenue in accounts receivable, respectively. The decrease in net accounts receivable was driven by decreased census relative to the COVID-19 pandemic as well as improved cash collections. We continue to evaluate and implement additional procedures to strengthen our collection efforts and reduce the incidence of uncollectible accounts.

Market Pressures

Since the end of the year, there have been additional cases of COVID-19 at some of our centers. The Company has continued to experience reduced occupancy and increased healthcare-related expenses attributable to COVID-19 at its centers in the form of increased wages and increased cost of personal protective equipment, food and certain other supplies. The Company expects such impacts to continue throughout 2021. We have incurred additional expenditures preparing our centers for potential outbreaks of COVID-19 and providing care to our residents during required or recommended periods of isolation as a result of increased demand and supply chain constraints. National purchasing contracts are in place for all major supplies, such as food, linens and medical supplies. These contracts assist in maintaining quality, consistency and also mitigating the impact of COVID-19 on our supply chain and the resulting price impacts.

Our team members are essential to our business. We rely on our ability to attract and retain qualified nurses, therapists, and other healthcare professionals. The market for these key personnel is highly competitive, and we could experience significant increases in our operating costs due to shortages in their availability, which has been exacerbated by the COVID-19 pandemic. Like other healthcare providers, we have at times experienced difficulties in attracting and retaining qualified personnel. We may continue to experience increases in our labor costs, primarily due to higher wages and greater benefits required to attract and retain qualified healthcare personnel, and such increases may adversely affect our profitability.

Off-Balance Sheet Arrangements

We have four letters of credit outstanding totaling approximately $12.4 million as of December 31, 2020. The letters of credit serve as security deposits for certain center leases. The letters of credit were issued under our revolving credit facility. Our accounts receivable serve as the collateral for this revolving credit facility.

Forward-Looking Statements

The foregoing discussion and analysis provides information deemed by management to be relevant to an assessment and understanding of our consolidated results of operations and financial condition. This discussion and analysis should be read in conjunction with our consolidated financial statements included herein. Certain statements made by or on behalf of us, including those contained in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere, are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those contemplated by the forward-looking statements made herein. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as "may," "will," "should," "expect," "believe," "estimate," "intend," and similar words indicating possible future expectations, events or actions. In addition to any assumptions and other factors referred to specifically in connection with such statements, other factors, many of which are beyond our ability to control or predict, could cause our actual results to differ materially from the results expressed or implied in any forward-looking statements including, but not limited to:

45

•the potential adverse effect of the COVID-19 pandemic on the economy, our patients and residents and supply chain, including, changes in the occupancy of our centers, increased operation costs in addressing COVID-19, supply chain disruptions and uncertain demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operations challenges faced by its patients served,

•the duration and severity of the COVID-19 pandemic and the extent and severity of the impact on the Company's patients and residents,

•actions governments take in response to the COVID-19 pandemic, including the introduction of public health measures and other regulations affecting our centers,

•the impact of the CARES Act, the PPPHCE Act and any other COVID-19 relief aid adopted by governments or the implementation or modifications to such acts, including any obligation of the Company to repay any stimulus payments received under such relief aid,

•perceptions regarding the safety of senior living communities during and after the pandemic, changes in demand for senior living communities and our ability to adapt our sales and marketing efforts to meet the demand, changes in the acuity levels of our new residents, the disproportionate impact of COVID-19 on seniors generally and those residing in our communities,

•increased regulatory requirements, including unfunded mandatory testing, increased and enforcement actions resulting from COVID-19, including those that may limit our collection efforts for delinquent accounts and the frequency and magnitude of legal actions and liability claims that may arise due to COVID-19 or our response efforts,

•our ability to successfully integrate the operations of new nursing centers, as well as successfully operate all of our centers,

•our ability to increase census at our centers and occupancy rates at our centers,

•changes in governmental reimbursement, including the new Patient-Driven Payment Model that was implemented in October of 2019,

•government regulation,

•the impact of the Affordable Care Act, efforts to repeal or further modify the Affordable Care Act, and other health care reform initiatives,

•any increases in the cost of borrowing under our credit agreements,

•our ability to comply with covenants contained in those credit agreements,

•our ability to comply with the terms of our master lease agreements,

•our ability to renew or extend our leases at or prior to the end of the existing lease terms,

•the outcome of professional liability lawsuits and claims,

•our ability to control ultimate professional liability costs,

•the accuracy of our estimate of our anticipated professional liability expense,

•the impact of future licensing surveys,

•our ability to comply with the terms of our Corporate Integrity Agreement,

•the outcome of proceedings alleging violations of state or Federal False Claims Acts,

•laws and regulations governing quality of care or other laws and regulations applicable to our business including HIPAA and laws governing reimbursement from government payors,

•the costs of investing in our business initiatives and development,

•our ability to control costs,

•our ability to attract and retain qualified healthcare professionals,

•changes to our valuation of deferred tax assets,

•changing economic and competitive conditions,

•changes in anticipated revenue and cost growth,

•changes in the anticipated results of operations,

•the effect of changes in accounting policies as well as others.  

46

Investors also should refer to the risks identified in this “Management's Discussion and Analysis of Financial Condition and Results of Operations” as well as risks identified in “Part I. Item 1A. Risk Factors” for a discussion of various risk factors of the Company and that are inherent in the health care industry. Given these risks and uncertainties, we can give no assurances that these forward-looking statements will, in fact, transpire and, therefore, caution investors not to place undue reliance on them. These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from anticipated results. These risks and uncertainties also may result in changes to the Company’s business plans and prospects. Such cautionary statements identify important factors that could cause our actual results to materially differ from those projected in forward-looking statements. In addition, we disclaim any intent or obligation to update these forward-looking statements.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The chief market risk factor affecting our financial condition and operating results is interest rate risk. As of December 31, 2020, we had outstanding borrowings of approximately $61.1 million, which were subject to variable interest rates.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Audited financial statements are contained on pages F-1 through F-33 of this Annual Report on Form 10-K and are incorporated herein by reference. Audited supplemental schedule data is contained on pages S-1 through S-2 of this Annual Report on Form 10-K and is incorporated herein by reference.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Not applicable.

ITEM 9A. CONTROLS AND PROCEDURES

Diversicare, with the participation of our principal executive and financial officers, has evaluated the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended, as of December 31, 2020. Based on this evaluation, the principal executive and financial officers have determined that such disclosure controls and procedures are effective to ensure that information required to be disclosed in our filings under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities Exchange Commission's rules and forms.

Management's Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended). Our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on this evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2020. Management reviewed the results of its assessment with our Audit Committee.

Changes in Internal Control over Financial Reporting

We implemented certain changes to our accounting processes and control activities related to the COVID-19 pandemic, specifically for identifying, capturing and recording all COVID-19 expenses, calculating lost revenue and recognizing stimulus revenue and other operating income. We continue to assess the potential impact of COVID-19 to our control environment and make changes as necessary.

Other than the items described above, there have been no changes to our internal control over financial reporting during the fiscal year ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Our management does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of

47

future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

ITEM 9B. OTHER INFORMATION

None.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Information concerning our Directors, Executive Officers and Corporate Governance is incorporated herein by reference to our definitive proxy statement for our 2021 Annual Meeting of Shareholders, which we will file within 120 days of the end of the fiscal year to which this Report relates.

ITEM 11. EXECUTIVE COMPENSATION

Information concerning Executive Compensation is incorporated herein by reference to our definitive proxy statement for our 2021 Annual Meeting of Shareholders, which we will file within 120 days of the end of the fiscal year to which this Report relates.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS

Information concerning Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters is incorporated herein by reference to our definitive proxy statement for our 2021 Annual Meeting of Shareholders, which we will file within 120 days of the end of the fiscal year to which this Report relates.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Information concerning Certain Relationships and Related Transactions, and Director Independence is incorporated herein by reference to our definitive proxy statement for our 2021 Annual Meeting of Shareholders, which we will file within 120 days of the end of the fiscal year to which this Report relates.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

Information concerning the fees and services provided by our principal accountant is incorporated herein by reference to our definitive proxy statement for our 2021 Annual Meeting of Shareholders, which we will file within 120 days of the end of the fiscal year to which this Report relates.

48

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

The Financial statements and schedule for us and our subsidiaries required to be included in Part II, Item 8 are listed below.

	Form 10-K Pages
Financial Statements
Report of Independent Registered Public Accounting Firm	F-1
Consolidated Balance Sheets as of December 31, 2020 and 2019	F-2
Consolidated Statements of Operations for the Years Ended December 31, 2020 and 2019	F-3
Consolidated Statements of Comprehensive Income (Loss) for the Years Ended December 31, 2020 and 2019	F-4
Consolidated Statements of Shareholders' Equity (Deficit) for the Years Ended December 31, 2020 and 2019	F-5
Consolidated Statements of Cash Flows for the Years Ended December 31, 2020 and 2019	F-6
Notes to Consolidated Financial Statements as of December 31, 2020 and 2019	F-8 to F-33
Financial Statement Schedule
Schedule II - Valuation and Qualifying Accounts	S-1 to S-2

Exhibits

The exhibits filed as part of this Report on Form 10-K are listed in the Exhibit Index below.

ITEM 16. FORM 10-K SUMMARY

None.

49

Exhibit
Number	Description of Exhibits

3.1	Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Company's Registration Statement No. 33-76150 on Form S-1, filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
3.2	Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.5 to the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2006).
3.3	Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company's Registration Statement No. 33-76150 on Form S-1, filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
3.4	Bylaw Amendment adopted November 5, 2007 (incorporated by reference to Exhibit 3.4 to the Company's annual report on Form 10-K for the year ended December 31, 2007).
3.5	Amendment to Certificate of Incorporation dated March 23, 1995 (incorporated by reference to Exhibit A of Exhibit 1 to the Company's Form 8-A filed March 30, 1995, filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
3.6	Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.4 to the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2001).
3.7	Certificate of Ownership and Merger of Diversicare Healthcare Services, Inc. with and into Advocat Inc. (incorporated by reference to Exhibit 3.1 to the Company's current report on Form 8-K filed March 14, 2013).
3.8	Amendment to Certificate of Incorporation dated June 9, 2016 (incorporated by reference to Exhibit 3.8 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2016).
3.9	Bylaw Second Amendment adopted April 14, 2016 (incorporated by reference to Exhibit 3.9 to the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2017.
4.1	Form of Common Stock Certificate (incorporated by reference to Exhibit 4 to the Company's Registration Statement No. 33-76150 on Form S-1, filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
4.2	Description of each class of securities registered under Section 12 of the Exchange Act.
*10.1	Master Agreement and Supplemental Executive Retirement Plan (incorporated by reference to Exhibit 10.6 to the Company's Registration Statement No. 33-76150 on Form S-1, filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
10.2	Form of Director Indemnification Agreement (incorporated by reference to Exhibit 10.8 to the Company's Registration Statement No. 33-76150 on Form S-1, filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
10.3	Management Agreement effective October 1, 2000, between Diversicare Leasing Corp. and Diversicare Management Services Co. (incorporated by reference to Exhibit 10.85 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2000).
*10.4	Advocat Inc. 2010 Long-Term Incentive Plan (incorporated by reference to Appendix A to the Company's Definitive Proxy Statement on Schedule 14A filed on April 28, 2010).
*10.5	First Amendment to the Diversicare Healthcare Services, Inc. 2010 Long-Term Incentive Plan (incorporated by reference to Appendix A to the Company's Definitive Proxy Statement on Schedule 14A filed on April 26, 2017).
*10.6	Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (incorporated by reference to Appendix A to the Company's Definitive Proxy Statement on Schedule 14A filed May 2, 2008).

50

*10.7	Employment Agreement effective January 1, 2013, between Leslie Campbell and Advocat Inc. (incorporated by reference to Exhibit 10.49 to the Company’s annual report on Form 10-K for the year ended December 31, 2012).
10.8	Second Amended and Restated Term Loan and Security Agreement dated February 26, 2016 (incorporated by reference to exhibit 10.1 to the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2016).
10.9	Second Amended and Restated Guaranty (Revolver) dated as of February 26, 2016, by the Company to and for the benefit of The PrivateBank in its capacity as administrative agent (incorporated by reference to Exhibit 10.29 to the Company's Annual Report of Form 10-K for the year ended December 31, 2018).
10.10	Second Amended and Restated Guaranty (Term) dated as of February 26, 2016, by the Company to and for the benefit of The PrivateBank in its capacity as administrative agent(incorporated by reference to Exhibit 10.30 to the Company's Annual Report of Form 10-K for the year ended December 31, 2018).
10.11	Third Amended and Restated Revolving Loan and Security Agreement dated February 26, 2016 (incorporated by reference to exhibit 10.2 to the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2016).
*10.12	Amendment to Diversicare Healthcare Services, Inc. 2008 Employee Stock Purchase Plan for Key Personnel (incorporated by reference to exhibit 10.1 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2016).
10.13	First Amendment to Third Amended and Restated Revolving Loan and Security Agreement dated August 3, 2016 (incorporated by reference to exhibit 10.12 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2016).
10.14	First Amendment to Second Amended and Restated Term Loan and Security Agreement dated August 3, 2016 (incorporated by reference to exhibit 10.3 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2016).
10.15	Second Amendment to Third Amended and Restated Revolving Loan and Security Agreement dated October 3, 2016 (incorporated by reference to exhibit 10.3 to the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2016).
10.16	Third Amendment to the Third Amended and Restated Revolving Loan and Security Agreement dated December 29, 2016 (incorporated by reference to Exhibit 10.55 to the Company's Annual Report of Form 10-K for the year ended December 31, 2016).
**10.17	Amended and Restated Golden Living Master Lease Agreement dated November 1, 2016 (incorporated by reference to Exhibit 10.57 to the Company's Annual Report of Form 10-K for the year ended December 31, 2016).
10.18	Fourth Amendment to the Third Amended and Restated Revolving Loan And Security Agreement dated June 30, 2017 (incorporated by reference to exhibit 10.1 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2017).
10.19	Second Amendment to the Second Amended and Restated Term Loan and Security Agreement dated June 30, 2017 (incorporated by reference to exhibit 10.2 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2017).
10.20	Fifth Amendment to Third Amended and Restated Revolving Loan and Security Agreement dated February 27, 2018 (incorporated by reference to Exhibit 10.61 to the Company's Annual Report of Form 10-K for the year ended December 31, 2017).
10.21	Third Amendment to Second Amended and Restated Term Loan and Security Agreement dated February 27, 2018 (incorporated by reference to Exhibit 10.62 to the Company's Annual Report on Form 10-K for the year ended December 31, 2017).
*10.22	Employment Agreement effective September 10, 2018, between Kerry D. Massey and Diversicare Healthcare Services, Inc. (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed September 5, 2018).
*10.23	Amended Employment Agreement effective July 6, 2018, between James R. McKnight, Jr. and Diversicare Healthcare Services, Inc. (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed September 20, 2018).

**10.24	Master Lease Agreement Effective October 1, 2018 by and between the Company and Omega Healthcare Investors (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2018).
10.25	Amended and Restated Guaranty in favor of Omega Healthcare Investors, Inc. dated October 1, 2018. (incorporated by reference to Exhibit 10.46 to the Company's Annual Report on Form 10-K for the year ended December 31, 2018).
10.26	Amended and Restated Security Agreement dated October 1, 2018 by and among the Company and a syndicate of financial institutions and banks (incorporated by reference to Exhibit 10.48 to the Company's Annual Report on Form 10-K for the year ended December 31, 2018).
10.27	Fourth Amendment to Second Amended and Restated Term Loan and Security Agreement dated December 1, 2018 (incorporated by reference to Exhibit 10.49 to the Company's Annual Report on Form 10-K for the year ended December 31, 2018).
10.28	Sixth Amendment to Third Amended and Restated Revolving Loan and Security Agreement dated December 1, 2018 (incorporated by reference to Exhibit 10.50 to the Company's Annual Report on Form 10-K for the year ended December 31, 2018).
10.29	Seventh Amendment to Third Amended and Restated Revolving Loan and Security Agreement dated May 13, 2019 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2019).
10.30	Fifth Amendment to Second Amended and Restated Term Loan and Security Agreement dated May 13, 2019 (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2019).
10.31	First Amendment to Omega Master Lease Agreement dated August 20, 2019 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019).
10.32	Eighth Amendment to Third Amended and Restated Revolving Loan and Security Agreement dated February 25, 2020 (incorporated by reference to Exhibit 10.36 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019).
10.33	Sixth Amendment to Second Amended and Restated Term Loan and Security Agreement dated February 25, 2020 (incorporated by reference to Exhibit 10.37 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019).
10.34	First Amendment to Revolving Loan and Security Agreement dated February 25, 2020 (incorporated by reference to Exhibit 10.38 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019).
10.35	Settlement Agreement with the U.S. Department of Justice and the State of Tennessee dated February 14, 2020 (incorporated by reference to Exhibit 10.39 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019).
10.36	Corporate Integrity Agreement with the Office of the Inspector General of CMS dated February 14, 2020 (incorporated by reference to Exhibit 10.40 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019).
*10.37	Leslie Campbell Separation Agreement (incorporated by reference to Exhibit 10.6 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020).
*10.38	Employment Agreement effective March 2, 2020, between Rebecca Bodie and Diversicare Healthcare Services, Inc. (incorporated by reference to Exhibit 10.7 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020).
10.39	Ninth Amendment to Third Amended and Restated Revolving Loan and Security Agreement Ninth Amendment to Third Amended and Restated Revolving Loan and Security Agreement dated April 3, 2020 (incorporated by reference to Exhibit 10.8 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020).
10.40	Seventh Amendment to Second Amended and Restated Term Loan and Security Agreement dated April 3, 2020 (incorporated by reference to Exhibit 10.9 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020).

10.41		Second Amendment to Revolving Loan and Security Agreement dated April 3, 2020 (incorporated by reference to Exhibit 10.10 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020).
10.42		Third Amended and Restated Term Loan and Security Agreement dated October 14, 2020 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020).
10.43		Fourth Amended Revolver and Security Agreement dated October 14, 2020 (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020).
10.44		Amended and Restated Revolving Loan and Security Agreement dated October 14, 2020 by and among affiliates of the Registrant and CIBC Bank (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020).
21		Subsidiaries of the Registrant.
23.1		Consent of BDO USA, LLP.
31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
31.2		Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
32		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).
101.INS		XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101
	*	Indicates management contract or compensatory plan or arrangement.
	**	Confidential treatment has been requested for portions of this exhibit

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

DIVERSICARE HEALTHCARE SERVICES, INC.

/s/ Chad A. McCurdy

Chad A. McCurdy

Chairman of the Board

March 11, 2021

/s/ James R. McKnight, Jr.

James R. McKnight, Jr.

President and Chief Executive Officer

(Principal Executive Officer)

March 11, 2021

/s/ Kerry D. Massey

Kerry D. Massey

Executive Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

March 11, 2021

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

/s/ Chad A. McCurdy	/s/ Robert Z. Hensley
Chad A. McCurdy	Robert Z. Hensley
Chairman of the Board and Director	Director
March 11, 2021	March 11, 2021
/s/ James R. McKnight, Jr.	/s/ Leslie K. Morgan
James R. McKnight, Jr.	Leslie K. Morgan
President and Chief Executive Officer	Director
Director	March 11, 2021
March 11, 2021
/s/ Robert A. McCabe, Jr.	/s/ Richard M. Brame
Robert A. McCabe, Jr.	Richard M. Brame
Director	Director
March 11, 2021	March 11, 2021
/s/ Ben R. Leedle, Jr.
Ben R. Leedle, Jr.
Director
March 11, 2021

54

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

Consolidated Financial Statements

For the Years Ended December 31, 2020 and 2019     

Together with Report of Independent Registered Public Accounting Firm

55

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Report of Independent Registered Public Accounting Firm	F-1
Consolidated Balance Sheets	F-3
Consolidated Statements of Operations	F-4
Consolidated Statements of Comprehensive Income (Loss)	F-5
Consolidated Statements of Shareholders' Equity (Deficit)	F-6
Consolidated Statements of Cash Flows	F-7
Notes to Consolidated Financial Statements	F-8 to F-33
Schedule II - Valuation and Qualifying Accounts	S-1 to S-2

56

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Shareholders and Board of Directors

Diversicare Healthcare Services, Inc.

Brentwood, Tennessee

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Diversicare Healthcare Services, Inc. (the “Company”) as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive income (loss), shareholders’ equity (deficit), and cash flows for the years then ended, and the related notes and financial statement schedule listed in the accompanying index (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Reserve for Professional and General Liability Claims

As described in Note 12 to the consolidated financial statements, the Company recorded a reserve for reported and estimated future self-insured professional and general liability claims of $24.7 million as of December 31, 2020. This reserve included estimates of liabilities for incurred but not reported claims, estimates of liabilities for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. Semi-annually, the Company engages a third-party actuary to assist management in the evaluation of this reserve.

We identified the determination of the reserve for reported and estimated future self-insured professional and general liability claims as a critical audit matter. Determination of the reserve includes: (i) judgments made by management when assessing claims, especially those which extend beyond a year, including assumptions related to anticipated total cost of the claims, (ii) assumptions developed by the third-party actuary for the current-year reserves and incurred but not reported estimates, and (iii) an assessment of the completeness and accuracy of the underlying data used in the estimation process including claims incurred and claims settlements. Auditing these

F-1

aspects of the reserve involved especially challenging auditor judgment due to the nature and extent of audit effort required to address these matters, including the specialized skills and knowledge needed.

The primary procedures we performed to address this critical audit matter included:

a.Obtaining an understanding and evaluating the design and implementation of certain controls relating to management’s evaluation and assessment of the reasonableness of significant judgments and assumptions developed by the third-party actuary, as well as controls over the completeness and accuracy of the underlying data used, including claims incurred and claims settlements.

b.Evaluating sources of data and assumptions used by management in determining the reserve for reported and estimated future self-insured professional and general liability claims by evaluating the reasonableness of management’s judgments regarding open claims, performing a retrospective review of historical claims experience, and analyzing industry and historical claims data used in developing the assumptions.

c.Testing the completeness and accuracy of the underlying reported claims data provided to the Company’s actuarial specialist.

d.Utilizing professionals with specialized skill and knowledge to assist in our evaluation of the complex assumptions and methodologies applied by management’s specialist and assessing the accuracy of the Company’s reserve for estimated future self-insured professional and general liability claims.

Recognition of Amounts Received From Provider Relief Fund

As described in Note 2 to the consolidated financial statements, during the year ended December 31, 2020, the Company received $47.2 million in cash distributed from the Public Health and Social Services Emergency Fund, also known as the Provider Relief Fund, as a result of the COVID-19 pandemic. During 2020, the Company recognized $19.8 million in “other operating income” in the Company’s results of operations for the year ended December 31, 2020 and utilized $1.5 million of these funds for capital improvements to prevent the spread of COVID-19. The remaining stimulus funds of $25.9 million as of December 31, 2020 are classified as "deferred income" on the consolidated balance sheet.

We identified the recognition of income related to the Provider Relief Fund as a critical audit matter. Significant auditor judgment was involved in evaluating the Company’s interpretation of applicable guidance and regulations used in determining the amount and supportability of income recognized, including a judgmental assessment of associated terms and conditions.

The primary procedures we performed to address this critical audit matter included:

a.Obtaining an understanding and evaluating the design and implementation of certain controls relating to management’s elected framework, as well as controls over the completeness and accuracy of the underlying data used.

b.Evaluating amounts recognized under management’s elected framework, specifically reviewing the estimate of lost revenues and quantification of permissible COVID-19 related healthcare expenses for reasonableness based on guidance issued by relevant regulatory agencies, including the U.S. Department of Health and Human Services.

c.Testing the completeness and accuracy of the underlying data used in management’s elected framework.

d.Testing a sample of attestations to evidence compliance with associated terms and conditions.

/s/ BDO USA, LLP

We have served as the Company's auditor since 2002.

Nashville, Tennessee

March 11, 2021

F-2

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

DECEMBER 31, 2020 AND 2019

(in thousands, except per share amounts)

ASSETS	2020		2019		LIABILITIES AND SHAREHOLDERS' DEFICIT	2020		2019
CURRENT ASSETS:					CURRENT LIABILITIES:
Cash	$	30,821	$	2,710	Current portion of long-term debt and finance lease obligations	$	1,660	$	3,498
Receivables	53,691		60,521		Current portion of operating lease liability	28,583		23,736
Self-insurance receivables	1,025		1,011		Trade accounts payable	13,901		14,641
Other receivables	4,622		2,534		Accrued expenses:
Prepaid expenses and other current assets	5,356		5,056		Payroll and employee benefits	15,393		16,780
Income tax refundable	1,746		484		Self-insurance reserves, current portion	12,665		13,829
Total current assets	97,261		72,316		Deferred income	25,900		—
					Other current liabilities	14,743		11,545
					Total current liabilities	112,845		84,029
PROPERTY AND EQUIPMENT, at cost	135,234		132,775		NONCURRENT LIABILITIES:
Less accumulated depreciation and amortization	(91,914)		(85,020)		Long-term debt and finance lease obligations, less current portion and deferred financing costs, net	58,526		70,637
Property and equipment, net	43,320		47,755		Operating lease liability, less current portion	274,155		295,636
					Self-insurance reserves, less current portion	15,476		16,291
					Government settlement accrual	8,000		9,000
					Other noncurrent liabilities	2,155		1,691
					Total noncurrent liabilities	358,312		393,255
OTHER ASSETS:					COMMITMENTS AND CONTINGENCIES
Operating lease right-of-use assets	290,296		310,238		SHAREHOLDERS’ DEFICIT:
Other noncurrent assets	3,773		4,323		Common stock, authorized 20,000 shares, $.01 par value, 7,079 and 6,908 shares issued, and 6,847 and 6,676 shares outstanding, respectively	71		69
Acquired leasehold interest, net	5,202		5,736		Treasury stock at cost, 232 shares of common stock	(2,500)		(2,500)
Total other assets	299,271		320,297		Paid-in capital	24,596		24,026
	$	439,852	$	440,368	Accumulated deficit	(53,510)		(59,079)
					Accumulated other comprehensive income	38		568
					Total shareholders’ deficit	(31,305)		(36,916)
						$	439,852	$	440,368

The accompanying notes are an integral part of these consolidated financial statements.

F-3

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

	Years Ended December 31,
	2020		2019
PATIENT REVENUES, NET	$	475,718	$	475,020
OTHER OPERATING INCOME	23,802		—
EXPENSES:
Operating	389,248		380,870
Lease and rent expense	54,001		52,990
Professional liability	8,310		6,996
Government settlement expense	—		3,100
General and administrative	27,691		28,009
Depreciation and amortization	9,069		9,122
Total expenses	488,319		481,087
OPERATING INCOME (LOSS)	11,201		(6,067)
OTHER INCOME (EXPENSE):
Other income	53		281
Interest expense, net	(5,008)		(5,994)
Debt retirement costs	(247)		—
Total other income (expense)	(5,202)		(5,713)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	5,999		(11,780)
(PROVISION) BENEFIT FOR INCOME TAXES	531		(15,694)
INCOME (LOSS) FROM CONTINUING OPERATIONS	6,530		(27,474)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS:
Operating loss, net of income tax (provision) benefit of $365 and ($517), respectively	(1,371)		(9,322)
Gain on lease modification, net of tax	—		733
INCOME (LOSS) FROM DISCONTINUED OPERATIONS	(1,371)		(8,589)
NET INCOME (LOSS)	$	5,159	$	(36,063)
NET INCOME (LOSS) PER COMMON SHARE:
Per common share – basic
Continuing operations	$	0.99	$	(4.25)
Discontinued operations	(0.21)		(1.33)
	$	0.78	$	(5.58)
Per common share – diluted
Continuing operations	$	0.97	$	(4.25)
Discontinued operations	(0.20)		(1.33)
	$	0.77	$	(5.58)
DIVIDENDS DECLARED PER SHARE OF COMMON STOCK	$	—	$	—
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	6,615		6,459
Diluted	6,705		6,459

The accompanying notes are an integral part of these consolidated financial statements.

F-4

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in thousands)

	Years Ended December 31,
	2020		2019
NET INCOME (LOSS)	$	5,159	$	(36,063)
OTHER COMPREHENSIVE INCOME (LOSS):
Change in fair value of cash flow hedge, net of tax	(530)		(269)
Total other comprehensive income (loss)	(530)		(269)
COMPREHENSIVE INCOME (LOSS)	$	4,629	$	(36,332)

The accompanying notes are an integral part of these consolidated financial statements.

F-5

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)

(in thousands)

	Common Stock			Treasury Stock			Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Income		Total Shareholders' Equity (Deficit)
	Shares Issued	Amount		Shares	Amount
BALANCE, DECEMBER 31, 2018	6,751	$	68	232	$	(2,500)	$	23,413	$	(23,016)	$	837	$	(1,198)
Net loss	—	—		—	—		—		(36,063)		—		(36,063)
Issuance/redemption of equity grants, net	157	1		—	—		40		—		—		41
Interest rate cash flow hedge	—	—		—	—		—		—		(269)		(269)
Stock based compensation	—	—		—	—		573		—		—		573
BALANCE, DECEMBER 31, 2019	6,908	69		232	(2,500)		24,026		(59,079)		568		(36,916)
Net income	—	—		—	—		—		5,159		—		5,159
Issuance/redemption of equity grants, net	171	2		—	—		—		—		—		2
Interest rate cash flow hedge	—	—		—	—		—		410		(530)		(120)
Stock based compensation	—	—		—	—		570		—		—		570
BALANCE, DECEMBER 31, 2020	7,079	$	71	232	$	(2,500)	$	24,596	$	(53,510)	$	38	$	(31,305)

The accompanying notes are an integral part of these consolidated financial statements.

F-6

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

	Years Ended December 31,
	2020		2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$	5,159	$	(36,063)
Loss from discontinued operations	(1,371)		(8,589)
Income (loss) from continuing operations	6,530		(27,474)
Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:
Depreciation and amortization	9,069		9,122
Deferred income tax provision (benefit)	(1,227)		15,421
Provision for self-insured professional liability, net of cash payments	372		4,739
Stock based and deferred compensation	570		573
Debt retirement costs	247		—
Provision for leases, net of cash payments	3,063		3,897
Amortization of right-of-use assets	23,942		21,890
Government settlement expense	—		3,100
Other	482		1,507
Changes in other assets and liabilities affecting operating activities:
Receivables	6,816		9,200
Prepaid expenses and other assets	(3,060)		(6,693)
Trade accounts payable and accrued expenses	(579)		(1,793)
Deferred income	25,900		—
Operating lease liabilities	(23,938)		(21,154)
Net cash provided by continuing operations	48,187		12,335
Net cash used in discontinued operations	(1,371)		(7,003)
Net cash provided by operating activities	46,816		5,332
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(4,100)		(4,980)
Purchases of property and equipment with stimulus funds	(1,496)		—
Net cash used in continuing operations	(5,596)		(4,980)
Net cash provided by discontinued operations	—		6
Net cash used in investing activities	(5,596)		(4,974)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt and finance lease obligations	(81,864)		(12,541)
Proceeds from issuance of debt	68,485		12,500
Proceeds from stimulus funds used to purchase property and equipment	1,496		—
Financing costs	(1,228)		(333)
Issuance and redemption of employee equity awards	2		41
Net cash used in continuing operations	(13,109)		(333)
Net cash provided by (used in) discontinued operations	—		—
Net cash used in financing activities	(13,109)		(333)

(Continued)

F-7

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(continued)

	Years Ended December 31,
	2020		2019
NET INCREASE IN CASH	$	28,111	$	25
CASH, beginning of period	2,710		2,685
CASH, end of period	$	30,821	$	2,710
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash payments of interest	$	4,483	$	5,390
Cash payments of income taxes	$	57	$	432
SUPPLEMENTAL INFORMATION ON NON-CASH INVESTING AND FINANCING TRANSACTIONS:
Acquisition of equipment through finance lease	$	44	$	483
Acquisition of operating leases through adoption of ASC Topic 842	$	—	$	389,403
Lease modification	$	7,051	$	(48,877)

The accompanying notes are an integral part of these consolidated financial statements.

F-8

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2020 and 2019

(Dollars and shares in thousands, except per share data)

1. BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Diversicare Healthcare Services, Inc. ("Diversicare" or the "Company") provides a broad range of post-acute care services to patients and residents including skilled nursing, ancillary health care services and assisted living. In addition to the nursing and social services usually provided in long-term care centers, we offer a variety of rehabilitative, nutritional, respiratory, and other specialized ancillary services. The Company operates and reports as one reportable operating segment. The Company believes that this structure reflects its current operational and financial management.

As of December 31, 2020, our continuing operations consist of 61 nursing centers with 7,250 licensed skilled nursing beds. Our nursing centers range in size from 50 to 320 licensed nursing beds. The licensed nursing bed count does not include 397 licensed assisted living and other residential beds. Our continuing operations include centers in Alabama, Indiana, Kansas, Mississippi, Missouri, Ohio, Tennessee, and Texas. The number of centers and beds denoted in these consolidated financial statements are unaudited.

COVID-19 Pandemic

In January 2020, the Secretary of U.S. Department of Health and Human Services (“HHS”) declared a national public health emergency due to a novel coronavirus. In March 2020, the World Health Organization categorized COVID-19, a disease caused by this coronavirus (“COVID-19”), as a pandemic. According to the Centers for Disease Control and Prevention (“CDC”), older adults and people with certain underlying medical conditions are at higher risk for serious illness from COVID-19. CDC has identified nursing home populations as being at high risk of being affected by pathogens like COVID-19 as a result of the congregate nature of nursing homes and the resident population served.

The Centers for Medicare & Medicaid Services (“CMS”) and the CDC have issued guidance to state and local governments and long-term care facilities to help mitigate the spread of COVID-19. For example, on March 13, 2020, CMS issued a memorandum directing long-term care facilities to significantly restrict visitors and nonessential workers and to restrict communal activities, among other measures. On May 18, 2020, CMS provided “reopening” recommendations for state and local officials to determine the level of mitigation needed to prevent the transmission of COVID-19 in nursing homes, including criteria for relaxing various restrictions. CMS has also announced COVID-19 reporting requirements and focused infection control surveys intended to assess long-term care facility compliance with infection control requirements in connection with the COVID-19 pandemic. CDC guidance includes infection prevention and control practices intended to protect both nursing home residents and healthcare personnel.

On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which includes, among other things, modifications to the limitation on business interest expense and net operating loss provisions relative to the payment of Federal income taxes and allows an optional payment deferral of the employer's portion of Social Security taxes that were otherwise due through December 31, 2020. These provisions of the CARES Act were effective after the date of enactment and also include the appropriation of stimulus funds to Medicare and Medicaid providers. The Paycheck Protection Program and Health Care Enhancement Act ("PPPHCE Act"), enacted on April 24, 2020, and the Consolidated Appropriations Act, 2021 ("CAA"), enacted December 27, 2020, provide for additional emergency appropriations for COVID-19 response.

Together, the CARES Act, PPPHCE Act, and CAA authorize funding to healthcare entities to be distributed through the Public Health and Social Services Emergency Fund ("PHSSEF"), also known as the Provider Relief Fund. Payments from PHSSEF are intended to compensate providers for lost revenues and healthcare-related expenses attributable to the COVID-19 pandemic only. As long as the recipient has sufficient COVID-19 attributable expenses and lost revenues, as defined by the PHSSEF, between January 1, 2020 and June 30, 2021 and complies with certain terms and conditions, these payments are not required to be repaid. The terms and conditions include, among others, requirements to comply with certain reporting requirements, limitations on balance billing and restrictions against using PHSSEF funds to reimburse expenses or losses that have been reimbursed from other sources or that other sources are obligated to reimburse. On December 27, 2020, the CAA was enacted which included clarifications addressing the calculation and reporting of lost revenue. Additionally, the CAA indicated that targeted distribution payments made to an eligible entity may be allocated by the entity's parent organization among its subsidiary eligible health care providers. On January 15, 2021, HHS released additional guidance explaining the updated requirements implemented by the CAA on calculating lost revenue and the reporting process. In addition, the CAA also indicates that targeted distribution payments made to an eligible entity may be allocated by the entity's parent organization

F-9

among its subsidiary eligible health care providers, and the entity receiving the targeted distribution payments remains responsible for reporting obligations. The Company is utilizing these funds to compensate for COVID-19 attributable lost revenues and pay for permissible expenses, including but are not limited to increased wages and increased costs for personal protective equipment, infection control supplies, and COVID-19 testing. The Company is still evaluating the most recent guidance; however, the Company currently anticipates, but cannot guarantee, that it will have sufficient COVID-19 attributable expenses and lost revenues to retain the PPSSEF payments it has received to date. The Company will not be able to determine the amount of used funds until the form, process and reporting rules are finalized by the federal- government, and the Company knows the full extent of its COVID-19 attributable expenses and lost revenues. There also can be no assurance that the PHSSEF funds will ultimately be enough to reimburse the Company for the full extent of its COVID-19 attributable expenses.

In addition, we have experienced and may continue to experience supply chain disruptions, including delays and price increases in equipment, pharmaceuticals, and medical supplies. Staffing, equipment, and pharmaceutical and medical supplies and vaccine shortages may impact our ability to admit and treat patients. We have incurred, and may continue to incur, increased expenses arising from the COVID-19 pandemic. We have also experienced reduced occupancy in our centers, in part due to perceived risks by patients and family members of residential care and their perception of restrictions such as limited visitation policies, a reduction in patients released to nursing homes from hospitals and other healthcare facilities, and a general reluctance to seek medical care or interface with the healthcare system during the pandemic or for an undetermined period of time. Occupancy may also be affected by the data each nursing home is required to report, including the number of confirmed and suspected cases of COVID-19 and resident deaths related to COVID-19, which is made publicly available through the CDC National Healthcare Safety Network.

Since the end of the year, there have been additional cases of COVID-19 at certain of our centers. The Company has continued to experience reduced occupancy and increased operating expenses at its centers in the form of increased wages and increased costs for personal protective equipment, food and certain other supplies. The Company expects such increased expenses to continue and likely increase further into 2021. Refer to Note 2 "COVID-19 Pandemic" for further information.

Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the financial position, operations and accounts of Diversicare and its subsidiaries, all wholly-owned. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Revenue Recognition

The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services.

Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.

The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts, within each respective group listed below, are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).

In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of

F-10

previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes.

The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized at a point in time, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.

The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed. See Note 5, “Revenue Recognition and Receivables.”

CARES Act and PPPHCE Act Funds

During 2020, the Company implemented certain changes to our accounting policies related to the recognition of stimulus funds through the CARES Act, the PPPHCE Act and CAA. There is no U.S. GAAP that explicitly covers accounting for government "grants" to for-profit entities with the exception of certain agricultural subsidies. In the absence of authoritative U.S. GAAP guidance, the Company considered the application of other authoritative accounting guidance by analogy and concluded that the guidance outlined in International Accounting Standard 20 - Accounting for Government Grants and Disclosures of Government Assistance ("IAS 20") was the most appropriate analogy for the purpose of recording and classifying the federal and state grant funds received by the Company. Under IAS 20, once it is reasonably assured that the entity will comply with the conditions of the grant, the grant money should be recognized on a systematic basis over the periods in which the entity recognizes the related expenses or losses for which the grant money is intended to compensate. The Company recognizes grants once both of the following conditions are met: (1) the Company is eligible to receive the grant, and (2) the Company is able to comply with the relevant conditions of the grant. In accordance with such conditions, Federal and state stimulus funds that are recognized to offset healthcare related expenses and/or lost revenue attributable to COVID-19 are reflected as "other operating income" on the accompanying consolidated statement of operations. Federal stimulus funds received and used toward capital improvements that assist with the response to and prevention and spread of COVID-19 is accounted for as a capital grant. For such an asset acquired with the use of a stimulus funds, the Company will recognize the asset as a net zero asset. Refer to Note 2, "COVID-19 Pandemic" for additional information.

Additionally, the Company has received Medicaid stimulus funds, which are recognized in accordance with ASC 606. Refer to Note 5, "Revenue Recognition and Receivables" for additional information.

Lease Expense

As of December 31, 2020, the Company operates 46 nursing centers under operating leases, including 23 owned by Omega, 20 owned by Golden Living and three owned by other parties. The Company's operating leases generally require the Company to pay stated rent, subject to increases based on changes in the Consumer Price Index or a minimum percentage increase. The Company's Master Lease Agreements with Omega and Golden Living require the Company to pay certain scheduled rent increases. Such scheduled rent increases are recorded as additional lease expense on a straight-line basis recognized over the term of the related leases and the difference between the amounts recorded for rent expense as compared to rent payments is recorded as an accrued liability.

See Note 3, "Business Development and Other Significant Transactions" and Note 12, "Commitments and Contingencies" for a discussion regarding the Company's Master Lease Agreements with Omega and Golden Living and the addition of certain leased centers.

Classification of Expenses

The Company classifies all expenses (except lease, interest, depreciation and amortization expenses) that are associated with its corporate and regional management support functions as general and administrative expenses within continuing operations. All other expenses (except lease, professional liability, government settlement expense, interest, depreciation and amortization expenses) incurred by the Company at the center level for continuing operations are classified as operating expenses.

Property and Equipment

F-11

Property and equipment are recorded at cost or at fair value determined on the respective dates of acquisition for assets obtained in a business combination, with depreciation and amortization being provided over the shorter of the remaining lease term (where applicable) or the assets' estimated useful lives on the straight-line basis as follows:

Buildings and improvements	-	5 to 40 years
Leasehold improvements	-	2 to 10 years
Furniture, fixtures and equipment	-	2 to 15 years

Interest incurred during construction periods for qualifying expenditures is capitalized as part of the building cost. Maintenance and repairs are expensed as incurred, and major betterments and improvements are capitalized.

The Company routinely evaluates the recoverability of the carrying value of its long-lived assets, including property and equipment and right of use assets. The evaluation for recoverability includes when significant adverse changes in the general economic conditions and significant deteriorations of the underlying undiscounted cash flows or fair values of the asset group indicate that the carrying amount of the asset group may not be recoverable. If circumstances suggest that the recorded amounts are not recoverable based upon estimated future undiscounted cash flows, the carrying values of such assets are reduced to fair value.

Cash

Cash and cash equivalents include cash on deposit with banks and all highly liquid investments with original maturities of three months or less when purchased. Our cash on deposit with banks was subject to the Federal Deposit Insurance Corporation ("FDIC") minimum insurance levels.

Deferred Financing and Other Costs

The Company records deferred financing and lease costs for direct and incremental expenditures related to entering into or amending debt and lease agreements. These expenditures include lenders' and attorneys' fees. Financing costs are amortized using the effective interest method over the term of the related debt. The amortization is reflected as interest expense in the accompanying consolidated statements of operations. See Note 8, "Long-term Debt, Interest Rate Swap and Finance Lease Obligations" for further discussion.

Acquired Leasehold Interest

The Company has recorded an acquired leasehold interest intangible asset related to an acquisition completed during 2007. The intangible asset is accounted for in accordance with the Financial Accounting Standards Board's ("FASB") guidance on goodwill and other intangible assets, and is amortized on a straight-line basis over the remaining life of the acquired lease. As discussed in Note 3, "Business Developments and Other Significant Transactions," the Company entered into a new Master Lease Agreement (the "Omega Master Lease") with  Omega Healthcare Investors ("Omega") on October 1, 2018, which was subsequently modified on August 30, 2019. The Omega Master Lease includes the seven centers to which the intangible asset relates. As such, the intangible asset is now being amortized over an adjusted remaining life, consistent with the term of the Omega Master Lease, which goes through September 30, 2030. Amortization expense of approximately $534 and $571 related to this intangible asset was recorded during each of the years ended December 31, 2020 and 2019, respectively.

The carrying value of the acquired leasehold interest intangible and the accumulated amortization are as follows:

	December 31,
	2020		2019
Acquired leasehold interest, gross	$	10,652	$	10,652
Accumulated amortization	(5,450)		(4,916)
Acquired leasehold interest, net	$	5,202	$	5,736

The Company evaluates the recoverability of the carrying value of the acquired leasehold intangible in accordance with the FASB's guidance on accounting for the impairment or disposal of long-lived assets. Included in this evaluation is whether significant adverse changes in general economic conditions, and significant deteriorations of the underlying cash flows or fair values of the intangible asset indicate that the carrying amount of the intangible asset may not be recoverable. The need to recognize an impairment charge is based on estimated future undiscounted cash flows from the asset compared to the carrying value of that asset. If recognition of an impairment charge is necessary, it is measured as the amount by which the carrying amount of the intangible asset exceeds the fair value of the intangible asset.

The expected amortization expense for the acquired leasehold interest intangible asset is as follows:

F-12

2021	$	534
2022	534
2023	534
2024	534
2025	534
Thereafter	2,532
	$	5,202

Self-Insurance

Self-insurance liabilities primarily represent the unfunded accrual for self-insured risks associated with general and professional liability claims, employee health insurance and workers' compensation. The Company's health insurance liability is based on known claims incurred and an estimate of incurred but unreported claims determined by an analysis of historical claims paid. The Company's workers' compensation liability relates primarily to periods of self-insurance and consists of an estimate of the future costs to be incurred for the known claims.

Final determination of the Company's actual liability for incurred general and professional liability claims is a process that may take years. The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this unfunded accrual. The actuary assists management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished by the Company. The actuary primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods.

On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company's insurers and a third party claims administrator, contain information relevant to the actual expense already incurred for each claim as well as the third-party administrator's estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company's evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual has an unfavorable impact on results of operations in the period and any reduction in the accrual increases results of operations during the period.

All losses are projected on an undiscounted basis. The self-insurance liabilities include estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of related legal costs incurred and expected to be incurred.

One of the key assumptions in the actuarial analysis is that historical losses provide an accurate forecast of future losses. Changes in legislation such as tort reform, changes in our financial condition, changes in our risk management practices and other factors may affect the severity and frequency of claims incurred in future periods as compared to historical claims.

The facts and circumstances of each claim vary significantly, and the amount of ultimate liability for an individual claim may vary due to many factors, including whether the case can be settled by agreement, the quality of legal representation, the individual jurisdiction in which the claim is pending, and the views of the particular judge or jury deciding the case.

Although the Company adjusts its unfunded accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company's actual liability for claims incurred in any given period is a process that takes years. As a result, the Company's actual liabilities may vary significantly from the unfunded accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company's results of operations and financial position for the period in which the change in accrual is made.

Income Taxes

The Company follows the FASB's guidance on Income Taxes, which requires the asset and liability method of accounting for income taxes whereby deferred income taxes are recorded for the future tax consequences attributable to differences between the financial statement and tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are provided against any estimated non-realizable deferred tax assets where necessary.

F-13

Where the Company believes that a tax position is supportable for income tax purposes, the item is included in its income tax returns. Where treatment of a position is uncertain, liabilities are recorded based upon the Company’s evaluation of the “more likely than not” outcome considering the technical merits of the position. While the judgments and estimates made by the Company are based on management’s evaluation of the technical merits of a matter, historical experience and other assumptions that management believes are appropriate and reasonable under current circumstances, actual resolution of these matters may differ from recorded estimated amounts, resulting in charges or credits that could materially affect future financial statements. See Note 11, "Income Taxes" for additional information related to the provision for income taxes.

Disclosure of Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. In calculating fair value, a company must maximize the use of observable market inputs, minimize the use of unobservable market inputs and disclose in the form of an outlined hierarchy the details of such fair value measurements. The carrying amounts of cash, receivables, trade accounts payable and accrued expenses approximate fair value because of the short-term nature of these accounts. The Company's self-insurance liabilities are reported on an undiscounted basis as the timing of estimated settlements cannot be determined.

The Company follows the FASB's guidance on Fair Value Measurements and Disclosures which provides rules for using fair value to measure assets and liabilities as well as a fair value hierarchy that prioritizes the information used to develop the measurements. It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As further discussed in Note 8, "Long-term Debt, Interest Rate Swap and Finance Lease Obligations", the Company terminated its interest rate swap in conjunction with refinancing its debt in October 2020.

As the Company's interest rate swap, a cash flow hedge, was not traded on a market exchange, the fair value was determined using a valuation model based on a discounted cash flow analysis. This analysis reflected the contractual terms of the interest rate swap agreement and used observable market-based inputs, including estimated future LIBOR interest rates. The fair value of the Company's interest rate swap was the net difference in the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts were based on the expectation of future interest rates and were observable inputs available to a market participant. The interest rate swap valuation was classified in Level 2 of the fair value hierarchy. The debt balances as presented in the consolidated balance sheets approximate the fair value of the respective instruments as the debt was at a variable rate, the estimates of which were considered Level 2 fair value calculations within the fair value hierarchy.

The following table presents by level, within the fair value hierarchy, assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 and 2019:

December 31, 2020	Fair Value Measurements - Assets (Liabilities)
	Total		Level 1		Level 2		Level 3
Interest rate swap	$	—	$	—	$	—	$	—
December 31, 2019	Fair Value Measurements - Assets (Liabilities)
	Total		Level 1		Level 2		Level 3
Interest rate swap	$	(57)	$	—	$	(57)	$	—

The change in fair value of the Company's cash flow hedge is detailed in the Company's Consolidated Statements of Comprehensive Income (Loss).

F-14

Net Income (Loss) per Common Share

The Company follows the FASB's guidance on Earnings Per Share for the financial reporting of net income (loss) per common share. Basic earnings per common share excludes dilution and restricted shares and is computed by dividing income available to common shareholders by the weighted-average number of common shares, excluding restricted shares, outstanding for the period. Diluted earnings per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or otherwise resulted in the issuance of common stock that then shared in the earnings of the Company. See Note 10, "Net Income (Loss) per Common Share" for additional disclosures about the Company's Net Income (Loss) per Common Share.

Stock Based Compensation

The Company follows the FASB's guidance on Stock Compensation to account for share-based payments granted to team members and recorded non-cash stock based compensation expense of $570 and $573 during the years ended December 31, 2020 and 2019, respectively. Such amounts are included as components of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. See Note 9, "Shareholders' Equity, Stock Plans and Preferred Stock" for additional disclosures about the Company's stock based compensation plans.

Accumulated Other Comprehensive Income (Loss)

Accumulated other comprehensive income consists of other comprehensive income (loss). Comprehensive income (loss) is a more inclusive financial reporting method that includes disclosure of financial information that historically has not been recognized in the calculation of net income (loss). Currently, the Company's other comprehensive income (loss) consists of the change in fair value of the Company's interest rate swap transaction previously accounted for as a cash flow hedge.

Accounting Standards Recently Issued

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new guidance intends to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for smaller reporting companies for the fiscal year beginning after December 15, 2022 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related disclosures.

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848). The new guidance contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU No. 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the first quarter of 2020, the Company has elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The amendments in the ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The Company continues to evaluate changes in the market and may apply other elections, as applicable, in the future as allowed under ASU No. 2020-04.

2. COVID-19 PANDEMIC

As of December 31, 2020, the Company has received $47,158 from the PHSSEF, and recognized $19,762 as income, which is included in "other operating income" in the Company's results of operations for the year ended December 31, 2020. For the year ended December 31, 2020, the Company utilized $1,496 of these stimulus dollars to fund capital improvements to prevent the spread of COVID-19. The remaining stimulus funds of $25,900 as of December 31, 2020 are classified as "deferred income" on the consolidated balance sheet, which also includes Nursing Home Infection Control Distributions. The Nursing Home Infection Control Distributions, which also include infection control quality incentive payments, are subject to terms and conditions that require recipients to use the funds for infection control expenses. HHS has not yet published reporting requirements for these distributions and has not yet stipulated a time period by which these funds must be used. Additionally, the Families First Coronavirus Response Act provided states with a temporary increase in the regular federal matching rate, or federal medical assistance percentage, used to determine the federal government's share of the cost of covered services in state Medicaid programs, provided the states agreed to certain conditions such as not imposing cost-sharing requirements for COVID-19-related testing and treatment. The Company recognized $4,040 of grant funds from states, which is included in "other operating income" in the Company's results of operations for the year ended December 31, 2020. The Company recognized $16,965 for the year ended December 31, 2020 of Medicaid and Hospice dollars related to this temporary increase

F-15

in the federal matching rate, which related to patient services rendered between March and December 2020 and is reflected in "patient revenues, net" in the Company's results of operations for the year ended December 31, 2020.

The Company initially elected to participate in the payment deferral of the employer's portion of Social Security taxes. During the third quarter of 2020, the Company ceased the deferral election and paid $3,185. As of December 31, 2020, the Company has no remaining liability related to the payment deferral and does not expect to participate in the payment deferral going forward.

The CARES Act and other stimulus legislation also include other provisions offering financial relief, for example suspending the Medicare sequestration from May 1, 2020 through March 31, 2021, which would have otherwise reduced payments to Medicare providers by 2%, although the sequestration was extended through 2030. For the twelve months ended December 31, 2020, the suspension of the Medicare sequestration positively impacted net patient revenues by $1,824.

The Company incurred an additional $21,211 of labor expenses, $4,661 of supplies expense, $5,978 of employee testing expense and $491 of travel expense related to the COVID-19 pandemic for the year ended December 31, 2020. These expenses are reflected in "operating expense" in the Company's results of operations for the year ended December 31, 2020.

The Company is closely monitoring and evaluating the impact of the COVID-19 pandemic on all aspects of its business. We have identified team members and patients who have tested positive for COVID-19 at all of our centers, and we have incurred an increase in the costs of caring for the team members, patients, and residents in those centers. The Company has also experienced reduced occupancy at its centers and has incurred additional expenditures preparing its centers for potential outbreaks and maintaining the healthcare delivery capacity of its centers. While we have experienced reduced occupancy and increased expenses, we received additional PHSSEF and other stimulus funds during 2020, which have been used and are expected to continue to be used to mitigate the impact of COVID-19 attributable lost revenues associated with the reduced occupancy as well as increased expenses, and any cash flow or liquidity impacts therefrom. The Company has an interdisciplinary team monitoring and staying up to date on the latest information about COVID-19. The Company has implemented precautionary measures and response protocols to minimize the spread of COVID-19, following guidance from CMS and the CDC. Nevertheless, the Company expects additional COVID-19 cases will occur at our facilities. The Company is continuing to evaluate and consider the potential impact that COVID-19 may have on its liquidity, financial condition and results of operations due to numerous uncertainties. However, given the uncertainty as to the duration of the COVID-19 pandemic and the timing and availability of effective medical treatment and vaccines, it could have a material adverse effect on the Company's future results of operations, financial condition and liquidity.

3. BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS

2018 Omega Master Lease

On October 1, 2018, the Company entered into the Omega Master Lease Agreement (the "Lease") with Omega to lease 34 centers currently owned by Omega and operated by Diversicare. The old Master Lease with the Lessor provided for its operation of 23 skilled nursing centers in Texas, Kentucky, Alabama, Tennessee, Florida, and Ohio. Additionally, Diversicare operated 11 centers owned by Omega under separate leases in Missouri, Kentucky, Indiana, and Ohio. The Omega Master Lease entered into by Diversicare and Omega consolidated the leases for all 34 centers under one new Master Lease Agreement. The Omega Master Lease has an initial term of twelve years with two optional 10-year extensions. The Lease has a common date of annual lease fixed escalators of 2.15% beginning on October 1, 2019.

On August 30, 2019, the Company terminated operations of ten centers in Kentucky and concurrently transferred operations to a new operator. The agreement effectively amended the Omega Master Lease to remove the ten Kentucky facilities, reduce the annual rent expense, and release the Company from any further obligations arising under the Omega Master Lease with respect to the Kentucky facilities. The remaining Lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15% beginning on October 1, 2019.

Therapy Services

Effective November 1, 2020, the Company entered into agreements with a third party therapy company to outsource the therapy services that were previously provided by the Company through its wholly owned subsidiary Diversicare Therapy Services. The outsourced services include all physical, occupational, and speech therapy provided to patients of the Company’s facilities. The contracts are for a three-year term, absent termination for cause by either party.

2020 Lease Amendment

On December 1, 2020, the Company entered into an agreement with Omega to transfer operations of a facility located in Florida to another operator. The agreement effectively amended the Omega Master Lease to remove this center, reduce the annual rent expense, and release the Company from any further obligations arising under the Omega Master Lease with respect to the Florida facility. The remaining Lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15%.

F-16

Quality Incentive Payment Program

The Company recently expanded its participation in a QIPP as administered by the Texas Health and Human Services Commission. QIPP provides supplemental Medicaid payments for skilled nursing centers that achieve certain quality measures. The Company previously had one of its Texas skilled nursing centers participating in the QIPP. During April 2019, the Company enrolled an additional eleven of its Texas skilled nursing centers in the program, such that eleven of the Company’s centers participate in the QIPP effective September 1, 2019. To allow four of these centers to meet the QIPP participation requirements, the Company entered into a transaction with a Texas medical district already participating in the QIPP, providing for the transfer of the provider license from the Company to the medical district. The Company’s operating subsidiary retained the management of the centers on behalf of the medical district.

4. DISCONTINUED OPERATIONS

Kentucky Disposition

On October 30, 2018, the Company entered into an Asset Purchase Agreement (the "Agreement") with Fulton Nursing and Rehabilitation, LLC, Holiday Fulton Propco LLC, Birchwood Nursing and Rehabilitation LLC, Padgett Clinton Propco LLC, Westwood Nursing and Rehabilitation LLC, and Westwood Glasgow Propco (the "Buyers") to sell the assets and transfer the operations of Diversicare of Fulton, LLC, Diversicare of Clinton, LLC and Diversicare of Glasgow, LLC (the "Kentucky Properties"). On December 1, 2018, the Company completed the sale of the Kentucky Properties with the Buyers for a purchase price of $18,700. The carrying value of these centers' assets was $13,331, resulting in a gain, net of miscellaneous closing costs, of $4,825. The proceeds were used to relieve debt, as required under the terms of the Company's Amended Mortgage Loan and Amended Revolver. Refer to Note 8, "Long-term Debt, Interest Rate Swap and Finance Lease Obligations" for more information on this transaction.

On May 22, 2019, the Company announced that it entered into an agreement with Omega to amend the Omega Master Lease to terminate operations of ten nursing facilities, totaling approximately 885 skilled nursing beds, located in Kentucky and to concurrently transfer operations to an operator selected by Omega. These ten centers are collectively referred to as the "Kentucky Centers." The sale of the Kentucky Properties and the termination of operations at the Kentucky Centers are referred to collectively as the "Kentucky Exit." On August 30, 2019, the Company completed the transaction and no longer operates any skilled nursing centers in the State of Kentucky. The Company's exit from the state represents a strategic shift that has (or will have) a major effect on the Company's operations and financial results. In accordance with ASC 205-20, Presentation of Financial Statements- Discontinued Operations, the Company's discontinued financial position, results of operations and cash flows have been reclassified on the face of the financial statements and footnotes for all periods presented to reflect the discontinued status of these operations.

The transaction resulted in a gain on the modification of the Lease, which is presented within Discontinued Operations on the Consolidated Statements of Operations. The net gain on the transaction was $733.

These centers contributed revenues of $46,019 during the year ended December 31, 2019, and net loss of $1,371 and $8,589 during the years ended December 31, 2020 and 2019, respectively. The net income or loss for the nursing centers included in discontinued operations does not reflect any allocation of corporate general and administrative expense. The Company considered these additional costs along with the centers' future prospects based upon operating history when determining the contribution of the skilled nursing centers to its operations.

The Company did not transfer the accounts receivable or liabilities, inclusive of the reserves for professional liability and workers' compensation, to the new operator. The Company expects to collect the balance of the accounts receivable and pay the remaining liabilities in the ordinary course of business through its future operating cash flows.

F-17

5. REVENUE RECOGNITION AND RECEIVABLES

The Company's revenue is derived from providing quality healthcare services to its patients. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. The promise to provide quality care is accounted for as a single performance obligation satisfied at a point in time, when those services are rendered on a daily basis.

The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts, within each respective group listed below, are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).

Disaggregation of Revenue and Accounts Receivable

In accordance with ASC 606, the Company recognized $16,142 and $823 of Medicaid and Hospice stimulus dollars, respectively, for the twelve months ended December 31, 2020 that are reflected as patient revenues in the Company's results of operations and in the table below. Refer to Note 2, "COVID-19 Pandemic" for more information. The following table set forth net patient revenues related to our continuing operations by payor source for the periods presented (dollar amounts in thousands):

	Twelve Months Ended December 31,
	2020				2019
Medicaid	$	217,147	45.6	%	$	222,560	46.9	%
Medicare	94,375		19.8	%	80,798		17.0	%
Managed Care	49,708		10.4	%	50,323		10.6	%
Private Pay and other	114,488		24.2	%	121,339		25.5	%
Total	$	475,718	100.0	%	$	475,020	100.0	%

Accounts receivable as of December 31, 2020 and 2019 is summarized in the following table:

	December 31,
	2020		2019
Medicaid	$	17,354	$	21,998
Medicare	14,273		11,811
Managed Care	8,021		9,103
Private Pay and other	14,043		17,609
Total accounts receivable	$	53,691	$	60,521

F-18

6. PROPERTY AND EQUIPMENT

Property and equipment, at cost, consists of the following:

	December 31,
	2020		2019
Land	$	5,265	$	5,265
Buildings and leasehold improvements	85,857		84,544
Furniture, fixtures and equipment	44,112		42,966
	135,234		132,775
Less: accumulated depreciation	(91,914)		(85,020)
Net property and equipment	$	43,320	$	47,755

As discussed further in Note 8, "Long-term Debt, Interest Rate Swap and Finance Lease Obligations", the property and equipment of certain skilled nursing centers are pledged as collateral for mortgage debt obligations. In addition, the Company has assets recorded as finance leased assets purchased through finance lease obligations. The Company capitalizes leasehold improvements which will revert back to the lessor of the property at the expiration or termination of the lease, and depreciates these improvements over the shorter of the remaining lease term or the assets' estimated useful lives.

7. LEASES

The Company has operating and finance leases for facilities, corporate offices, and certain equipment. The Company recognizes lease expense for these operating leases on a straight-line basis over the lease term. Leases with an initial term of one year or less are not recorded on the consolidated balance sheet. The Company's other leases have original lease terms of one to twelve years, some of which include options to extend the lease for up to twenty years, and some of which include options to terminate the leases within one year. The exercise of lease renewal options is at our sole discretion. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. Upon adoption of Topic 842, the Company elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs.

On December 1, 2020, the Company entered into an agreement with Omega to transfer operations of the facility located in Florida to another operator. The agreement effectively amended the Omega Master Lease to remove this center, reduce the annual rent expense, and release the Company from any further obligations arising under the Omega Master Lease with respect to the Florida facility. In accordance with ASC 842, the amended lease agreement is considered to be modified and subject to lease modification guidance. The right-of-use asset and lease liabilities related to these agreements were remeasured based on the change in the lease conditions such as rent payment. The remaining Lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15%. The incremental borrowing rate was adjusted to reflect the revised lease terms with became effective at the date of the modification. The net impact of the lease modification is an increase in right-of-use asset and lease liabilities of approximately $7,051.

F-19

Leases

	Classification	December 31, 2020		December 31, 2019
Assets
Operating lease assets	Operating lease right-of-use assets	$	290,296	$	310,238
Finance lease assets	Property and equipment, net (a)	508		906
Total leased assets		$	290,804	$	311,144
Liabilities
Current
Operating	Current portion of operating lease liability	$	28,583	$	23,736
Finance	Current portion of long-term debt and finance lease obligations, net	251		231
Noncurrent
Operating	Operating lease liability, less current portion	274,155		295,636
Finance	Long-term debt and finance lease obligations, less current portion and deferred financing costs, net	280		445
Total lease liabilities		$	303,269	$	320,048
(a) Finance lease assets are recorded net of accumulated amortization of $471 and $1,522 as of December 31, 2020 and 2019, respectively.

Lease Cost

		Year Ended		Year Ended
	Classification	December 31, 2020		December 31, 2019
Operating lease cost (a)	Lease and rent expense	$	54,001	$	52,990
Finance lease cost:
Amortization of finance lease assets	Depreciation and amortization	226		263
Interest on finance lease liabilities	Interest expense, net	36		48
Short term lease cost	Operating expense	581		649
Net lease cost		$	54,844	$	53,950
(a) Includes variable lease costs, which are immaterial

Maturity of Lease Liabilities

	As of December 31, 2020
	Operating Leases (a)		Finance Leases (a)		Total
2021	$	51,165	$	282	$	51,447
2022	52,142		209		52,351
2023	53,120		62		53,182
2024	53,064		20		53,084
2025	53,921		—		53,921
After 2025	141,875		—		141,875
Total lease payments	$	405,287	$	573	$	405,860
Less: Interest	(102,549)		(42)		(102,591)
Present value of lease liabilities	$	302,738	$	531	$	303,269
(a) Operating and Finance lease payments exclude options to extend lease terms that are not reasonably certain of being exercised.

F-20

The measurement of right-of-use assets and lease liabilities requires the Company to estimate appropriate discount rates. To the extent the rate implicit in the lease is readily determinable, such rate is utilized. However, based on information available at lease commencement for the majority of our leases, the rate implicit in the lease is not known. In these instances, the Company utilizes an incremental borrowing rate, which represents the rate of interest that it would pay to borrow on a fully collateralized basis over a similar term.

Lease Term and Discount Rate

	December 31, 2020	December 31, 2019
Weighted-average remaining lease term (years)
Operating leases	7.91	8.81
Finance leases	2.26	3.00
Weighted-average discount rate
Operating leases	7.9%	8.9%
Finance leases	6.2%	6.1%

Other Information

	Year Ended		Year Ended
	December 31, 2020		December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$	50,869	$	55,485
Operating cash flows for finance leases	36		48
Financing cash flows for finance leases	235		471
Acquisition of operating leases though adoption of Topic 842	—		389,403
Lease modification	$	7,051	$	(48,877)

8. LONG-TERM DEBT, INTEREST RATE SWAP AND FINANCE LEASE OBLIGATIONS

Long-term debt consists of the following:

	December 31,
	2020		2019
Mortgage loan	$	61,087	$	49,743
Acquisition loan	—		9,400
Revolver	—		14,000
Affiliated revolver	—		1,000
	61,087		74,143
Plus finance lease obligations	531		857
Less current portion	(1,660)		(3,498)
	59,958		71,502
Less deferred financing costs, net	(1,432)		(865)
Long-term debt and finance lease obligation, net	$	58,526	$	70,637

The Company maintains a credit facility with a syndicate of banks. The Company originally entered into the credit facility in May 2013, and subsequently amended the facility. As of December 31, 2019, the credit facility consisted of a mortgage loan $67,500, an acquisition loan with a borrowing capacity of $12,500, a revolver with a borrowing capacity of $40,250 and an affiliated revolver with a borrowing capacity of $2,000.

On October 14, 2020, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") with a syndicate of banks, which consists of a $62,000 mortgage loan subsequently amended ("Amended Mortgage Loan"), a $36,000

F-21

revolver subsequently amended ("Amended Revolver") and a $2,000 affiliated revolver amended ("Amended Affiliated Revolver"). The Amended Mortgage Loan, Amended Revolver and Amended Affiliated Revolver have a 3-year maturity through September 30, 2023. The Amended Mortgage Loan has a term of 3 years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term loan facility is based on LIBOR plus 4.0% with a 1.0% floor. The Amended Mortgage Loan balance was $61,087 as of December 31, 2020 with an interest rate of 5.0%. The Amended Mortgage Loan consolidated the mortgage and acquisition loans. The Amended Mortgage Loan is secured by 15 owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan, the Amended Revolver and the Amended Affiliated Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver and Amended Affiliated Revolver have an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.

As of December 31, 2020, the Company's weighted average interest rate on long-term debt was approximately 5.0%.

As of December 31, 2020, the Company did not have any borrowings outstanding under its revolvers compared to $15,000 outstanding as of December 31, 2019. Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has 4 letters of credit with a total value of $12,387 outstanding as of December 31, 2020. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolvers and the maximum loan amount, the amount available for borrowing under the revolvers was $16,446 at December 31, 2020.

Our lending agreements contain various financial covenants, the most restrictive of which relate to debt service charge coverage ratios. The Company is in compliance with all such covenants at December 31, 2020.

In connection with the Company's loan agreements, the Company recorded the following amounts related to deferred loan costs:

	2020		2019
Write-off of deferred financing costs	$	247	$	—
Deferred financing costs capitalized	$	1,228	$	333

Scheduled principal payments of long-term debt are as follows:

2021	$	1,404
2022	1,368
2023	58,315
Total	$	61,087

Interest Rate Swap Cash Flow Hedge

The Company terminated its interest rate swap in conjunction with refinancing its debt in October 2020. The applicable guidance requires companies to recognize all derivative instruments as either assets or liabilities at fair value in a company's balance sheets. The interest rate swap had a net zero balance at December 31, 2020.

Finance Lease Obligations

Upon acquisition of some centers, we assumed certain leases, primarily related to equipment, that constitute finance leases. As a result, we have recorded the underlying lease liabilities and financed lease obligations of $531 and $857 as of December 31, 2020 and 2019, respectively. These lease agreements provide three to five year terms.

Scheduled payments of the financed lease obligations are as follows:

2021	$	282
2022	209
2023	62
2024	20
Total	573
Amounts related to interest	(42)
Principal payments on finance lease obligation	$	531

F-22

9. SHAREHOLDERS' EQUITY, STOCK PLANS AND PREFERRED STOCK

Stock Based Compensation Plans

The Company follows the FASB's guidance on Stock Compensation to account for stock-based payments granted to employees and non-employee directors.

Overview of Plans

In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers and 150 shares of the Company's common stock has been reserved for issuance under the Stock Purchase Plan. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period and are subject to forfeiture. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150 shares to 350 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.

In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the Long-Term Incentive Plan to increase the number of shares of our common stock authorized under the Plan from 380 shares to 680 shares. No grants can be made under the 2010 Plan after May 31, 2027.

Equity Grants and Valuations

During 2020 and 2019, the Compensation Committee of the Board of Directors approved grants totaling 198 and 151, respectively, shares of restricted common stock to certain employees and members of the Board of Directors. These restricted shares vest one-third on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed. Our policy is to account for forfeitures of share-based compensation awards as they occur. On March 31, 2020, the Compensation Committee of the Board of Directors approved the grant of 100 shares of common stock to the Company's Chief Executive Officer, as a one-time bonus in lieu of a 2020 salary increase and as recognition for completing the settlement with the Office of the Inspector General and the disposition of all the Company's facilities in the State of Kentucky. The stock was fully vested on the date of the grant, and the grant date fair value of which was expensed during the quarter ended March 31, 2020.

The Company recorded non-cash stock-based compensation expense from continuing operations for equity grants and RSU's issued under the Plans of $570 and $573 during the years ended December 31, 2020 and 2019, respectively. Such amounts are included as components of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. As of December 31, 2020, there was $196 in unrecognized compensation costs related to stock-based compensation to be recognized over the applicable remaining vesting periods. The Company estimated the total recognized and unrecognized compensation for all options and SOSARs using the Black-Scholes-Merton equity grant valuation model. Restricted stock awards are valued using the market price on the grant date.

The table below shows the weighted average assumptions the Company used to develop the fair value estimates under its option valuation model:

	Year Ended December 31,
	2020	2019
Expected volatility (range)	N/A(1)	N/A(1)
Risk free interest rate (range)	N/A(1)	N/A(1)
Expected dividends	N/A(1)	N/A(1)
Weighted average expected term (years)	N/A(1)	N/A(1)

___________

(1)The Company did not issue any options or other equity grants that would require application of the Black-Scholes-Merton equity grant valuation model during the years ended December 31, 2020 and 2019. All equity grants during

F-23

these periods were restricted common shares which are valued using an intrinsic valuation method based on market price.

In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.

In computing the fair value of these equity grants, the Company estimated the equity grants' expected term based on the average of the vesting term and the original contractual terms of the grants.

The table below describes the resulting weighted average grant date fair values calculated as well as the intrinsic value of options exercised under the Company's equity awards during each of the following years:

	Year Ended December 31,
	2020(1)		2019(1)
Weighted average grant date fair value	$	—	$	—
Total intrinsic value of exercises	$	—	$	3

___________

(1)The Company did not issue any options or other equity grants that would require application of the Black-Scholes-Merton equity grant valuation model during the years ended December 31, 2020 and 2019. All equity grants during this period were restricted common shares which are valued using an intrinsic valuation method based on market price.

The following table summarizes information regarding stock options and SOSAR grants outstanding as of December 31, 2020:

		Weighted
		Average			Intrinsic			Intrinsic
Range of		Exercise		Grants	Value-Grants		Grants	Value-Grants
Exercise Prices1		Prices		Outstanding	Outstanding		Exercisable	Exercisable
$8.14 to $10.21		$	8.83	45	$	—	45	$	—
$	5.86	$	5.86	20	$	—	20	$	—
				65			65

As of December 31, 2020, the outstanding equity grants have a weighted average remaining life of 5.26 years and those outstanding equity grants that are exercisable have a weighted average remaining life of 5.26 years. During the year ended December 31, 2020, no stock option and SOSAR grants were exercised under these plans.

Summarized activity of the equity compensation plans is presented below:

		Weighted
	SOSARs/	Average
	Options	Exercise Price
Outstanding, December 31, 2019	76	$	7.55
Granted	—	—
Exercised	—	—
Expired or cancelled	(11)	5.45
Outstanding, December 31, 2020	65	$	7.92
Exercisable, December 31, 2020	65	$	7.92

1

F-24

		Weighted
		Average
	Restricted	Grant Date
	Shares	Fair Value
Outstanding, December 31, 2019	207	$	5.28
Granted	198	2.00
Dividend Equivalents	—	—
Vested	(187)	3.93
Cancelled	(25)	4.55
Outstanding, December 31, 2020	193	$	3.32

Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:

		Weighted
		Average
	Restricted	Grant Date
	Share Units	Fair Value
Outstanding, December 31, 2019	48	$	5.08
Granted	28	2.00
Dividend Equivalents	—	—
Vested	(21)	6.45
Cancelled	—	—
Outstanding December 31, 2020	55	$	2.92

Preferred Stock

The Company is authorized to issue up to 195 shares of Preferred Stock. The Company's Board of Directors is authorized to establish the terms and rights of each series, including the voting powers, designations, preferences, and other special rights, qualifications, limitations, or restrictions thereof.

F-25

10.    NET INCOME (LOSS) PER COMMON SHARE

Information with respect to the calculation of basic and diluted net income (loss) per common share is presented below:

	Years Ended December 31,
	2020		2019
Numerator: Income (loss):
Income (loss) from continuing operations	$	6,530	$	(27,474)
Loss from discontinued operations, net of income taxes	(1,371)		(8,589)
Net income (loss)	$	5,159	$	(36,063)
Denominator: Basic Weighted Average Common Shares Outstanding:	6,615		6,459
Dilutive effect of stock options, SOSARs, Restricted Shares and Restricted Share Units	90		—
Adjusted weighted average common shares outstanding	6,705		6,459
Basic net income (loss) per common share
Income (loss) from continuing operations	$	0.99	$	(4.25)
Loss from discontinued operations
Operating loss, net of taxes	(0.21)		(1.33)
Discontinued operations, net of taxes	(0.21)		(1.33)
Basic net income (loss) per common share	$	0.78	$	(5.58)
Diluted net income (loss) per common share
Income (loss) from continuing operations	$	0.97	$	(4.25)
Loss from discontinued operations
Operating loss, net of taxes	(0.20)		(1.33)
Discontinued operations, net of taxes	(0.20)		(1.33)
Diluted net income (loss) per common share	$	0.77	$	(5.58)

The dilutive effects of the Company's stock options, SOSARs, Restricted Shares and Restricted Share Units are included in the computation of diluted income per common share during the periods they are considered dilutive.

The following table reflects the weighted average outstanding SOSARs and Options that were excluded from the computation of diluted earnings per share, as they would have been anti-dilutive:

	2020	2019
SOSARs/Options Excluded	65	76

The weighted average common shares for basic and diluted earnings for common shares was the same due to the loss in 2019.

F-26

11. INCOME TAXES

Overview

The provision (benefit) for income taxes on continuing operations for the years ended December 31, 2020 and 2019 is summarized as follows:

	Year Ended December 31,
	2020		2019
Current provision (benefit) :
Federal	$	719	$	197
State	(23)		76
	696		273
Deferred provision (benefit):
Federal	(1,227)		12,439
State	—		2,982
	(1,227)		15,421
Provision (benefit) for income taxes of continuing operations	$	(531)	$	15,694

A reconciliation of taxes computed at statutory income tax rates on income (loss) from continuing operations is as follows:

	Year Ended December 31,
	2020		2019
Provision (benefit) for federal income taxes at statutory rates	$	1,260	$	(2,469)
Provision (benefit) for state income taxes, net of federal benefit	478		(106)
Valuation allowance changes affecting the provision for income taxes	(2,922)		19,002
Employment tax credits	(355)		(210)
Nondeductible expenses	251		122
Stock based compensation expense	98		80
WOTC Credit and Other	931		(1,349)
Other	(272)		624
Provision (benefit) for income taxes of continuing operations	$	(531)	$	15,694

Deferred Taxes

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets are reduced by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will realize only some portion of the deferred tax assets. The net deferred tax assets and liabilities, at the respective income tax rates, are as follows:

F-27

	December 31,
	2020		2019
Deferred tax assets (liabilities):
Net operating loss and other carryforwards	$	67	$	859
Credit carryforwards	1,777		3,118
Accounts receivable	4,652		4,852
Prepaid expenses	(938)		(1,015)
Interest rate limitation	—		971
Right-of-use lease liability	78,674		82,194
Right-of-use lease asset	(75,443)		(79,843)
Depreciation	1,731		1,863
Tax goodwill and intangibles	(1,098)		(1,066)
Stock-based compensation	164		183
Accrued liabilities	124		504
Accrued rent	340		380
Impairment of long-lived assets	177		176
Interest rate swap	—		(4)
Hedge Ineffectiveness	—		(155)
Noncurrent self-insurance liabilities	6,350		6,363
Restitution	2,329		2,445
Other	28		30
	18,934		21,855
Less valuation allowance	(18,934)		(21,855)
	$	—	$	—

Deferred Tax Valuation Allowance

The assessment of the amount of value assigned to our deferred tax assets under the applicable accounting standards is highly judgmental. We are required to consider all available positive and negative evidence in evaluating the likelihood that we will be able to realize the benefit of our deferred tax assets in the future. Such evidence includes scheduled reversals of deferred tax assets and liabilities, projected future taxable income, tax-planning strategies, and the results of recent operations. Since this evaluation requires consideration of historical and future events, there is significant judgment involved, and our conclusion could be materially different should certain of our expectations not transpire.

When assessing all available evidence, we consider the weight of the evidence, both positive and negative, based on the objectivity of the underlying evidence and the extent to which it can be verified. For the three-year period ended December 31, 2020, the Company had a cumulative pre-tax loss from continuing operations of $18,526. Additionally, the Company recognized governmental and regulatory changes have put downward revenue pressure on the long-term care industry as a piece of negative evidence in the analysis. In 2019 and 2018 combined, the Company recognized a total expense of $9,500 related to the CID settlement. Because of these items and other financial results, the Company entered a cumulative loss for the 36 preceding months ended June 30, 2019 and performed a thorough assessment of the available positive and negative evidence in order to ascertain whether it is more likely than not that in future periods the Company will generate sufficient pre-tax income to utilize all of its federal deferred tax assets and its net operating loss and other carryforwards and credits.

The Company also identified several pieces of positive evidence that were considered and weighed in the analysis performed regarding the valuation of deferred tax assets. The evidence included the termination of operations for 10 nursing facilities in Kentucky completed in the third quarter of 2019, the related corporate and regional restructuring and other cost saving initiatives already in process. The evidence also included consideration of participation in revenue incentive programs that are expected to generate additional revenue, the long-term expiration dates of a majority of the net operating losses and credits, and the Company’s history of not having carryforwards or credits expire unutilized.

In performing the analysis, the Company contemplated utilization of the recorded deferred tax assets under multiple scenarios. After consideration of these factors, the Company determined that a full valuation allowance was necessary. As of December 31, 2020, the Company has a valuation allowance in the amount of $18,934.  The Company will continue to periodically assess the realizability of its future deferred tax assets.

F-28

On March 27, 2020, the CARES Act was enacted and signed into law. Certain provisions of the CARES Act impacted the 2019 income tax provision computations of the Company and were reflected in the first quarter of 2020, or the period of enactment. The CARES Act contains modifications on the depreciation of qualified improvement property, as well as the limitation of business interest for tax years beginning in 2019 and 2020. The new life classification of the qualified improvement property, allowing for bonus depreciation to be taken, along with the modification to Section 163(j) to increase the allowable business interest deduction from 30% of adjusted taxable income to 50% of adjusted taxable income significantly increased the allowable deductions of the Company and result in additional taxable losses for the year-ended 2019, resulting in greater net operating losses (“NOL”) to be carried back. The NOL carryback resulted in a tax refund of $1,227 and a decrease to the Work Opportunity Tax Credit (“WOTC”) deferred tax asset, which is offset by a full valuation allowance. These changes pursuant to the CARES Act did not have a significant impact during the twelve-month period ended December 31, 2020, other than the tax refund and net adjustments to the WOTC credit and NOL deferred tax assets, which are offset by a valuation allowance.

At December 31, 2020, the Company had $5,576 of federal net operating losses, which expire at various dates beginning in 2021. The use of a portion of these loss carryforwards is limited by change in ownership provisions of the Federal tax code to a maximum of approximately $257. The Company has reduced the deferred tax asset and the corresponding valuation allowances for net operating loss deductions permanently lost as a result of the change in ownership provisions.

Under the Work WOTC program, the Company recorded $355 and $210 in Work Opportunity Tax Credits during 2020 and 2019, respectively.

The Company is not currently under examination by any major income tax jurisdiction. During 2020, the statutes of limitations lapsed on the Company's 2016 Federal tax year and certain 2015 and 2016 state tax years. The Company does not believe the Federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months.

12. COMMITMENTS AND CONTINGENCIES

Lease Commitments

The Company is committed under long-term operating leases with various expiration dates and varying renewal options. Under these lease agreements, the Company's lease payments are subject to periodic annual escalations as described below and in Note 1, "Business and Summary of Significant Accounting Policies". Total lease expense for continuing operations was $54,001 and $52,990 for the years ended December 31, 2020 and 2019, respectively. The accrued liability related to straight line rent was $12,382 and $9,325 at December 31, 2020 and 2019, respectively, and is recorded as an offset to the right-of-use asset on the accompanying consolidated balance sheets.

Omega Master Lease

On October 1, 2018, the Company entered into the Omega Master Lease to lease 34 centers currently owned by Omega and operated by Diversicare. The old Master Lease with Omega provided for its operation of 23 skilled nursing centers in Texas, Kentucky, Alabama, Tennessee, Florida, and Ohio. Additionally, Diversicare operates 11 centers owned by Omega, previously under separate leases in Missouri, Kentucky, Indiana, and Ohio. The Omega Master Lease entered into by Diversicare and Omega consolidated the leases for all 34 centers under one new Master Lease Agreement. The Omega Master Lease has an initial term of twelve years with the option of two ten year extensions at the Company's election. The Omega Master Lease has annual rent escalators of 2.15% beginning on October 1, 2019.

On August 30, 2019, the Company terminated operations of 10 centers in Kentucky and concurrently transferred operations to a new operator. The agreement effectively amended the Master Lease Agreement with Omega Healthcare Investors to remove the 10 Kentucky facilities, reduce the annual rent expense, and release the Company from any further obligations arising under the Master Lease Agreement with respect to the Kentucky facilities. The remaining lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15% beginning on October 1, 2019.

On December 1, 2020, the Company terminated operations at a facility located in Florida and concurrently transferred operations to a new operator. The agreement effectively amended the Omega Master Lease to remove the Florida facility, reduce the annual rent expense, and release the Company from any further obligations arising under the Omega Master Lease with respect to the Florida facility. The remaining Omega Master Lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15%.

Under generally accepted accounting principles, the Company is required to report these scheduled rent increases on a straight line basis over the term of the lease. These scheduled increases had no effect on cash rent payments at the start of the lease term and only result in additional cash outlay as the annual increases take effect each year.

The Omega Master Lease requires the Company to fund annual capital expenditures related to the leased centers at an amount currently equal to four hundred three dollars per licensed bed. These amounts are subject to adjustment for increases in the

F-29

Consumer Price Index. The Company is in compliance with the capital expenditure requirements. Total required capital expenditures during the remaining lease term are $10,118. These capital expenditures are being depreciated on a straight-line basis over the shorter of the asset life or the appropriate lease term.

Upon expiration of the Omega Master Lease or in the event of a default under the Omega Master Lease, the Company is required to transfer all of the leasehold improvements, equipment, furniture and fixtures of the leased centers to Omega. The assets to be transferred to Omega are being amortized on a straight-line basis over the shorter of the remaining lease term, excluding the renewal options, or estimated useful life, and will be fully depreciated upon the expiration of the lease. All of the equipment, inventory and other related assets of the centers leased pursuant to the Omega Master Lease have been pledged as security under the Omega Master Lease. In addition, the Company has a letter of credit of $5,447 as a security deposit for the Company's leases with Omega, as described in Note 8, "Long-term Debt, Interest Rate Swap and Finance Lease Obligations".

Golden Living Master Lease

The Company leases 20 nursing centers from Golden Living. On October 1, 2016, the Company and Golden Living entered into a Master Lease ("Golden Living Lease") agreement to lease eight centers located in Mississippi. On November 1, 2016, the Company and Golden Living entered into an Amended and Restated Master Lease ("Amended Lease") to extend the term of its centers leased from Golden Living and lease an additional twelve centers located in Alabama. The Amended Lease is triple net and has an initial term of ten years with two separate five year options to extend the term. The annual lease fixed escalator is 2%. Under generally accepted accounting principles, the Company is required to report these scheduled rent increases on a straight line basis over the term of the lease including the 10 year term of the renewal period. These scheduled increases had no effect on cash rent payments at the start of the lease term and only result in additional cash outlay as the annual increases take effect each year.

The Amended Lease requires the Company to fund annual capital expenditures related to the leased centers at an amount currently equal to five hundred thirty dollars per licensed bed. These amounts are subject to adjustment for increases in the Consumer Price Index. The Company is in compliance with the capital expenditure requirements. Total required capital expenditures during the remaining lease term and renewal options are $5,432. These capital expenditures are being depreciated on a straight-line basis over the shorter of the asset life or the appropriate lease term.

Upon expiration of the Amended Lease or in the event of a default under the Amended Lease, the Company is required to transfer all of the leasehold improvements, equipment, furniture and fixtures of the leased centers to Golden Living. The assets to be transferred to Golden Living are being amortized on a straight-line basis over the shorter of the remaining lease term or estimated useful life, and will be fully depreciated upon the expiration of the lease. All of the equipment, inventory and other related assets of the center leased pursuant to the Amended Lease have been pledged as security under the Amended Lease. In addition, the Company has a letter of credit of $6,610 as a security deposit for the Company's leases with Golden Living, as described in Note 8, "Long-term Debt, Interest Rate Swap and Finance Lease Obligations".

Insurance Matters

Professional Liability and Other Liability Insurance

The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Tennessee are now covered under the captive insurance policies along with several of the Company's nursing centers in Alabama, Ohio, and Texas and several of the Company's prior nursing centers in Kentucky and Florida for claims prior to the transfer of such operation. The insurance coverage provided for these centers under the SHC policy includes coverage limits of at least $1,000 per medical incident with a sublimit per center of $3,000 and total annual aggregate policy limits of $5,000. All other centers within the Company’s portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers.  The deductibles for these policies vary in amount and are covered through the insurance subsidiary.

The Company follows the FASB Accounting Standards Update, “Presentation of Insurance Claims and Related Insurance Recoveries,” that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Self-insurance receivable" on the Consolidated Balance Sheet. As of December 31, 2020 and 2019, there were $1,025 and $1,011, respectively, estimated insurance recovery receivables.

F-30

Reserve for Estimated Self-Insured Professional Liability Claims

Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $24,744 and $27,390 as of December 31, 2020 and 2019, respectively. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.

The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, the actuary has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. The actuary primarily utilizes historical data regarding the frequency and cost of the Company’s past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company’s ultimate professional liability cost for current periods.

On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.

The Company’s cash expenditures for self-insured professional liability costs were $5,514 and $4,578 for the years ended December 31, 2020 and 2019, respectively.

Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.

Other Insurance

With respect to workers' compensation insurance, substantially all of our employees are covered under either a prefunded deductible policy or state-sponsored program. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2008 through December 31, 2019, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500 per claim, subject to an aggregate maximum of $3,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $1,039 and $921 at December 31, 2020 and 2019, respectively. The Company has a non-current receivable for workers’ compensation policies covering previous years of $2,050 and $1,575 as of December 31, 2020 and 2019, respectively. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.

As of December 31, 2020, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $200 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $2,358 and $1,810 at December 31, 2020 and 2019, respectively. The differences between actual settlements and reserves are included in expense in the period finalized.

F-31

Employment Agreements

The Company has employment agreements with certain members of management that provide for the payment to these members of amounts up to 2.0 times their annual salary in the event of a termination without cause, a constructive discharge (as defined in each employee agreement), or upon a change in control of the Company (as defined in each employee agreement). The maximum contingent liability under these agreements is $1,500 as of December 31, 2020. The terms of such agreements are from 1 to 3 years and automatically renew for 1 year if not terminated by the employee or the Company.

No amounts have been accrued for these contingent liabilities for members of management the Company currently employs.

Health Care Industry and Legal Proceedings

The provision of health care services entails an inherent risk of liability. Participants in the health care industry are subject to lawsuits alleging malpractice, violations of false claims acts, product liability, or related legal theories, many of which involve large claims and significant defense costs. Like many other companies engaged in the long-term care profession in the United States, we have numerous pending liability claims, disputes and legal actions for professional liability and other related issues. Further, as with all health care providers, we are periodically subject to regulatory actions seeking fines and penalties for alleged violations of health care laws and are potentially subject to the increased scrutiny of regulators for issues related to compliance with health care fraud and abuse laws and with respect to the quality of care provided to residents of our center. Like other health care providers, in the ordinary course of our business, we are also subject to claims made by employees and other disputes and litigation arising from the conduct of our business.

As of December 31, 2020, we are engaged in 79 professional liability lawsuits, of which 36 relate to centers we no longer operate, which are reserved for as discussed above. Twenty-two lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The ultimate results of any of our professional liability claims and disputes cannot be predicted. We have limited, and sometimes no, professional liability insurance with regard to most of these claims. A significant judgment entered against us in one or more of these legal actions could have a material adverse impact on our financial position and cash flows.

In February 2020, the Company entered into a settlement agreement with the U.S. Department of Justice and the State of Tennessee of actions alleging violations of the federal False Claims Act in connection with our provision of therapy and the completion of certain resident admission forms. This settlement of $9,500 resolved an investigation that had begun in 2012 and covers the time period from January 1, 2010 through December 31, 2015. This agreement required an initial payment of $500 within ten days of the effective date, which was February 14, 2020, and material annual interest bearing payments for a period of five years thereafter ending in February 2025, and also requires a contingent payment in the event the Company sells any of its owned facilities during the five year payment period. Failure to make timely any of these payments could result in rescission of the settlement and in the government having a very large claim against us, including penalties, and/or make us ineligible to participate in certain government funded healthcare programs, any of which could in turn significantly harm our business and financial condition. As of December 31, 2020 the Company has $9,000 outstanding related to the settlement agreement, $1,000 of which reflected as "Other Current Liabilities" and the remaining $8,000 is reflected as "Government Settlement Accrual" on the balance sheet.

In conjunction with the settlement of the government investigation related to our therapy practices, the Company entered into a corporate integrity agreement with the Office of the Inspector General of CMS. This agreement has a term of five years and imposes material burdens on the Company, its officers and directors to take actions designed to ensure compliance with applicable healthcare laws, including requirements to maintain specific compliance positions within the Company, to report any non-compliance with the terms of the agreement, to return any overpayments received, to submit annual reports and to have an annual audit of submitted claims performed by an independent review organization. The CIA sets forth penalties for non-compliance by the Company with the terms of the agreement, including possible exclusion from federally funded healthcare programs for material violations of the agreement.

In January 2009, a purported class action complaint was filed in the Circuit Court of Garland County, Arkansas against the Company and certain of its subsidiaries and Garland Nursing & Rehabilitation Center (the “Center”). The complaint alleges that the defendants breached their statutory and contractual obligations to the patients of the Center over the five-year period prior to the filing of the complaints. The lawsuit remains in its early stages and has not yet been certified by the court as a class action. The Company intends to defend the lawsuit vigorously.

We cannot currently predict with certainty the ultimate impact of any of the above cases on our financial condition, cash flows or results of operations. Our reserve for professional liability expenses does not include the amounts that will be owed under the settlement agreement with the DOJ and State of Tennessee or the purported class action against the Arkansas centers. An unfavorable outcome in any of these lawsuits or any of our professional liability actions, any regulatory action, any investigation or lawsuit alleging violations of fraud and abuse laws or of elderly abuse laws or any state or Federal False Claims

F-32

Act case could subject us to fines, penalties and damages, including exclusion from the Medicare or Medicaid programs, and could have a material adverse impact on our financial condition, cash flows or results of operations.

F-33

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

(in thousands)

Column A	Column B	Column C		Column D	Column E
				Deductions
Description	Balance at Beginning of Period	Charged to Costs and Expenses	Other	Payments (1)	Balance at End of Period
Year ended December 31, 2020:
Professional Liability Reserve	$27,390	$6,919	$(1,625)	$(7,940)	$24,744
Workers Compensation Reserve	$921	$1,352	$—	$(1,234)	$1,039
Health Insurance Reserve	$1,810	$14,003	$—	$(13,455)	$2,358
Year ended December 31, 2019:
Professional Liability Reserve	$27,201	$10,435	$(3,020)	$(7,226)	$27,390
Workers Compensation Reserve	$618	$400	$—	$(97)	$921
Health Insurance Reserve	$1,396	$16,733	$—	$(16,319)	$1,810

(1)Payments for the Professional Liability Reserve include amounts paid for claims settled during the period as well as payments made under structured arrangements for claims settled in earlier periods.

S-1

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

OF CONTINUING OPERATIONS

(in thousands)

Description	Balance at Beginning of Period	Additions Charged to Costs and Expenses (1)	Deductions	Balance at End of Period
Year ended December 31, 2020: Deferred Tax Valuation Allowance	$21,855	$—	$(2,921)	$18,934
Year ended December 31, 2019: Deferred Tax Valuation Allowance	$228	$21,627	$—	$21,855

(1) The Company initially recorded a full valuation allowance of $20.0 million during the second quarter of 2019.

S-2

EX-21

Exhibit 21

Subsidiaries

Advocat Finance, Inc.

Diversicare Afton Oaks, LLC

Diversicare Afton Oaks Property, LLC

Diversicare Ballinger, LLC

Diversicare Briarcliff, LLC

Diversicare Briarcliff Property, LLC

Diversicare Chanute Property, LLC

Diversicare Chisolm, LLC

Diversicare Chisolm Property, LLC

Diversicare of Clinton, LLC

Diversicare of Clinton Property, LLC

Diversicare Council Grove Property, LLC

Diversicare Doctors, LLC

Diversicare Estates, LLC

Diversicare Hartford, LLC

Diversicare Hartford Property, LLC

Diversicare Haysville Property, LLC

Diversicare Highlands, LLC

Diversicare Hillcrest, LLC

Diversicare Hillcrest Property, LLC

Diversicare Holding Company, LLC

Diversicare Humble, LLC

Diversicare Hutchinson Property, LLC

Diversicare Kansas, LLC

Diversicare Katy, LLC

Diversicare Lampasas, LLC

Diversicare Lampasas Property, LLC

Diversicare Larned Property, LLC

Diversicare Leasing Company II, LLC

Diversicare Leasing Company III, LLC

Diversicare Leasing Corp.

Diversicare Management Services Co.

Diversicare Normandy Terrace, LLC

Diversicare of Avon, LLC

Diversicare of Big Springs, LLC

Diversicare of Bradford Place, LLC

Diversicare of Chanute, LLC

Diversicare of Chateau, LLC

Diversicare of Council Grove, LLC

Diversicare of Fulton, LLC

Diversicare of Glasgow, LLC

Diversicare of Greenville, LLC

Diversicare of Haysville, LLC

Diversicare of Hutchinson, LLC

Diversicare of Larned, LLC

Diversicare of Nicholasville, LLC

Diversicare of Providence, LLC

Diversicare of Riverside, LLC

Diversicare of Sedgwick, LLC

Diversicare of Selma, LLC

Diversicare of Seneca Place, LLC

Diversicare of Siena Woods, LLC

Diversicare of St. Joseph, LLC

Diversicare of St. Theresa, LLC

Diversicare Paris, LLC

Diversicare Pharmacy Holdings, LLC

Diversicare Pinedale, LLC

Diversicare Property Co., LLC

Diversicare Rose Terrace, LLC

Diversicare Sedgwick Property, LLC

Diversicare Selma Property, LLC

Diversicare Texas I, LLC

Diversicare Therapy Services, LLC

Diversicare Treemont, LLC

Diversicare Windsor House, LLC

Diversicare Windsor House Property, LLC

Diversicare Yorktown, LLC

Diversicare Yorktown Property, LLC

Diversicare of Amory, LLC

Diversicare of Arab, LLC

Diversicare of Batesville, LLC

Diversicare of Bessemer, LLC

Diversicare of Boaz, LLC

Diversicare of Brookhaven, LLC

Diversicare of Eupora, LLC

Diversicare of Foley, LLC

Diversicare of Hueytown, LLC

Diversicare of Lanett, LLC

Diversicare of Montgomery, LLC

Diversicare of Oneonta, LLC

Diversicare of Oxford, LLC

Diversicare of Pell City, LLC

Diversicare of Ripley, LLC

Diversicare of Riverchase, LLC

Diversicare of Southaven, LLC

Diversicare of Tupelo, LLC

Diversicare of Tylertown, LLC

Diversicare of Winfield, LLC

Diversicare of Meridian, LLC

Senior Care Cedar Hills, LLC

Senior Care Florida Leasing, LLC

Senior Care Golfcrest, LLC

Senior Care Golfview, LLC

Senior Care Southern Pines, LLC

SHC Risk Carrier, Inc.

Sterling Health Care Management, Inc.

EX-23.1

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Diversicare Healthcare Services, Inc.

Brentwood, Tennessee

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-151565, 333-167630, 333-212928 and 333-219696) of Diversicare Healthcare Services, Inc. of our report dated March 11, 2021, relating to the consolidated financial statements and financial statement schedule, which appears in this Form 10-K.

/s/ BDO USA, LLP

Nashville, Tennessee

March 11, 2021

EX-31.1

Exhibit 31.1

CERTIFICATIONS PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

(i) CERTIFICATION

I, James R. McKnight, Jr., certify that:

1. I have reviewed this annual report on Form 10-K of Diversicare Healthcare Services, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 11, 2021

/s/ James R. McKnight, Jr.

James R. McKnight, Jr.

President and Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATIONS PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

(ii) CERTIFICATION

I, Kerry D. Massey, certify that:

1. I have reviewed this annual report on Form 10-K of Diversicare Healthcare Services, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 11, 2021

/s/ Kerry D. Massey

Kerry D. Massey

Executive Vice President and Chief Financial Officer

EX-32

Exhibit 32

CERTIFICATION OF ANNUAL REPORT ON FORM 10-K

OF DIVERSICARE HEALTHCARE SERVICES, INC.

FOR THE YEAR ENDED DECEMBER 31, 2020

The undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the undersigned's best knowledge and belief, the Annual Report on Form 10-K for Diversicare Healthcare Services, Inc. (the “Company”) for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”):

(a)    fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(b)    the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This Certification is executed as of March 11, 2021.

/s/ James R. McKnight, Jr.

James R. McKnight, Jr.

President and Chief Executive Officer

/s/ Kerry D. Massey

Kerry D. Massey

Executive Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Cover Page - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Mar. 01, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	1-12996
Entity Registrant Name	Diversicare Healthcare Services, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	62-1559667
Entity Address, Address Line One	1621 Galleria Boulevard
Entity Address, City or Town	Brentwood
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37027
City Area Code	615
Local Phone Number	771-7575
Title of 12(b) Security	Common Stock, $0.01 par value per share
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag
Entity Shell Company	false
Entity Public Float			$ 7,441
Entity Common Stock, Shares Outstanding		6,847,305
Documents Incorporated by Reference	Registrant's definitive proxy materials for its 2021 annual meeting of shareholders are incorporated by reference into Part III, Items 10, 11, 12, 13 and 14 of this Form 10-K.
Entity Central Index Key	0000919956
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY

XML

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash	$ 30,821	$ 2,710
Receivables	53,691	60,521
Self-insurance receivables	1,025	1,011
Other receivables	4,622	2,534
Prepaid expenses and other current assets	5,356	5,056
Income tax refundable	1,746	484
Total current assets	97,261	72,316
PROPERTY AND EQUIPMENT, at cost	135,234	132,775
Less accumulated depreciation and amortization	(91,914)	(85,020)
Property and equipment, net	43,320	47,755
OTHER ASSETS:
Operating lease right-of-use assets	290,296	310,238
Other noncurrent assets	3,773	4,323
Acquired leasehold interest, net	5,202	5,736
Total other assets	299,271	320,297
Total assets	439,852	440,368
CURRENT LIABILITIES:
Current portion of long-term debt and finance lease obligations	1,660	3,498
Current portion of operating lease liability	28,583	23,736
Trade accounts payable	13,901	14,641
Accrued expenses:
Payroll and employee benefits	15,393	16,780
Self-insurance reserves, current portion	12,665	13,829
Deferred income	25,900	0
Other Liabilities, Current	14,743	11,545
Total current liabilities	112,845	84,029
NONCURRENT LIABILITIES:
Long-term debt and finance lease obligations, less current portion and deferred financing costs, net	58,526	70,637
Operating lease liability, less current portion	274,155	295,636
Self-insurance reserves, less current portion	15,476	16,291
Government settlement accrual	8,000	9,000
Other noncurrent liabilities	2,155	1,691
Total noncurrent liabilities	358,312	393,255
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ DEFICIT:
Common stock, authorized 20,000 shares, $.01 par value, 7,079 and 6,908 shares issued, and 6,847 and 6,676 shares outstanding, respectively	71	69
Treasury stock at cost, 232 shares of common stock	(2,500)	(2,500)
Paid-in capital	24,596	24,026
Accumulated deficit	(53,510)	(59,079)
Accumulated other comprehensive income	38	568
Total shareholders’ deficit	(31,305)	(36,916)
Total liabilities and shareholder's equity	$ 439,852	$ 440,368

XML

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares issued (in shares)	7,079,000	6,908,000
Common stock, shares outstanding (in shares)	6,847,000	6,676,000
Treasury stock, shares (in shares)	232,000	232,000

XML

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
PATIENT REVENUES, NET	$ 475,718	$ 475,020
OTHER OPERATING INCOME	23,802	0
EXPENSES:
Operating	389,248	380,870
Lease and rent expense	54,001	52,990
Professional liability	8,310	6,996
Government settlement expense	0	3,100
General and administrative	27,691	28,009
Depreciation and amortization	9,069	9,122
Total expenses	488,319	481,087
OPERATING INCOME (LOSS)	11,201	(6,067)
OTHER INCOME (EXPENSE):
Other income	53	281
Interest expense, net	(5,008)	(5,994)
Debt retirement costs	(247)	0
Total other income (expense)	(5,202)	(5,713)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	5,999	(11,780)
(PROVISION) BENEFIT FOR INCOME TAXES	531	(15,694)
INCOME (LOSS) FROM CONTINUING OPERATIONS	6,530	(27,474)
INCOME (LOSS) FROM DISCONTINUED OPERATIONS:
Operating loss, net of income tax (provision) benefit of $365 and ($517), respectively	(1,371)	(9,322)
Gain on lease modification, net of tax	0	733
INCOME (LOSS) FROM DISCONTINUED OPERATIONS	(1,371)	(8,589)
NET INCOME (LOSS)	$ 5,159	$ (36,063)
Per common share – basic
Continuing operations (in dollars per share)	$ 0.99	$ (4.25)
Discontinued operations (in dollars per share)	(0.21)	(1.33)
Net income (loss) (in dollars per share)	0.78	(5.58)
Per common share – diluted
Continuing operations (in dollars per share)	0.97	(4.25)
Discontinued operations (in dollars per share)	(0.20)	(1.33)
Diluted net income (loss) per common share (in dollars per share)	0.77	(5.58)
DIVIDENDS DECLARED PER SHARE OF COMMON STOCK (in dollars per share)	$ 0	$ 0
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic (in shares)	6,615	6,459
Diluted (in shares)	6,705	6,459

XML

Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Tax benefit on operating income	$ 365	$ (517)

XML

Consolidated Statements Of Comprehensive Income (loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statement of Comprehensive Income [Abstract]
NET INCOME (LOSS)	$ 5,159	$ (36,063)
OTHER COMPREHENSIVE INCOME (LOSS):
Change in fair value of cash flow hedge, net of tax	(530)	(269)
Total other comprehensive income (loss)	(530)	(269)
COMPREHENSIVE INCOME (LOSS)	$ 4,629	$ (36,332)

XML

Consolidated Statements of Shareholders' Equity (Deficit) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Treasury Stock	Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income
Balance (in shares) at Dec. 31, 2018		6,751	232
Balance at Dec. 31, 2018	$ (1,198)	$ 68	$ (2,500)	$ 23,413	$ (23,016)	$ 837
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(36,063)				(36,063)
Issuance/redemption of equity grants, net (in shares)		157
Issuance/redemption of equity grants, net	41	$ 1		40
Interest rate cash flow hedge	(269)					(269)
Stock based compensation	573			573
Balance (in shares) at Dec. 31, 2019		6,908	232
Balance at Dec. 31, 2019	(36,916)	$ 69	$ (2,500)	24,026	(59,079)	568
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	5,159				5,159
Issuance/redemption of equity grants, net (in shares)		171
Issuance/redemption of equity grants, net	2	$ 2
Interest rate cash flow hedge	(120)				410	(530)
Stock based compensation	570			570
Balance (in shares) at Dec. 31, 2020		7,079	232
Balance at Dec. 31, 2020	$ (31,305)	$ 71	$ (2,500)	$ 24,596	$ (53,510)	$ 38

XML

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
NET INCOME (LOSS)	$ 5,159	$ (36,063)
Loss from discontinued operations	(1,371)	(8,589)
Income (loss) from continuing operations	6,530	(27,474)
Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:
Depreciation and amortization	9,069	9,122
Deferred income tax provision (benefit)	(1,227)	15,421
Provision for self-insured professional liability, net of cash payments	372	4,739
Stock based and deferred compensation	570	573
Debt retirement costs	247	0
Provision for leases, net of cash payments	3,063	3,897
Amortization of right-of-use assets	23,942	21,890
Government settlement expense	0	3,100
Other	482	1,507
Changes in other assets and liabilities affecting operating activities:
Receivables	6,816	9,200
Prepaid expenses and other assets	(3,060)	(6,693)
Trade accounts payable and accrued expenses	(579)	(1,793)
Deferred income	25,900	0
Operating lease liabilities	(23,938)	(21,154)
Net cash provided by continuing operations	48,187	12,335
Net cash used in discontinued operations	(1,371)	(7,003)
Net cash provided by operating activities	46,816	5,332
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(4,100)	(4,980)
Purchases of property and equipment with stimulus funds	(1,496)	0
Net cash used in continuing operations	(5,596)	(4,980)
Net cash provided by discontinued operations	0	6
Net cash used in investing activities	(5,596)	(4,974)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt and finance lease obligations	(81,864)	(12,541)
Proceeds from issuance of debt	68,485	12,500
Proceeds from stimulus funds used to purchase property and equipment	1,496	0
Financing costs	(1,228)	(333)
Issuance and redemption of employee equity awards	2	41
Net cash used in continuing operations	(13,109)	(333)
Net cash provided by (used in) discontinued operations	0	0
Net cash used in financing activities	(13,109)	(333)
NET INCREASE IN CASH	28,111	25
CASH, beginning of period	2,710	2,685
CASH, end of period	30,821	2,710
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash payments of interest	4,483	5,390
Cash payments of income taxes	57	432
SUPPLEMENTAL INFORMATION ON NON-CASH INVESTING AND FINANCING TRANSACTIONS:
Acquisition of equipment through finance lease	44	483
Acquisition of operating leases through adoption of ASC Topic 842	0	389,403
Lease modification	$ 7,051	$ (48,877)

XML

Business and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Business and Summary of Significant Accounting Policies

BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Diversicare Healthcare Services, Inc. ("Diversicare" or the "Company") provides a broad range of post-acute care services to patients and residents including skilled nursing, ancillary health care services and assisted living. In addition to the nursing and social services usually provided in long-term care centers, we offer a variety of rehabilitative, nutritional, respiratory, and other specialized ancillary services. The Company operates and reports as one reportable operating segment. The Company believes that this structure reflects its current operational and financial management.

As of December 31, 2020, our continuing operations consist of 61 nursing centers with 7,250 licensed skilled nursing beds. Our nursing centers range in size from 50 to 320 licensed nursing beds. The licensed nursing bed count does not include 397 licensed assisted living and other residential beds. Our continuing operations include centers in Alabama, Indiana, Kansas, Mississippi, Missouri, Ohio, Tennessee, and Texas. The number of centers and beds denoted in these consolidated financial statements are unaudited.

COVID-19 Pandemic

In January 2020, the Secretary of U.S. Department of Health and Human Services (“HHS”) declared a national public health emergency due to a novel coronavirus. In March 2020, the World Health Organization categorized COVID-19, a disease caused by this coronavirus (“COVID-19”), as a pandemic. According to the Centers for Disease Control and Prevention (“CDC”), older adults and people with certain underlying medical conditions are at higher risk for serious illness from COVID-19. CDC has identified nursing home populations as being at high risk of being affected by pathogens like COVID-19 as a result of the congregate nature of nursing homes and the resident population served.

The Centers for Medicare & Medicaid Services (“CMS”) and the CDC have issued guidance to state and local governments and long-term care facilities to help mitigate the spread of COVID-19. For example, on March 13, 2020, CMS issued a memorandum directing long-term care facilities to significantly restrict visitors and nonessential workers and to restrict communal activities, among other measures. On May 18, 2020, CMS provided “reopening” recommendations for state and local officials to determine the level of mitigation needed to prevent the transmission of COVID-19 in nursing homes, including criteria for relaxing various restrictions. CMS has also announced COVID-19 reporting requirements and focused infection control surveys intended to assess long-term care facility compliance with infection control requirements in connection with the COVID-19 pandemic. CDC guidance includes infection prevention and control practices intended to protect both nursing home residents and healthcare personnel.

On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) which includes, among other things, modifications to the limitation on business interest expense and net operating loss provisions relative to the payment of Federal income taxes and allows an optional payment deferral of the employer's portion of Social Security taxes that were otherwise due through December 31, 2020. These provisions of the CARES Act were effective after the date of enactment and also include the appropriation of stimulus funds to Medicare and Medicaid providers. The Paycheck Protection Program and Health Care Enhancement Act ("PPPHCE Act"), enacted on April 24, 2020, and the Consolidated Appropriations Act, 2021 ("CAA"), enacted December 27, 2020, provide for additional emergency appropriations for COVID-19 response.

Together, the CARES Act, PPPHCE Act, and CAA authorize funding to healthcare entities to be distributed through the Public Health and Social Services Emergency Fund ("PHSSEF"), also known as the Provider Relief Fund. Payments from PHSSEF are intended to compensate providers for lost revenues and healthcare-related expenses attributable to the COVID-19 pandemic only. As long as the recipient has sufficient COVID-19 attributable expenses and lost revenues, as defined by the PHSSEF, between January 1, 2020 and June 30, 2021 and complies with certain terms and conditions, these payments are not required to be repaid. The terms and conditions include, among others, requirements to comply with certain reporting requirements, limitations on balance billing and restrictions against using PHSSEF funds to reimburse expenses or losses that have been reimbursed from other sources or that other sources are obligated to reimburse. On December 27, 2020, the CAA was enacted which included clarifications addressing the calculation and reporting of lost revenue. Additionally, the CAA indicated that targeted distribution payments made to an eligible entity may be allocated by the entity's parent organization among its subsidiary eligible health care providers. On January 15, 2021, HHS released additional guidance explaining the updated requirements implemented by the CAA on calculating lost revenue and the reporting process. In addition, the CAA also indicates that targeted distribution payments made to an eligible entity may be allocated by the entity's parent organization

among its subsidiary eligible health care providers, and the entity receiving the targeted distribution payments remains responsible for reporting obligations. The Company is utilizing these funds to compensate for COVID-19 attributable lost revenues and pay for permissible expenses, including but are not limited to increased wages and increased costs for personal protective equipment, infection control supplies, and COVID-19 testing. The Company is still evaluating the most recent guidance; however, the Company currently anticipates, but cannot guarantee, that it will have sufficient COVID-19 attributable expenses and lost revenues to retain the PPSSEF payments it has received to date. The Company will not be able to determine the amount of used funds until the form, process and reporting rules are finalized by the federal- government, and the Company knows the full extent of its COVID-19 attributable expenses and lost revenues. There also can be no assurance that the PHSSEF funds will ultimately be enough to reimburse the Company for the full extent of its COVID-19 attributable expenses.

In addition, we have experienced and may continue to experience supply chain disruptions, including delays and price increases in equipment, pharmaceuticals, and medical supplies. Staffing, equipment, and pharmaceutical and medical supplies and vaccine shortages may impact our ability to admit and treat patients. We have incurred, and may continue to incur, increased expenses arising from the COVID-19 pandemic. We have also experienced reduced occupancy in our centers, in part due to perceived risks by patients and family members of residential care and their perception of restrictions such as limited visitation policies, a reduction in patients released to nursing homes from hospitals and other healthcare facilities, and a general reluctance to seek medical care or interface with the healthcare system during the pandemic or for an undetermined period of time. Occupancy may also be affected by the data each nursing home is required to report, including the number of confirmed and suspected cases of COVID-19 and resident deaths related to COVID-19, which is made publicly available through the CDC National Healthcare Safety Network.

Since the end of the year, there have been additional cases of COVID-19 at certain of our centers. The Company has continued to experience reduced occupancy and increased operating expenses at its centers in the form of increased wages and increased costs for personal protective equipment, food and certain other supplies. The Company expects such increased expenses to continue and likely increase further into 2021. Refer to Note 2 "COVID-19 Pandemic" for further information.

Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the financial position, operations and accounts of Diversicare and its subsidiaries, all wholly-owned. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Revenue Recognition

The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services.

Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.

The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts, within each respective group listed below, are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).

In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of

previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes.

The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized at a point in time, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.

The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed. See Note 5, “Revenue Recognition and Receivables.”

CARES Act and PPPHCE Act Funds

During 2020, the Company implemented certain changes to our accounting policies related to the recognition of stimulus funds through the CARES Act, the PPPHCE Act and CAA. There is no U.S. GAAP that explicitly covers accounting for government "grants" to for-profit entities with the exception of certain agricultural subsidies. In the absence of authoritative U.S. GAAP guidance, the Company considered the application of other authoritative accounting guidance by analogy and concluded that the guidance outlined in International Accounting Standard 20 - Accounting for Government Grants and Disclosures of Government Assistance ("IAS 20") was the most appropriate analogy for the purpose of recording and classifying the federal and state grant funds received by the Company. Under IAS 20, once it is reasonably assured that the entity will comply with the conditions of the grant, the grant money should be recognized on a systematic basis over the periods in which the entity recognizes the related expenses or losses for which the grant money is intended to compensate. The Company recognizes grants once both of the following conditions are met: (1) the Company is eligible to receive the grant, and (2) the Company is able to comply with the relevant conditions of the grant. In accordance with such conditions, Federal and state stimulus funds that are recognized to offset healthcare related expenses and/or lost revenue attributable to COVID-19 are reflected as "other operating income" on the accompanying consolidated statement of operations. Federal stimulus funds received and used toward capital improvements that assist with the response to and prevention and spread of COVID-19 is accounted for as a capital grant. For such an asset acquired with the use of a stimulus funds, the Company will recognize the asset as a net zero asset. Refer to Note 2, "COVID-19 Pandemic" for additional information.

Additionally, the Company has received Medicaid stimulus funds, which are recognized in accordance with ASC 606. Refer to Note 5, "Revenue Recognition and Receivables" for additional information.

Lease Expense

As of December 31, 2020, the Company operates 46 nursing centers under operating leases, including 23 owned by Omega, 20 owned by Golden Living and three owned by other parties. The Company's operating leases generally require the Company to pay stated rent, subject to increases based on changes in the Consumer Price Index or a minimum percentage increase. The Company's Master Lease Agreements with Omega and Golden Living require the Company to pay certain scheduled rent increases. Such scheduled rent increases are recorded as additional lease expense on a straight-line basis recognized over the term of the related leases and the difference between the amounts recorded for rent expense as compared to rent payments is recorded as an accrued liability.

See Note 3, "Business Development and Other Significant Transactions" and Note 12, "Commitments and Contingencies" for a discussion regarding the Company's Master Lease Agreements with Omega and Golden Living and the addition of certain leased centers.

Classification of Expenses

The Company classifies all expenses (except lease, interest, depreciation and amortization expenses) that are associated with its corporate and regional management support functions as general and administrative expenses within continuing operations. All other expenses (except lease, professional liability, government settlement expense, interest, depreciation and amortization expenses) incurred by the Company at the center level for continuing operations are classified as operating expenses.

Property and Equipment

Property and equipment are recorded at cost or at fair value determined on the respective dates of acquisition for assets obtained in a business combination, with depreciation and amortization being provided over the shorter of the remaining lease term (where applicable) or the assets' estimated useful lives on the straight-line basis as follows:

Buildings and improvements	-	5 to 40 years
Leasehold improvements	-	2 to 10 years
Furniture, fixtures and equipment	-	2 to 15 years

Interest incurred during construction periods for qualifying expenditures is capitalized as part of the building cost. Maintenance and repairs are expensed as incurred, and major betterments and improvements are capitalized.

The Company routinely evaluates the recoverability of the carrying value of its long-lived assets, including property and equipment and right of use assets. The evaluation for recoverability includes when significant adverse changes in the general economic conditions and significant deteriorations of the underlying undiscounted cash flows or fair values of the asset group indicate that the carrying amount of the asset group may not be recoverable. If circumstances suggest that the recorded amounts are not recoverable based upon estimated future undiscounted cash flows, the carrying values of such assets are reduced to fair value.

Cash

Cash and cash equivalents include cash on deposit with banks and all highly liquid investments with original maturities of three months or less when purchased. Our cash on deposit with banks was subject to the Federal Deposit Insurance Corporation ("FDIC") minimum insurance levels.

Deferred Financing and Other Costs

The Company records deferred financing and lease costs for direct and incremental expenditures related to entering into or amending debt and lease agreements. These expenditures include lenders' and attorneys' fees. Financing costs are amortized using the effective interest method over the term of the related debt. The amortization is reflected as interest expense in the accompanying consolidated statements of operations. See Note 8, "Long-term Debt, Interest Rate Swap and Finance Lease Obligations" for further discussion.

Acquired Leasehold Interest

The Company has recorded an acquired leasehold interest intangible asset related to an acquisition completed during 2007. The intangible asset is accounted for in accordance with the Financial Accounting Standards Board's ("FASB") guidance on goodwill and other intangible assets, and is amortized on a straight-line basis over the remaining life of the acquired lease. As discussed in Note 3, "Business Developments and Other Significant Transactions," the Company entered into a new Master Lease Agreement (the "Omega Master Lease") with  Omega Healthcare Investors ("Omega") on October 1, 2018, which was subsequently modified on August 30, 2019. The Omega Master Lease includes the seven centers to which the intangible asset relates. As such, the intangible asset is now being amortized over an adjusted remaining life, consistent with the term of the Omega Master Lease, which goes through September 30, 2030. Amortization expense of approximately $534 and $571 related to this intangible asset was recorded during each of the years ended December 31, 2020 and 2019, respectively.

The carrying value of the acquired leasehold interest intangible and the accumulated amortization are as follows:

	December 31,
	2020		2019
Acquired leasehold interest, gross	$	10,652	$	10,652
Accumulated amortization	(5,450)		(4,916)
Acquired leasehold interest, net	$	5,202	$	5,736

The Company evaluates the recoverability of the carrying value of the acquired leasehold intangible in accordance with the FASB's guidance on accounting for the impairment or disposal of long-lived assets. Included in this evaluation is whether significant adverse changes in general economic conditions, and significant deteriorations of the underlying cash flows or fair values of the intangible asset indicate that the carrying amount of the intangible asset may not be recoverable. The need to recognize an impairment charge is based on estimated future undiscounted cash flows from the asset compared to the carrying value of that asset. If recognition of an impairment charge is necessary, it is measured as the amount by which the carrying amount of the intangible asset exceeds the fair value of the intangible asset.

The expected amortization expense for the acquired leasehold interest intangible asset is as follows:

2021	$	534
2022	534
2023	534
2024	534
2025	534
Thereafter	2,532
	$	5,202

Self-Insurance

Self-insurance liabilities primarily represent the unfunded accrual for self-insured risks associated with general and professional liability claims, employee health insurance and workers' compensation. The Company's health insurance liability is based on known claims incurred and an estimate of incurred but unreported claims determined by an analysis of historical claims paid. The Company's workers' compensation liability relates primarily to periods of self-insurance and consists of an estimate of the future costs to be incurred for the known claims.

Final determination of the Company's actual liability for incurred general and professional liability claims is a process that may take years. The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this unfunded accrual. The actuary assists management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished by the Company. The actuary primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods.

On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company's insurers and a third party claims administrator, contain information relevant to the actual expense already incurred for each claim as well as the third-party administrator's estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company's evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual has an unfavorable impact on results of operations in the period and any reduction in the accrual increases results of operations during the period.

All losses are projected on an undiscounted basis. The self-insurance liabilities include estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of related legal costs incurred and expected to be incurred.

One of the key assumptions in the actuarial analysis is that historical losses provide an accurate forecast of future losses. Changes in legislation such as tort reform, changes in our financial condition, changes in our risk management practices and other factors may affect the severity and frequency of claims incurred in future periods as compared to historical claims.

The facts and circumstances of each claim vary significantly, and the amount of ultimate liability for an individual claim may vary due to many factors, including whether the case can be settled by agreement, the quality of legal representation, the individual jurisdiction in which the claim is pending, and the views of the particular judge or jury deciding the case.

Although the Company adjusts its unfunded accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company's actual liability for claims incurred in any given period is a process that takes years. As a result, the Company's actual liabilities may vary significantly from the unfunded accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company's results of operations and financial position for the period in which the change in accrual is made.

Income Taxes

The Company follows the FASB's guidance on Income Taxes, which requires the asset and liability method of accounting for income taxes whereby deferred income taxes are recorded for the future tax consequences attributable to differences between the financial statement and tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are provided against any estimated non-realizable deferred tax assets where necessary.

Where the Company believes that a tax position is supportable for income tax purposes, the item is included in its income tax returns. Where treatment of a position is uncertain, liabilities are recorded based upon the Company’s evaluation of the “more likely than not” outcome considering the technical merits of the position. While the judgments and estimates made by the Company are based on management’s evaluation of the technical merits of a matter, historical experience and other assumptions that management believes are appropriate and reasonable under current circumstances, actual resolution of these matters may differ from recorded estimated amounts, resulting in charges or credits that could materially affect future financial statements. See Note 11, "Income Taxes" for additional information related to the provision for income taxes.

Disclosure of Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. In calculating fair value, a company must maximize the use of observable market inputs, minimize the use of unobservable market inputs and disclose in the form of an outlined hierarchy the details of such fair value measurements. The carrying amounts of cash, receivables, trade accounts payable and accrued expenses approximate fair value because of the short-term nature of these accounts. The Company's self-insurance liabilities are reported on an undiscounted basis as the timing of estimated settlements cannot be determined.

The Company follows the FASB's guidance on Fair Value Measurements and Disclosures which provides rules for using fair value to measure assets and liabilities as well as a fair value hierarchy that prioritizes the information used to develop the measurements. It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As further discussed in Note 8, "Long-term Debt, Interest Rate Swap and Finance Lease Obligations", the Company terminated its interest rate swap in conjunction with refinancing its debt in October 2020.

As the Company's interest rate swap, a cash flow hedge, was not traded on a market exchange, the fair value was determined using a valuation model based on a discounted cash flow analysis. This analysis reflected the contractual terms of the interest rate swap agreement and used observable market-based inputs, including estimated future LIBOR interest rates. The fair value of the Company's interest rate swap was the net difference in the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts were based on the expectation of future interest rates and were observable inputs available to a market participant. The interest rate swap valuation was classified in Level 2 of the fair value hierarchy. The debt balances as presented in the consolidated balance sheets approximate the fair value of the respective instruments as the debt was at a variable rate, the estimates of which were considered Level 2 fair value calculations within the fair value hierarchy.

The following table presents by level, within the fair value hierarchy, assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 and 2019:

December 31, 2020	Fair Value Measurements - Assets (Liabilities)
	Total		Level 1		Level 2		Level 3
Interest rate swap	$	—	$	—	$	—	$	—
December 31, 2019	Fair Value Measurements - Assets (Liabilities)
	Total		Level 1		Level 2		Level 3
Interest rate swap	$	(57)	$	—	$	(57)	$	—

The change in fair value of the Company's cash flow hedge is detailed in the Company's Consolidated Statements of Comprehensive Income (Loss).

Net Income (Loss) per Common Share

The Company follows the FASB's guidance on Earnings Per Share for the financial reporting of net income (loss) per common share. Basic earnings per common share excludes dilution and restricted shares and is computed by dividing income available to common shareholders by the weighted-average number of common shares, excluding restricted shares, outstanding for the period. Diluted earnings per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or otherwise resulted in the issuance of common stock that then shared in the earnings of the Company. See Note 10, "Net Income (Loss) per Common Share" for additional disclosures about the Company's Net Income (Loss) per Common Share.

Stock Based Compensation

The Company follows the FASB's guidance on Stock Compensation to account for share-based payments granted to team members and recorded non-cash stock based compensation expense of $570 and $573 during the years ended December 31, 2020 and 2019, respectively. Such amounts are included as components of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. See Note 9, "Shareholders' Equity, Stock Plans and Preferred Stock" for additional disclosures about the Company's stock based compensation plans.

Accumulated Other Comprehensive Income (Loss)

Accumulated other comprehensive income consists of other comprehensive income (loss). Comprehensive income (loss) is a more inclusive financial reporting method that includes disclosure of financial information that historically has not been recognized in the calculation of net income (loss). Currently, the Company's other comprehensive income (loss) consists of the change in fair value of the Company's interest rate swap transaction previously accounted for as a cash flow hedge.

Accounting Standards Recently Issued

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new guidance intends to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for smaller reporting companies for the fiscal year beginning after December 15, 2022 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related disclosures.

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848). The new guidance contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU No. 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the first quarter of 2020, the Company has elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The amendments in the ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The Company continues to evaluate changes in the market and may apply other elections, as applicable, in the future as allowed under ASU No. 2020-04.

XML

COVID-19 PANDEMIC

12 Months Ended

Dec. 31, 2020

Unusual or Infrequent Items, or Both [Abstract]

COVID-19 PANDEMIC

COVID-19 PANDEMICAs of December 31, 2020, the Company has received $47,158 from the PHSSEF, and recognized $19,762 as income, which is included in "other operating income" in the Company's results of operations for the year ended December 31, 2020. For the year ended December 31, 2020, the Company utilized $1,496 of these stimulus dollars to fund capital improvements to prevent the spread of COVID-19. The remaining stimulus funds of $25,900 as of December 31, 2020 are classified as "deferred income" on the consolidated balance sheet, which also includes Nursing Home Infection Control Distributions. The Nursing Home Infection Control Distributions, which also include infection control quality incentive payments, are subject to terms and conditions that require recipients to use the funds for infection control expenses. HHS has not yet published reporting requirements for these distributions and has not yet stipulated a time period by which these funds must be used. Additionally, the Families First Coronavirus Response Act provided states with a temporary increase in the regular federal matching rate, or federal medical assistance percentage, used to determine the federal government's share of the cost of covered services in state Medicaid programs, provided the states agreed to certain conditions such as not imposing cost-sharing requirements for COVID-19-related testing and treatment. The Company recognized $4,040 of grant funds from states, which is included in "other operating income" in the Company's results of operations for the year ended December 31, 2020. The Company recognized $16,965 for the year ended December 31, 2020 of Medicaid and Hospice dollars related to this temporary increase

in the federal matching rate, which related to patient services rendered between March and December 2020 and is reflected in "patient revenues, net" in the Company's results of operations for the year ended December 31, 2020.

The Company initially elected to participate in the payment deferral of the employer's portion of Social Security taxes. During the third quarter of 2020, the Company ceased the deferral election and paid $3,185. As of December 31, 2020, the Company has no remaining liability related to the payment deferral and does not expect to participate in the payment deferral going forward.

The CARES Act and other stimulus legislation also include other provisions offering financial relief, for example suspending the Medicare sequestration from May 1, 2020 through March 31, 2021, which would have otherwise reduced payments to Medicare providers by 2%, although the sequestration was extended through 2030. For the twelve months ended December 31, 2020, the suspension of the Medicare sequestration positively impacted net patient revenues by $1,824.

The Company incurred an additional $21,211 of labor expenses, $4,661 of supplies expense, $5,978 of employee testing expense and $491 of travel expense related to the COVID-19 pandemic for the year ended December 31, 2020. These expenses are reflected in "operating expense" in the Company's results of operations for the year ended December 31, 2020.

The Company is closely monitoring and evaluating the impact of the COVID-19 pandemic on all aspects of its business. We have identified team members and patients who have tested positive for COVID-19 at all of our centers, and we have incurred an increase in the costs of caring for the team members, patients, and residents in those centers. The Company has also experienced reduced occupancy at its centers and has incurred additional expenditures preparing its centers for potential outbreaks and maintaining the healthcare delivery capacity of its centers. While we have experienced reduced occupancy and increased expenses, we received additional PHSSEF and other stimulus funds during 2020, which have been used and are expected to continue to be used to mitigate the impact of COVID-19 attributable lost revenues associated with the reduced occupancy as well as increased expenses, and any cash flow or liquidity impacts therefrom. The Company has an interdisciplinary team monitoring and staying up to date on the latest information about COVID-19. The Company has implemented precautionary measures and response protocols to minimize the spread of COVID-19, following guidance from CMS and the CDC. Nevertheless, the Company expects additional COVID-19 cases will occur at our facilities. The Company is continuing to evaluate and consider the potential impact that COVID-19 may have on its liquidity, financial condition and results of operations due to numerous uncertainties. However, given the uncertainty as to the duration of the COVID-19 pandemic and the timing and availability of effective medical treatment and vaccines, it could have a material adverse effect on the Company's future results of operations, financial condition and liquidity.

XML

Business Developments and Other Significant Transactions

12 Months Ended

Dec. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Developments and Other Significant Transactions

BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS

2018 Omega Master Lease

On October 1, 2018, the Company entered into the Omega Master Lease Agreement (the "Lease") with Omega to lease 34 centers currently owned by Omega and operated by Diversicare. The old Master Lease with the Lessor provided for its operation of 23 skilled nursing centers in Texas, Kentucky, Alabama, Tennessee, Florida, and Ohio. Additionally, Diversicare operated 11 centers owned by Omega under separate leases in Missouri, Kentucky, Indiana, and Ohio. The Omega Master Lease entered into by Diversicare and Omega consolidated the leases for all 34 centers under one new Master Lease Agreement. The Omega Master Lease has an initial term of twelve years with two optional 10-year extensions. The Lease has a common date of annual lease fixed escalators of 2.15% beginning on October 1, 2019.

On August 30, 2019, the Company terminated operations of ten centers in Kentucky and concurrently transferred operations to a new operator. The agreement effectively amended the Omega Master Lease to remove the ten Kentucky facilities, reduce the annual rent expense, and release the Company from any further obligations arising under the Omega Master Lease with respect to the Kentucky facilities. The remaining Lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15% beginning on October 1, 2019.

Therapy Services

Effective November 1, 2020, the Company entered into agreements with a third party therapy company to outsource the therapy services that were previously provided by the Company through its wholly owned subsidiary Diversicare Therapy Services. The outsourced services include all physical, occupational, and speech therapy provided to patients of the Company’s facilities. The contracts are for a three-year term, absent termination for cause by either party.

2020 Lease Amendment

On December 1, 2020, the Company entered into an agreement with Omega to transfer operations of a facility located in Florida to another operator. The agreement effectively amended the Omega Master Lease to remove this center, reduce the annual rent expense, and release the Company from any further obligations arising under the Omega Master Lease with respect to the Florida facility. The remaining Lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15%.

Quality Incentive Payment Program

The Company recently expanded its participation in a QIPP as administered by the Texas Health and Human Services Commission. QIPP provides supplemental Medicaid payments for skilled nursing centers that achieve certain quality measures. The Company previously had one of its Texas skilled nursing centers participating in the QIPP. During April 2019, the Company enrolled an additional eleven of its Texas skilled nursing centers in the program, such that eleven of the Company’s centers participate in the QIPP effective September 1, 2019. To allow four of these centers to meet the QIPP participation requirements, the Company entered into a transaction with a Texas medical district already participating in the QIPP, providing for the transfer of the provider license from the Company to the medical district. The Company’s operating subsidiary retained the management of the centers on behalf of the medical district.

XML

Discontinued Operations

12 Months Ended

Dec. 31, 2020

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

DISCONTINUED OPERATIONS

Kentucky Disposition

On October 30, 2018, the Company entered into an Asset Purchase Agreement (the "Agreement") with Fulton Nursing and Rehabilitation, LLC, Holiday Fulton Propco LLC, Birchwood Nursing and Rehabilitation LLC, Padgett Clinton Propco LLC, Westwood Nursing and Rehabilitation LLC, and Westwood Glasgow Propco (the "Buyers") to sell the assets and transfer the operations of Diversicare of Fulton, LLC, Diversicare of Clinton, LLC and Diversicare of Glasgow, LLC (the "Kentucky Properties"). On December 1, 2018, the Company completed the sale of the Kentucky Properties with the Buyers for a purchase price of $18,700. The carrying value of these centers' assets was $13,331, resulting in a gain, net of miscellaneous closing costs, of $4,825. The proceeds were used to relieve debt, as required under the terms of the Company's Amended Mortgage Loan and Amended Revolver. Refer to Note 8, "Long-term Debt, Interest Rate Swap and Finance Lease Obligations" for more information on this transaction.

On May 22, 2019, the Company announced that it entered into an agreement with Omega to amend the Omega Master Lease to terminate operations of ten nursing facilities, totaling approximately 885 skilled nursing beds, located in Kentucky and to concurrently transfer operations to an operator selected by Omega. These ten centers are collectively referred to as the "Kentucky Centers." The sale of the Kentucky Properties and the termination of operations at the Kentucky Centers are referred to collectively as the "Kentucky Exit." On August 30, 2019, the Company completed the transaction and no longer operates any skilled nursing centers in the State of Kentucky. The Company's exit from the state represents a strategic shift that has (or will have) a major effect on the Company's operations and financial results. In accordance with ASC 205-20, Presentation of Financial Statements- Discontinued Operations, the Company's discontinued financial position, results of operations and cash flows have been reclassified on the face of the financial statements and footnotes for all periods presented to reflect the discontinued status of these operations.

The transaction resulted in a gain on the modification of the Lease, which is presented within Discontinued Operations on the Consolidated Statements of Operations. The net gain on the transaction was $733.

These centers contributed revenues of $46,019 during the year ended December 31, 2019, and net loss of $1,371 and $8,589 during the years ended December 31, 2020 and 2019, respectively. The net income or loss for the nursing centers included in discontinued operations does not reflect any allocation of corporate general and administrative expense. The Company considered these additional costs along with the centers' future prospects based upon operating history when determining the contribution of the skilled nursing centers to its operations.

The Company did not transfer the accounts receivable or liabilities, inclusive of the reserves for professional liability and workers' compensation, to the new operator. The Company expects to collect the balance of the accounts receivable and pay the remaining liabilities in the ordinary course of business through its future operating cash flows.

XML

Revenue Recognition and Receivables

12 Months Ended

Dec. 31, 2020

Revenue from Contract with Customer [Abstract]

Revenue Recognition and Receivables

REVENUE RECOGNITION AND RECEIVABLES

The Company's revenue is derived from providing quality healthcare services to its patients. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. The promise to provide quality care is accounted for as a single performance obligation satisfied at a point in time, when those services are rendered on a daily basis.

The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts, within each respective group listed below, are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).

Disaggregation of Revenue and Accounts Receivable

In accordance with ASC 606, the Company recognized $16,142 and $823 of Medicaid and Hospice stimulus dollars, respectively, for the twelve months ended December 31, 2020 that are reflected as patient revenues in the Company's results of operations and in the table below. Refer to Note 2, "COVID-19 Pandemic" for more information. The following table set forth net patient revenues related to our continuing operations by payor source for the periods presented (dollar amounts in thousands):

	Twelve Months Ended December 31,
	2020				2019
Medicaid	$	217,147	45.6	%	$	222,560	46.9	%
Medicare	94,375		19.8	%	80,798		17.0	%
Managed Care	49,708		10.4	%	50,323		10.6	%
Private Pay and other	114,488		24.2	%	121,339		25.5	%
Total	$	475,718	100.0	%	$	475,020	100.0	%

Accounts receivable as of December 31, 2020 and 2019 is summarized in the following table:

	December 31,
	2020		2019
Medicaid	$	17,354	$	21,998
Medicare	14,273		11,811
Managed Care	8,021		9,103
Private Pay and other	14,043		17,609
Total accounts receivable	$	53,691	$	60,521

XML

Property and Equipment

12 Months Ended

Dec. 31, 2020

Property, Plant and Equipment [Abstract]

Property and Equipment

PROPERTY AND EQUIPMENT

Property and equipment, at cost, consists of the following:

	December 31,
	2020		2019
Land	$	5,265	$	5,265
Buildings and leasehold improvements	85,857		84,544
Furniture, fixtures and equipment	44,112		42,966
	135,234		132,775
Less: accumulated depreciation	(91,914)		(85,020)
Net property and equipment	$	43,320	$	47,755

As discussed further in Note 8, "Long-term Debt, Interest Rate Swap and Finance Lease Obligations", the property and equipment of certain skilled nursing centers are pledged as collateral for mortgage debt obligations. In addition, the Company has assets recorded as finance leased assets purchased through finance lease obligations. The Company capitalizes leasehold improvements which will revert back to the lessor of the property at the expiration or termination of the lease, and depreciates these improvements over the shorter of the remaining lease term or the assets' estimated useful lives.

XML

Leases

12 Months Ended

Dec. 31, 2020

Leases [Abstract]

Leases

LEASES

The Company has operating and finance leases for facilities, corporate offices, and certain equipment. The Company recognizes lease expense for these operating leases on a straight-line basis over the lease term. Leases with an initial term of one year or less are not recorded on the consolidated balance sheet. The Company's other leases have original lease terms of one to twelve years, some of which include options to extend the lease for up to twenty years, and some of which include options to terminate the leases within one year. The exercise of lease renewal options is at our sole discretion. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. Upon adoption of Topic 842, the Company elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs.

On December 1, 2020, the Company entered into an agreement with Omega to transfer operations of the facility located in Florida to another operator. The agreement effectively amended the Omega Master Lease to remove this center, reduce the annual rent expense, and release the Company from any further obligations arising under the Omega Master Lease with respect to the Florida facility. In accordance with ASC 842, the amended lease agreement is considered to be modified and subject to lease modification guidance. The right-of-use asset and lease liabilities related to these agreements were remeasured based on the change in the lease conditions such as rent payment. The remaining Lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15%. The incremental borrowing rate was adjusted to reflect the revised lease terms with became effective at the date of the modification. The net impact of the lease modification is an increase in right-of-use asset and lease liabilities of approximately $7,051.

Leases

	Classification	December 31, 2020		December 31, 2019
Assets
Operating lease assets	Operating lease right-of-use assets	$	290,296	$	310,238
Finance lease assets	Property and equipment, net (a)	508		906
Total leased assets		$	290,804	$	311,144
Liabilities
Current
Operating	Current portion of operating lease liability	$	28,583	$	23,736
Finance	Current portion of long-term debt and finance lease obligations, net	251		231
Noncurrent
Operating	Operating lease liability, less current portion	274,155		295,636
Finance	Long-term debt and finance lease obligations, less current portion and deferred financing costs, net	280		445
Total lease liabilities		$	303,269	$	320,048
(a) Finance lease assets are recorded net of accumulated amortization of $471 and $1,522 as of December 31, 2020 and 2019, respectively.

Lease Cost

		Year Ended		Year Ended
	Classification	December 31, 2020		December 31, 2019
Operating lease cost (a)	Lease and rent expense	$	54,001	$	52,990
Finance lease cost:
Amortization of finance lease assets	Depreciation and amortization	226		263
Interest on finance lease liabilities	Interest expense, net	36		48
Short term lease cost	Operating expense	581		649
Net lease cost		$	54,844	$	53,950
(a) Includes variable lease costs, which are immaterial

Maturity of Lease Liabilities

	As of December 31, 2020
	Operating Leases (a)		Finance Leases (a)		Total
2021	$	51,165	$	282	$	51,447
2022	52,142		209		52,351
2023	53,120		62		53,182
2024	53,064		20		53,084
2025	53,921		—		53,921
After 2025	141,875		—		141,875
Total lease payments	$	405,287	$	573	$	405,860
Less: Interest	(102,549)		(42)		(102,591)
Present value of lease liabilities	$	302,738	$	531	$	303,269
(a) Operating and Finance lease payments exclude options to extend lease terms that are not reasonably certain of being exercised.

The measurement of right-of-use assets and lease liabilities requires the Company to estimate appropriate discount rates. To the extent the rate implicit in the lease is readily determinable, such rate is utilized. However, based on information available at lease commencement for the majority of our leases, the rate implicit in the lease is not known. In these instances, the Company utilizes an incremental borrowing rate, which represents the rate of interest that it would pay to borrow on a fully collateralized basis over a similar term.

Lease Term and Discount Rate

	December 31, 2020	December 31, 2019
Weighted-average remaining lease term (years)
Operating leases	7.91	8.81
Finance leases	2.26	3.00
Weighted-average discount rate
Operating leases	7.9%	8.9%
Finance leases	6.2%	6.1%

Other Information

	Year Ended		Year Ended
	December 31, 2020		December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$	50,869	$	55,485
Operating cash flows for finance leases	36		48
Financing cash flows for finance leases	235		471
Acquisition of operating leases though adoption of Topic 842	—		389,403
Lease modification	$	7,051	$	(48,877)

Leases

LEASES

The Company has operating and finance leases for facilities, corporate offices, and certain equipment. The Company recognizes lease expense for these operating leases on a straight-line basis over the lease term. Leases with an initial term of one year or less are not recorded on the consolidated balance sheet. The Company's other leases have original lease terms of one to twelve years, some of which include options to extend the lease for up to twenty years, and some of which include options to terminate the leases within one year. The exercise of lease renewal options is at our sole discretion. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants. Upon adoption of Topic 842, the Company elected the practical expedient to not separate lease and non-lease components for all of its leases as the non-lease components are not significant to the overall lease costs.

On December 1, 2020, the Company entered into an agreement with Omega to transfer operations of the facility located in Florida to another operator. The agreement effectively amended the Omega Master Lease to remove this center, reduce the annual rent expense, and release the Company from any further obligations arising under the Omega Master Lease with respect to the Florida facility. In accordance with ASC 842, the amended lease agreement is considered to be modified and subject to lease modification guidance. The right-of-use asset and lease liabilities related to these agreements were remeasured based on the change in the lease conditions such as rent payment. The remaining Lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15%. The incremental borrowing rate was adjusted to reflect the revised lease terms with became effective at the date of the modification. The net impact of the lease modification is an increase in right-of-use asset and lease liabilities of approximately $7,051.

Leases

	Classification	December 31, 2020		December 31, 2019
Assets
Operating lease assets	Operating lease right-of-use assets	$	290,296	$	310,238
Finance lease assets	Property and equipment, net (a)	508		906
Total leased assets		$	290,804	$	311,144
Liabilities
Current
Operating	Current portion of operating lease liability	$	28,583	$	23,736
Finance	Current portion of long-term debt and finance lease obligations, net	251		231
Noncurrent
Operating	Operating lease liability, less current portion	274,155		295,636
Finance	Long-term debt and finance lease obligations, less current portion and deferred financing costs, net	280		445
Total lease liabilities		$	303,269	$	320,048
(a) Finance lease assets are recorded net of accumulated amortization of $471 and $1,522 as of December 31, 2020 and 2019, respectively.

Lease Cost

		Year Ended		Year Ended
	Classification	December 31, 2020		December 31, 2019
Operating lease cost (a)	Lease and rent expense	$	54,001	$	52,990
Finance lease cost:
Amortization of finance lease assets	Depreciation and amortization	226		263
Interest on finance lease liabilities	Interest expense, net	36		48
Short term lease cost	Operating expense	581		649
Net lease cost		$	54,844	$	53,950
(a) Includes variable lease costs, which are immaterial

Maturity of Lease Liabilities

	As of December 31, 2020
	Operating Leases (a)		Finance Leases (a)		Total
2021	$	51,165	$	282	$	51,447
2022	52,142		209		52,351
2023	53,120		62		53,182
2024	53,064		20		53,084
2025	53,921		—		53,921
After 2025	141,875		—		141,875
Total lease payments	$	405,287	$	573	$	405,860
Less: Interest	(102,549)		(42)		(102,591)
Present value of lease liabilities	$	302,738	$	531	$	303,269
(a) Operating and Finance lease payments exclude options to extend lease terms that are not reasonably certain of being exercised.

The measurement of right-of-use assets and lease liabilities requires the Company to estimate appropriate discount rates. To the extent the rate implicit in the lease is readily determinable, such rate is utilized. However, based on information available at lease commencement for the majority of our leases, the rate implicit in the lease is not known. In these instances, the Company utilizes an incremental borrowing rate, which represents the rate of interest that it would pay to borrow on a fully collateralized basis over a similar term.

Lease Term and Discount Rate

	December 31, 2020	December 31, 2019
Weighted-average remaining lease term (years)
Operating leases	7.91	8.81
Finance leases	2.26	3.00
Weighted-average discount rate
Operating leases	7.9%	8.9%
Finance leases	6.2%	6.1%

Other Information

	Year Ended		Year Ended
	December 31, 2020		December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$	50,869	$	55,485
Operating cash flows for finance leases	36		48
Financing cash flows for finance leases	235		471
Acquisition of operating leases though adoption of Topic 842	—		389,403
Lease modification	$	7,051	$	(48,877)

XML

Long-Term Debt, Interest Rate Swap and Finance Lease Obligations

12 Months Ended

Dec. 31, 2020

Debt Disclosure [Abstract]

Long-Term Debt, Interest Rate Swap and Finance Lease Obligations

LONG-TERM DEBT, INTEREST RATE SWAP AND FINANCE LEASE OBLIGATIONS

Long-term debt consists of the following:

	December 31,
	2020		2019
Mortgage loan	$	61,087	$	49,743
Acquisition loan	—		9,400
Revolver	—		14,000
Affiliated revolver	—		1,000
	61,087		74,143
Plus finance lease obligations	531		857
Less current portion	(1,660)		(3,498)
	59,958		71,502
Less deferred financing costs, net	(1,432)		(865)
Long-term debt and finance lease obligation, net	$	58,526	$	70,637

The Company maintains a credit facility with a syndicate of banks. The Company originally entered into the credit facility in May 2013, and subsequently amended the facility. As of December 31, 2019, the credit facility consisted of a mortgage loan $67,500, an acquisition loan with a borrowing capacity of $12,500, a revolver with a borrowing capacity of $40,250 and an affiliated revolver with a borrowing capacity of $2,000.

On October 14, 2020, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") with a syndicate of banks, which consists of a $62,000 mortgage loan subsequently amended ("Amended Mortgage Loan"), a $36,000

revolver subsequently amended ("Amended Revolver") and a $2,000 affiliated revolver amended ("Amended Affiliated Revolver"). The Amended Mortgage Loan, Amended Revolver and Amended Affiliated Revolver have a 3-year maturity through September 30, 2023. The Amended Mortgage Loan has a term of 3 years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term loan facility is based on LIBOR plus 4.0% with a 1.0% floor. The Amended Mortgage Loan balance was $61,087 as of December 31, 2020 with an interest rate of 5.0%. The Amended Mortgage Loan consolidated the mortgage and acquisition loans. The Amended Mortgage Loan is secured by 15 owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan, the Amended Revolver and the Amended Affiliated Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver and Amended Affiliated Revolver have an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.

As of December 31, 2020, the Company's weighted average interest rate on long-term debt was approximately 5.0%.

As of December 31, 2020, the Company did not have any borrowings outstanding under its revolvers compared to $15,000 outstanding as of December 31, 2019. Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has 4 letters of credit with a total value of $12,387 outstanding as of December 31, 2020. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolvers and the maximum loan amount, the amount available for borrowing under the revolvers was $16,446 at December 31, 2020.

Our lending agreements contain various financial covenants, the most restrictive of which relate to debt service charge coverage ratios. The Company is in compliance with all such covenants at December 31, 2020.

In connection with the Company's loan agreements, the Company recorded the following amounts related to deferred loan costs:

	2020		2019
Write-off of deferred financing costs	$	247	$	—
Deferred financing costs capitalized	$	1,228	$	333

Scheduled principal payments of long-term debt are as follows:

2021	$	1,404
2022	1,368
2023	58,315
Total	$	61,087

Interest Rate Swap Cash Flow Hedge

The Company terminated its interest rate swap in conjunction with refinancing its debt in October 2020. The applicable guidance requires companies to recognize all derivative instruments as either assets or liabilities at fair value in a company's balance sheets. The interest rate swap had a net zero balance at December 31, 2020.

Finance Lease Obligations

Upon acquisition of some centers, we assumed certain leases, primarily related to equipment, that constitute finance leases. As a result, we have recorded the underlying lease liabilities and financed lease obligations of $531 and $857 as of December 31, 2020 and 2019, respectively. These lease agreements provide three to five year terms.

Scheduled payments of the financed lease obligations are as follows:

2021	$	282
2022	209
2023	62
2024	20
Total	573
Amounts related to interest	(42)
Principal payments on finance lease obligation	$	531

XML

Shareholders' Equity, Stock Plans and Preferred Stock

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Shareholders' Equity, Stock Plans and Preferred Stock

SHAREHOLDERS' EQUITY, STOCK PLANS AND PREFERRED STOCK

Stock Based Compensation Plans

The Company follows the FASB's guidance on Stock Compensation to account for stock-based payments granted to employees and non-employee directors.

Overview of Plans

In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers and 150 shares of the Company's common stock has been reserved for issuance under the Stock Purchase Plan. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period and are subject to forfeiture. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150 shares to 350 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.

In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the Long-Term Incentive Plan to increase the number of shares of our common stock authorized under the Plan from 380 shares to 680 shares. No grants can be made under the 2010 Plan after May 31, 2027.

Equity Grants and Valuations

During 2020 and 2019, the Compensation Committee of the Board of Directors approved grants totaling 198 and 151, respectively, shares of restricted common stock to certain employees and members of the Board of Directors. These restricted shares vest one-third on the first, second and third anniversaries of the grant date. Unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed. Our policy is to account for forfeitures of share-based compensation awards as they occur. On March 31, 2020, the Compensation Committee of the Board of Directors approved the grant of 100 shares of common stock to the Company's Chief Executive Officer, as a one-time bonus in lieu of a 2020 salary increase and as recognition for completing the settlement with the Office of the Inspector General and the disposition of all the Company's facilities in the State of Kentucky. The stock was fully vested on the date of the grant, and the grant date fair value of which was expensed during the quarter ended March 31, 2020.

The Company recorded non-cash stock-based compensation expense from continuing operations for equity grants and RSU's issued under the Plans of $570 and $573 during the years ended December 31, 2020 and 2019, respectively. Such amounts are included as components of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. As of December 31, 2020, there was $196 in unrecognized compensation costs related to stock-based compensation to be recognized over the applicable remaining vesting periods. The Company estimated the total recognized and unrecognized compensation for all options and SOSARs using the Black-Scholes-Merton equity grant valuation model. Restricted stock awards are valued using the market price on the grant date.

The table below shows the weighted average assumptions the Company used to develop the fair value estimates under its option valuation model:

	Year Ended December 31,
	2020	2019
Expected volatility (range)	N/A(1)	N/A(1)
Risk free interest rate (range)	N/A(1)	N/A(1)
Expected dividends	N/A(1)	N/A(1)
Weighted average expected term (years)	N/A(1)	N/A(1)

___________

(1)The Company did not issue any options or other equity grants that would require application of the Black-Scholes-Merton equity grant valuation model during the years ended December 31, 2020 and 2019. All equity grants during

these periods were restricted common shares which are valued using an intrinsic valuation method based on market price.

In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.

In computing the fair value of these equity grants, the Company estimated the equity grants' expected term based on the average of the vesting term and the original contractual terms of the grants.

The table below describes the resulting weighted average grant date fair values calculated as well as the intrinsic value of options exercised under the Company's equity awards during each of the following years:

	Year Ended December 31,
	2020(1)		2019(1)
Weighted average grant date fair value	$	—	$	—
Total intrinsic value of exercises	$	—	$	3

___________

(1)The Company did not issue any options or other equity grants that would require application of the Black-Scholes-Merton equity grant valuation model during the years ended December 31, 2020 and 2019. All equity grants during this period were restricted common shares which are valued using an intrinsic valuation method based on market price.

The following table summarizes information regarding stock options and SOSAR grants outstanding as of December 31, 2020:

		Weighted
		Average			Intrinsic			Intrinsic
Range of		Exercise		Grants	Value-Grants		Grants	Value-Grants
Exercise Prices1		Prices		Outstanding	Outstanding		Exercisable	Exercisable
$8.14 to $10.21		$	8.83	45	$	—	45	$	—
$	5.86	$	5.86	20	$	—	20	$	—
				65			65

As of December 31, 2020, the outstanding equity grants have a weighted average remaining life of 5.26 years and those outstanding equity grants that are exercisable have a weighted average remaining life of 5.26 years. During the year ended December 31, 2020, no stock option and SOSAR grants were exercised under these plans.

Summarized activity of the equity compensation plans is presented below:

		Weighted
	SOSARs/	Average
	Options	Exercise Price
Outstanding, December 31, 2019	76	$	7.55
Granted	—	—
Exercised	—	—
Expired or cancelled	(11)	5.45
Outstanding, December 31, 2020	65	$	7.92
Exercisable, December 31, 2020	65	$	7.92

		Weighted
		Average
	Restricted	Grant Date
	Shares	Fair Value
Outstanding, December 31, 2019	207	$	5.28
Granted	198	2.00
Dividend Equivalents	—	—
Vested	(187)	3.93
Cancelled	(25)	4.55
Outstanding, December 31, 2020	193	$	3.32

Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:

		Weighted
		Average
	Restricted	Grant Date
	Share Units	Fair Value
Outstanding, December 31, 2019	48	$	5.08
Granted	28	2.00
Dividend Equivalents	—	—
Vested	(21)	6.45
Cancelled	—	—
Outstanding December 31, 2020	55	$	2.92

Preferred Stock

The Company is authorized to issue up to 195 shares of Preferred Stock. The Company's Board of Directors is authorized to establish the terms and rights of each series, including the voting powers, designations, preferences, and other special rights, qualifications, limitations, or restrictions thereof.

XML

Net Income (Loss) Per Common Share

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Net Income (loss) Per Common Share

NET INCOME (LOSS) PER COMMON SHARE

Information with respect to the calculation of basic and diluted net income (loss) per common share is presented below:

	Years Ended December 31,
	2020		2019
Numerator: Income (loss):
Income (loss) from continuing operations	$	6,530	$	(27,474)
Loss from discontinued operations, net of income taxes	(1,371)		(8,589)
Net income (loss)	$	5,159	$	(36,063)
Denominator: Basic Weighted Average Common Shares Outstanding:	6,615		6,459
Dilutive effect of stock options, SOSARs, Restricted Shares and Restricted Share Units	90		—
Adjusted weighted average common shares outstanding	6,705		6,459
Basic net income (loss) per common share
Income (loss) from continuing operations	$	0.99	$	(4.25)
Loss from discontinued operations
Operating loss, net of taxes	(0.21)		(1.33)
Discontinued operations, net of taxes	(0.21)		(1.33)
Basic net income (loss) per common share	$	0.78	$	(5.58)
Diluted net income (loss) per common share
Income (loss) from continuing operations	$	0.97	$	(4.25)
Loss from discontinued operations
Operating loss, net of taxes	(0.20)		(1.33)
Discontinued operations, net of taxes	(0.20)		(1.33)
Diluted net income (loss) per common share	$	0.77	$	(5.58)

The dilutive effects of the Company's stock options, SOSARs, Restricted Shares and Restricted Share Units are included in the computation of diluted income per common share during the periods they are considered dilutive.

The following table reflects the weighted average outstanding SOSARs and Options that were excluded from the computation of diluted earnings per share, as they would have been anti-dilutive:

	2020	2019
SOSARs/Options Excluded	65	76

The weighted average common shares for basic and diluted earnings for common shares was the same due to the loss in 2019.

XML

Income Taxes

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

Overview

The provision (benefit) for income taxes on continuing operations for the years ended December 31, 2020 and 2019 is summarized as follows:

	Year Ended December 31,
	2020		2019
Current provision (benefit) :
Federal	$	719	$	197
State	(23)		76
	696		273
Deferred provision (benefit):
Federal	(1,227)		12,439
State	—		2,982
	(1,227)		15,421
Provision (benefit) for income taxes of continuing operations	$	(531)	$	15,694

A reconciliation of taxes computed at statutory income tax rates on income (loss) from continuing operations is as follows:

	Year Ended December 31,
	2020		2019
Provision (benefit) for federal income taxes at statutory rates	$	1,260	$	(2,469)
Provision (benefit) for state income taxes, net of federal benefit	478		(106)
Valuation allowance changes affecting the provision for income taxes	(2,922)		19,002
Employment tax credits	(355)		(210)
Nondeductible expenses	251		122
Stock based compensation expense	98		80
WOTC Credit and Other	931		(1,349)
Other	(272)		624
Provision (benefit) for income taxes of continuing operations	$	(531)	$	15,694

Deferred Taxes

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets are reduced by a valuation allowance if, based upon the weight of available evidence, it is more likely than not that we will realize only some portion of the deferred tax assets. The net deferred tax assets and liabilities, at the respective income tax rates, are as follows:

	December 31,
	2020		2019
Deferred tax assets (liabilities):
Net operating loss and other carryforwards	$	67	$	859
Credit carryforwards	1,777		3,118
Accounts receivable	4,652		4,852
Prepaid expenses	(938)		(1,015)
Interest rate limitation	—		971
Right-of-use lease liability	78,674		82,194
Right-of-use lease asset	(75,443)		(79,843)
Depreciation	1,731		1,863
Tax goodwill and intangibles	(1,098)		(1,066)
Stock-based compensation	164		183
Accrued liabilities	124		504
Accrued rent	340		380
Impairment of long-lived assets	177		176
Interest rate swap	—		(4)
Hedge Ineffectiveness	—		(155)
Noncurrent self-insurance liabilities	6,350		6,363
Restitution	2,329		2,445
Other	28		30
	18,934		21,855
Less valuation allowance	(18,934)		(21,855)
	$	—	$	—

Deferred Tax Valuation Allowance

The assessment of the amount of value assigned to our deferred tax assets under the applicable accounting standards is highly judgmental. We are required to consider all available positive and negative evidence in evaluating the likelihood that we will be able to realize the benefit of our deferred tax assets in the future. Such evidence includes scheduled reversals of deferred tax assets and liabilities, projected future taxable income, tax-planning strategies, and the results of recent operations. Since this evaluation requires consideration of historical and future events, there is significant judgment involved, and our conclusion could be materially different should certain of our expectations not transpire.

When assessing all available evidence, we consider the weight of the evidence, both positive and negative, based on the objectivity of the underlying evidence and the extent to which it can be verified. For the three-year period ended December 31, 2020, the Company had a cumulative pre-tax loss from continuing operations of $18,526. Additionally, the Company recognized governmental and regulatory changes have put downward revenue pressure on the long-term care industry as a piece of negative evidence in the analysis. In 2019 and 2018 combined, the Company recognized a total expense of $9,500 related to the CID settlement. Because of these items and other financial results, the Company entered a cumulative loss for the 36 preceding months ended June 30, 2019 and performed a thorough assessment of the available positive and negative evidence in order to ascertain whether it is more likely than not that in future periods the Company will generate sufficient pre-tax income to utilize all of its federal deferred tax assets and its net operating loss and other carryforwards and credits.

The Company also identified several pieces of positive evidence that were considered and weighed in the analysis performed regarding the valuation of deferred tax assets. The evidence included the termination of operations for 10 nursing facilities in Kentucky completed in the third quarter of 2019, the related corporate and regional restructuring and other cost saving initiatives already in process. The evidence also included consideration of participation in revenue incentive programs that are expected to generate additional revenue, the long-term expiration dates of a majority of the net operating losses and credits, and the Company’s history of not having carryforwards or credits expire unutilized.

In performing the analysis, the Company contemplated utilization of the recorded deferred tax assets under multiple scenarios. After consideration of these factors, the Company determined that a full valuation allowance was necessary. As of December 31, 2020, the Company has a valuation allowance in the amount of $18,934.  The Company will continue to periodically assess the realizability of its future deferred tax assets.

On March 27, 2020, the CARES Act was enacted and signed into law. Certain provisions of the CARES Act impacted the 2019 income tax provision computations of the Company and were reflected in the first quarter of 2020, or the period of enactment. The CARES Act contains modifications on the depreciation of qualified improvement property, as well as the limitation of business interest for tax years beginning in 2019 and 2020. The new life classification of the qualified improvement property, allowing for bonus depreciation to be taken, along with the modification to Section 163(j) to increase the allowable business interest deduction from 30% of adjusted taxable income to 50% of adjusted taxable income significantly increased the allowable deductions of the Company and result in additional taxable losses for the year-ended 2019, resulting in greater net operating losses (“NOL”) to be carried back. The NOL carryback resulted in a tax refund of $1,227 and a decrease to the Work Opportunity Tax Credit (“WOTC”) deferred tax asset, which is offset by a full valuation allowance. These changes pursuant to the CARES Act did not have a significant impact during the twelve-month period ended December 31, 2020, other than the tax refund and net adjustments to the WOTC credit and NOL deferred tax assets, which are offset by a valuation allowance.

At December 31, 2020, the Company had $5,576 of federal net operating losses, which expire at various dates beginning in 2021. The use of a portion of these loss carryforwards is limited by change in ownership provisions of the Federal tax code to a maximum of approximately $257. The Company has reduced the deferred tax asset and the corresponding valuation allowances for net operating loss deductions permanently lost as a result of the change in ownership provisions.

Under the Work WOTC program, the Company recorded $355 and $210 in Work Opportunity Tax Credits during 2020 and 2019, respectively.

The Company is not currently under examination by any major income tax jurisdiction. During 2020, the statutes of limitations lapsed on the Company's 2016 Federal tax year and certain 2015 and 2016 state tax years. The Company does not believe the Federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months.

XML

Commitments and Contingencies

12 Months Ended

Dec. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

COMMITMENTS AND CONTINGENCIES

Lease Commitments

The Company is committed under long-term operating leases with various expiration dates and varying renewal options. Under these lease agreements, the Company's lease payments are subject to periodic annual escalations as described below and in Note 1, "Business and Summary of Significant Accounting Policies". Total lease expense for continuing operations was $54,001 and $52,990 for the years ended December 31, 2020 and 2019, respectively. The accrued liability related to straight line rent was $12,382 and $9,325 at December 31, 2020 and 2019, respectively, and is recorded as an offset to the right-of-use asset on the accompanying consolidated balance sheets.

Omega Master Lease

On October 1, 2018, the Company entered into the Omega Master Lease to lease 34 centers currently owned by Omega and operated by Diversicare. The old Master Lease with Omega provided for its operation of 23 skilled nursing centers in Texas, Kentucky, Alabama, Tennessee, Florida, and Ohio. Additionally, Diversicare operates 11 centers owned by Omega, previously under separate leases in Missouri, Kentucky, Indiana, and Ohio. The Omega Master Lease entered into by Diversicare and Omega consolidated the leases for all 34 centers under one new Master Lease Agreement. The Omega Master Lease has an initial term of twelve years with the option of two ten year extensions at the Company's election. The Omega Master Lease has annual rent escalators of 2.15% beginning on October 1, 2019.

On August 30, 2019, the Company terminated operations of 10 centers in Kentucky and concurrently transferred operations to a new operator. The agreement effectively amended the Master Lease Agreement with Omega Healthcare Investors to remove the 10 Kentucky facilities, reduce the annual rent expense, and release the Company from any further obligations arising under the Master Lease Agreement with respect to the Kentucky facilities. The remaining lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15% beginning on October 1, 2019.

On December 1, 2020, the Company terminated operations at a facility located in Florida and concurrently transferred operations to a new operator. The agreement effectively amended the Omega Master Lease to remove the Florida facility, reduce the annual rent expense, and release the Company from any further obligations arising under the Omega Master Lease with respect to the Florida facility. The remaining Omega Master Lease terms remain unchanged with an initial term of twelve years and two optional 10-year extensions. The annual lease fixed escalator remains at 2.15%.

Under generally accepted accounting principles, the Company is required to report these scheduled rent increases on a straight line basis over the term of the lease. These scheduled increases had no effect on cash rent payments at the start of the lease term and only result in additional cash outlay as the annual increases take effect each year.

The Omega Master Lease requires the Company to fund annual capital expenditures related to the leased centers at an amount currently equal to four hundred three dollars per licensed bed. These amounts are subject to adjustment for increases in the

Consumer Price Index. The Company is in compliance with the capital expenditure requirements. Total required capital expenditures during the remaining lease term are $10,118. These capital expenditures are being depreciated on a straight-line basis over the shorter of the asset life or the appropriate lease term.

Upon expiration of the Omega Master Lease or in the event of a default under the Omega Master Lease, the Company is required to transfer all of the leasehold improvements, equipment, furniture and fixtures of the leased centers to Omega. The assets to be transferred to Omega are being amortized on a straight-line basis over the shorter of the remaining lease term, excluding the renewal options, or estimated useful life, and will be fully depreciated upon the expiration of the lease. All of the equipment, inventory and other related assets of the centers leased pursuant to the Omega Master Lease have been pledged as security under the Omega Master Lease. In addition, the Company has a letter of credit of $5,447 as a security deposit for the Company's leases with Omega, as described in Note 8, "Long-term Debt, Interest Rate Swap and Finance Lease Obligations".

Golden Living Master Lease

The Company leases 20 nursing centers from Golden Living. On October 1, 2016, the Company and Golden Living entered into a Master Lease ("Golden Living Lease") agreement to lease eight centers located in Mississippi. On November 1, 2016, the Company and Golden Living entered into an Amended and Restated Master Lease ("Amended Lease") to extend the term of its centers leased from Golden Living and lease an additional twelve centers located in Alabama. The Amended Lease is triple net and has an initial term of ten years with two separate five year options to extend the term. The annual lease fixed escalator is 2%. Under generally accepted accounting principles, the Company is required to report these scheduled rent increases on a straight line basis over the term of the lease including the 10 year term of the renewal period. These scheduled increases had no effect on cash rent payments at the start of the lease term and only result in additional cash outlay as the annual increases take effect each year.

The Amended Lease requires the Company to fund annual capital expenditures related to the leased centers at an amount currently equal to five hundred thirty dollars per licensed bed. These amounts are subject to adjustment for increases in the Consumer Price Index. The Company is in compliance with the capital expenditure requirements. Total required capital expenditures during the remaining lease term and renewal options are $5,432. These capital expenditures are being depreciated on a straight-line basis over the shorter of the asset life or the appropriate lease term.

Upon expiration of the Amended Lease or in the event of a default under the Amended Lease, the Company is required to transfer all of the leasehold improvements, equipment, furniture and fixtures of the leased centers to Golden Living. The assets to be transferred to Golden Living are being amortized on a straight-line basis over the shorter of the remaining lease term or estimated useful life, and will be fully depreciated upon the expiration of the lease. All of the equipment, inventory and other related assets of the center leased pursuant to the Amended Lease have been pledged as security under the Amended Lease. In addition, the Company has a letter of credit of $6,610 as a security deposit for the Company's leases with Golden Living, as described in Note 8, "Long-term Debt, Interest Rate Swap and Finance Lease Obligations".

Insurance Matters

Professional Liability and Other Liability Insurance

The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Tennessee are now covered under the captive insurance policies along with several of the Company's nursing centers in Alabama, Ohio, and Texas and several of the Company's prior nursing centers in Kentucky and Florida for claims prior to the transfer of such operation. The insurance coverage provided for these centers under the SHC policy includes coverage limits of at least $1,000 per medical incident with a sublimit per center of $3,000 and total annual aggregate policy limits of $5,000. All other centers within the Company’s portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers.  The deductibles for these policies vary in amount and are covered through the insurance subsidiary.

The Company follows the FASB Accounting Standards Update, “Presentation of Insurance Claims and Related Insurance Recoveries,” that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Self-insurance receivable" on the Consolidated Balance Sheet. As of December 31, 2020 and 2019, there were $1,025 and $1,011, respectively, estimated insurance recovery receivables.

Reserve for Estimated Self-Insured Professional Liability Claims

Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $24,744 and $27,390 as of December 31, 2020 and 2019, respectively. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.

The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, the actuary has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. The actuary primarily utilizes historical data regarding the frequency and cost of the Company’s past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company’s ultimate professional liability cost for current periods.

On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.

The Company’s cash expenditures for self-insured professional liability costs were $5,514 and $4,578 for the years ended December 31, 2020 and 2019, respectively.

Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.

Other Insurance

With respect to workers' compensation insurance, substantially all of our employees are covered under either a prefunded deductible policy or state-sponsored program. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2008 through December 31, 2019, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500 per claim, subject to an aggregate maximum of $3,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $1,039 and $921 at December 31, 2020 and 2019, respectively. The Company has a non-current receivable for workers’ compensation policies covering previous years of $2,050 and $1,575 as of December 31, 2020 and 2019, respectively. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.

As of December 31, 2020, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $200 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $2,358 and $1,810 at December 31, 2020 and 2019, respectively. The differences between actual settlements and reserves are included in expense in the period finalized.

Employment Agreements

The Company has employment agreements with certain members of management that provide for the payment to these members of amounts up to 2.0 times their annual salary in the event of a termination without cause, a constructive discharge (as defined in each employee agreement), or upon a change in control of the Company (as defined in each employee agreement). The maximum contingent liability under these agreements is $1,500 as of December 31, 2020. The terms of such agreements are from 1 to 3 years and automatically renew for 1 year if not terminated by the employee or the Company.

No amounts have been accrued for these contingent liabilities for members of management the Company currently employs.

Health Care Industry and Legal Proceedings

The provision of health care services entails an inherent risk of liability. Participants in the health care industry are subject to lawsuits alleging malpractice, violations of false claims acts, product liability, or related legal theories, many of which involve large claims and significant defense costs. Like many other companies engaged in the long-term care profession in the United States, we have numerous pending liability claims, disputes and legal actions for professional liability and other related issues. Further, as with all health care providers, we are periodically subject to regulatory actions seeking fines and penalties for alleged violations of health care laws and are potentially subject to the increased scrutiny of regulators for issues related to compliance with health care fraud and abuse laws and with respect to the quality of care provided to residents of our center. Like other health care providers, in the ordinary course of our business, we are also subject to claims made by employees and other disputes and litigation arising from the conduct of our business.

As of December 31, 2020, we are engaged in 79 professional liability lawsuits, of which 36 relate to centers we no longer operate, which are reserved for as discussed above. Twenty-two lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The ultimate results of any of our professional liability claims and disputes cannot be predicted. We have limited, and sometimes no, professional liability insurance with regard to most of these claims. A significant judgment entered against us in one or more of these legal actions could have a material adverse impact on our financial position and cash flows.

In February 2020, the Company entered into a settlement agreement with the U.S. Department of Justice and the State of Tennessee of actions alleging violations of the federal False Claims Act in connection with our provision of therapy and the completion of certain resident admission forms. This settlement of $9,500 resolved an investigation that had begun in 2012 and covers the time period from January 1, 2010 through December 31, 2015. This agreement required an initial payment of $500 within ten days of the effective date, which was February 14, 2020, and material annual interest bearing payments for a period of five years thereafter ending in February 2025, and also requires a contingent payment in the event the Company sells any of its owned facilities during the five year payment period. Failure to make timely any of these payments could result in rescission of the settlement and in the government having a very large claim against us, including penalties, and/or make us ineligible to participate in certain government funded healthcare programs, any of which could in turn significantly harm our business and financial condition. As of December 31, 2020 the Company has $9,000 outstanding related to the settlement agreement, $1,000 of which reflected as "Other Current Liabilities" and the remaining $8,000 is reflected as "Government Settlement Accrual" on the balance sheet.

In conjunction with the settlement of the government investigation related to our therapy practices, the Company entered into a corporate integrity agreement with the Office of the Inspector General of CMS. This agreement has a term of five years and imposes material burdens on the Company, its officers and directors to take actions designed to ensure compliance with applicable healthcare laws, including requirements to maintain specific compliance positions within the Company, to report any non-compliance with the terms of the agreement, to return any overpayments received, to submit annual reports and to have an annual audit of submitted claims performed by an independent review organization. The CIA sets forth penalties for non-compliance by the Company with the terms of the agreement, including possible exclusion from federally funded healthcare programs for material violations of the agreement.

In January 2009, a purported class action complaint was filed in the Circuit Court of Garland County, Arkansas against the Company and certain of its subsidiaries and Garland Nursing & Rehabilitation Center (the “Center”). The complaint alleges that the defendants breached their statutory and contractual obligations to the patients of the Center over the five-year period prior to the filing of the complaints. The lawsuit remains in its early stages and has not yet been certified by the court as a class action. The Company intends to defend the lawsuit vigorously.

We cannot currently predict with certainty the ultimate impact of any of the above cases on our financial condition, cash flows or results of operations. Our reserve for professional liability expenses does not include the amounts that will be owed under the settlement agreement with the DOJ and State of Tennessee or the purported class action against the Arkansas centers. An unfavorable outcome in any of these lawsuits or any of our professional liability actions, any regulatory action, any investigation or lawsuit alleging violations of fraud and abuse laws or of elderly abuse laws or any state or Federal False Claims

Act case could subject us to fines, penalties and damages, including exclusion from the Medicare or Medicaid programs, and could have a material adverse impact on our financial condition, cash flows or results of operations.

XML

Schedule II - Valuation of Qualifying Accounts of Continuing Operations

12 Months Ended

Dec. 31, 2020

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

SCHEDULE II - VALUATION OF QUALIFYING ACCOUNTS OF CONTINUING OPERATIONS

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

(in thousands)

Column A	Column B	Column C		Column D	Column E
				Deductions
Description	Balance at Beginning of Period	Charged to Costs and Expenses	Other	Payments (1)	Balance at End of Period
Year ended December 31, 2020:
Professional Liability Reserve	$27,390	$6,919	$(1,625)	$(7,940)	$24,744
Workers Compensation Reserve	$921	$1,352	$—	$(1,234)	$1,039
Health Insurance Reserve	$1,810	$14,003	$—	$(13,455)	$2,358
Year ended December 31, 2019:
Professional Liability Reserve	$27,201	$10,435	$(3,020)	$(7,226)	$27,390
Workers Compensation Reserve	$618	$400	$—	$(97)	$921
Health Insurance Reserve	$1,396	$16,733	$—	$(16,319)	$1,810

(1)Payments for the Professional Liability Reserve include amounts paid for claims settled during the period as well as payments made under structured arrangements for claims settled in earlier periods.

DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

OF CONTINUING OPERATIONS

(in thousands)

Description	Balance at Beginning of Period	Additions Charged to Costs and Expenses (1)	Deductions	Balance at End of Period
Year ended December 31, 2020: Deferred Tax Valuation Allowance	$21,855	$—	$(2,921)	$18,934
Year ended December 31, 2019: Deferred Tax Valuation Allowance	$228	$21,627	$—	$21,855

(1) The Company initially recorded a full valuation allowance of $20.0 million during the second quarter of 2019.

XML

Business and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Principles of Consolidation

Principles of ConsolidationThe consolidated financial statements include the financial position, operations and accounts of Diversicare and its subsidiaries, all wholly-owned. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Revenue Recognition

Revenue Recognition

The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services.

Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.

The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts, within each respective group listed below, are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).

In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of

previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes.

The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized at a point in time, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.

The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.

Lease Expense

Lease ExpenseAs of December 31, 2020, the Company operates 46 nursing centers under operating leases, including 23 owned by Omega, 20 owned by Golden Living and three owned by other parties. The Company's operating leases generally require the Company to pay stated rent, subject to increases based on changes in the Consumer Price Index or a minimum percentage increase. The Company's Master Lease Agreements with Omega and Golden Living require the Company to pay certain scheduled rent increases. Such scheduled rent increases are recorded as additional lease expense on a straight-line basis recognized over the term of the related leases and the difference between the amounts recorded for rent expense as compared to rent payments is recorded as an accrued liability.

Classification of Expenses

Classification of ExpensesThe Company classifies all expenses (except lease, interest, depreciation and amortization expenses) that are associated with its corporate and regional management support functions as general and administrative expenses within continuing operations. All other expenses (except lease, professional liability, government settlement expense, interest, depreciation and amortization expenses) incurred by the Company at the center level for continuing operations are classified as operating expenses.

Property and Equipment

Property and Equipment

Property and equipment are recorded at cost or at fair value determined on the respective dates of acquisition for assets obtained in a business combination, with depreciation and amortization being provided over the shorter of the remaining lease term (where applicable) or the assets' estimated useful lives on the straight-line basis as follows:

Buildings and improvements	-	5 to 40 years
Leasehold improvements	-	2 to 10 years
Furniture, fixtures and equipment	-	2 to 15 years

Interest incurred during construction periods for qualifying expenditures is capitalized as part of the building cost. Maintenance and repairs are expensed as incurred, and major betterments and improvements are capitalized.

The Company routinely evaluates the recoverability of the carrying value of its long-lived assets, including property and equipment and right of use assets. The evaluation for recoverability includes when significant adverse changes in the general economic conditions and significant deteriorations of the underlying undiscounted cash flows or fair values of the asset group indicate that the carrying amount of the asset group may not be recoverable. If circumstances suggest that the recorded amounts are not recoverable based upon estimated future undiscounted cash flows, the carrying values of such assets are reduced to fair value.

Cash

CashCash and cash equivalents include cash on deposit with banks and all highly liquid investments with original maturities of three months or less when purchased. Our cash on deposit with banks was subject to the Federal Deposit Insurance Corporation ("FDIC") minimum insurance levels.

Deferred Financing and Other Costs

Deferred Financing and Other CostsThe Company records deferred financing and lease costs for direct and incremental expenditures related to entering into or amending debt and lease agreements. These expenditures include lenders' and attorneys' fees. Financing costs are amortized using the effective interest method over the term of the related debt. The amortization is reflected as interest expense in the accompanying consolidated statements of operations. See Note 8, "Long-term Debt, Interest Rate Swap and Finance Lease Obligations" for further discussion.

Acquired Leasehold Interest

Acquired Leasehold Interest

The Company has recorded an acquired leasehold interest intangible asset related to an acquisition completed during 2007. The intangible asset is accounted for in accordance with the Financial Accounting Standards Board's ("FASB") guidance on goodwill and other intangible assets, and is amortized on a straight-line basis over the remaining life of the acquired lease. As discussed in Note 3, "Business Developments and Other Significant Transactions," the Company entered into a new Master Lease Agreement (the "Omega Master Lease") with  Omega Healthcare Investors ("Omega") on October 1, 2018, which was subsequently modified on August 30, 2019. The Omega Master Lease includes the seven centers to which the intangible asset relates. As such, the intangible asset is now being amortized over an adjusted remaining life, consistent with the term of the Omega Master Lease, which goes through September 30, 2030. Amortization expense of approximately $534 and $571 related to this intangible asset was recorded during each of the years ended December 31, 2020 and 2019, respectively.

The carrying value of the acquired leasehold interest intangible and the accumulated amortization are as follows:

	December 31,
	2020		2019
Acquired leasehold interest, gross	$	10,652	$	10,652
Accumulated amortization	(5,450)		(4,916)
Acquired leasehold interest, net	$	5,202	$	5,736

The Company evaluates the recoverability of the carrying value of the acquired leasehold intangible in accordance with the FASB's guidance on accounting for the impairment or disposal of long-lived assets. Included in this evaluation is whether significant adverse changes in general economic conditions, and significant deteriorations of the underlying cash flows or fair values of the intangible asset indicate that the carrying amount of the intangible asset may not be recoverable. The need to recognize an impairment charge is based on estimated future undiscounted cash flows from the asset compared to the carrying value of that asset. If recognition of an impairment charge is necessary, it is measured as the amount by which the carrying amount of the intangible asset exceeds the fair value of the intangible asset.

Self Insurance

Self-Insurance

Self-insurance liabilities primarily represent the unfunded accrual for self-insured risks associated with general and professional liability claims, employee health insurance and workers' compensation. The Company's health insurance liability is based on known claims incurred and an estimate of incurred but unreported claims determined by an analysis of historical claims paid. The Company's workers' compensation liability relates primarily to periods of self-insurance and consists of an estimate of the future costs to be incurred for the known claims.

Final determination of the Company's actual liability for incurred general and professional liability claims is a process that may take years. The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this unfunded accrual. The actuary assists management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished by the Company. The actuary primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods.

On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company's insurers and a third party claims administrator, contain information relevant to the actual expense already incurred for each claim as well as the third-party administrator's estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company's evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual has an unfavorable impact on results of operations in the period and any reduction in the accrual increases results of operations during the period.

All losses are projected on an undiscounted basis. The self-insurance liabilities include estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of related legal costs incurred and expected to be incurred.

One of the key assumptions in the actuarial analysis is that historical losses provide an accurate forecast of future losses. Changes in legislation such as tort reform, changes in our financial condition, changes in our risk management practices and other factors may affect the severity and frequency of claims incurred in future periods as compared to historical claims.

The facts and circumstances of each claim vary significantly, and the amount of ultimate liability for an individual claim may vary due to many factors, including whether the case can be settled by agreement, the quality of legal representation, the individual jurisdiction in which the claim is pending, and the views of the particular judge or jury deciding the case.

Although the Company adjusts its unfunded accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company's actual liability for claims incurred in any given period is a process that takes years. As a result, the Company's actual liabilities may vary significantly from the unfunded accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company's results of operations and financial position for the period in which the change in accrual is made.

Income Taxes

Income Taxes

The Company follows the FASB's guidance on Income Taxes, which requires the asset and liability method of accounting for income taxes whereby deferred income taxes are recorded for the future tax consequences attributable to differences between the financial statement and tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are provided against any estimated non-realizable deferred tax assets where necessary.

Where the Company believes that a tax position is supportable for income tax purposes, the item is included in its income tax returns. Where treatment of a position is uncertain, liabilities are recorded based upon the Company’s evaluation of the “more likely than not” outcome considering the technical merits of the position. While the judgments and estimates made by the Company are based on management’s evaluation of the technical merits of a matter, historical experience and other assumptions that management believes are appropriate and reasonable under current circumstances, actual resolution of these matters may differ from recorded estimated amounts, resulting in charges or credits that could materially affect future financial statements. See Note 11, "Income Taxes" for additional information related to the provision for income taxes.

Disclosure of Fair Value of Financial Instruments

Disclosure of Fair Value of Financial Instruments

Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. In calculating fair value, a company must maximize the use of observable market inputs, minimize the use of unobservable market inputs and disclose in the form of an outlined hierarchy the details of such fair value measurements. The carrying amounts of cash, receivables, trade accounts payable and accrued expenses approximate fair value because of the short-term nature of these accounts. The Company's self-insurance liabilities are reported on an undiscounted basis as the timing of estimated settlements cannot be determined.

The Company follows the FASB's guidance on Fair Value Measurements and Disclosures which provides rules for using fair value to measure assets and liabilities as well as a fair value hierarchy that prioritizes the information used to develop the measurements. It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As further discussed in Note 8, "Long-term Debt, Interest Rate Swap and Finance Lease Obligations", the Company terminated its interest rate swap in conjunction with refinancing its debt in October 2020.

As the Company's interest rate swap, a cash flow hedge, was not traded on a market exchange, the fair value was determined using a valuation model based on a discounted cash flow analysis. This analysis reflected the contractual terms of the interest rate swap agreement and used observable market-based inputs, including estimated future LIBOR interest rates. The fair value of the Company's interest rate swap was the net difference in the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts were based on the expectation of future interest rates and were observable inputs available to a market participant. The interest rate swap valuation was classified in Level 2 of the fair value hierarchy. The debt balances as presented in the consolidated balance sheets approximate the fair value of the respective instruments as the debt was at a variable rate, the estimates of which were considered Level 2 fair value calculations within the fair value hierarchy.

Net Income (Loss) per Common Share

Net Income (Loss) per Common ShareThe Company follows the FASB's guidance on Earnings Per Share for the financial reporting of net income (loss) per common share. Basic earnings per common share excludes dilution and restricted shares and is computed by dividing income available to common shareholders by the weighted-average number of common shares, excluding restricted shares, outstanding for the period. Diluted earnings per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or otherwise resulted in the issuance of common stock that then shared in the earnings of the Company.

Stock Based Compensation

Stock Based Compensation The Company follows the FASB's guidance on Stock Compensation to account for share-based payments granted to team members and recorded non-cash stock based compensation expense of $570 and $573 during the years ended December 31, 2020 and 2019, respectively. Such amounts are included as components of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees.

Accumulated Other Comprehensive Income (Loss)

Accumulated Other Comprehensive Income (Loss)

Accumulated other comprehensive income consists of other comprehensive income (loss). Comprehensive income (loss) is a more inclusive financial reporting method that includes disclosure of financial information that historically has not been recognized in the calculation of net income (loss). Currently, the Company's other comprehensive income (loss) consists of the change in fair value of the Company's interest rate swap transaction previously accounted for as a cash flow hedge.

Accounting Standards Recently Issued

Accounting Standards Recently Issued

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new guidance intends to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for smaller reporting companies for the fiscal year beginning after December 15, 2022 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related disclosures.

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848). The new guidance contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU No. 2020-04 is optional and may be elected over time as reference rate reform activities occur. During the first quarter of 2020, the Company has elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of derivatives consistent with past presentation. The amendments in the ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The Company continues to evaluate changes in the market and may apply other elections, as applicable, in the future as allowed under ASU No. 2020-04.

Revenue from Contract with Customer

The Company's revenue is derived from providing quality healthcare services to its patients. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. The promise to provide quality care is accounted for as a single performance obligation satisfied at a point in time, when those services are rendered on a daily basis.The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts, within each respective group listed below, are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).

XML

Business and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Schedule of Estimated Useful Lives

Property and equipment are recorded at cost or at fair value determined on the respective dates of acquisition for assets obtained in a business combination, with depreciation and amortization being provided over the shorter of the remaining lease term (where applicable) or the assets' estimated useful lives on the straight-line basis as follows:

Buildings and improvements	-	5 to 40 years
Leasehold improvements	-	2 to 10 years
Furniture, fixtures and equipment	-	2 to 15 years

Property and equipment, at cost, consists of the following:

	December 31,
	2020		2019
Land	$	5,265	$	5,265
Buildings and leasehold improvements	85,857		84,544
Furniture, fixtures and equipment	44,112		42,966
	135,234		132,775
Less: accumulated depreciation	(91,914)		(85,020)
Net property and equipment	$	43,320	$	47,755

Schedule of Acquired Leasehold Interest

The carrying value of the acquired leasehold interest intangible and the accumulated amortization are as follows:

	December 31,
	2020		2019
Acquired leasehold interest, gross	$	10,652	$	10,652
Accumulated amortization	(5,450)		(4,916)
Acquired leasehold interest, net	$	5,202	$	5,736

Schedule of Expected Amortization Expense

The expected amortization expense for the acquired leasehold interest intangible asset is as follows:

2021	$	534
2022	534
2023	534
2024	534
2025	534
Thereafter	2,532
	$	5,202

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table presents by level, within the fair value hierarchy, assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 and 2019:

December 31, 2020	Fair Value Measurements - Assets (Liabilities)
	Total		Level 1		Level 2		Level 3
Interest rate swap	$	—	$	—	$	—	$	—
December 31, 2019	Fair Value Measurements - Assets (Liabilities)
	Total		Level 1		Level 2		Level 3
Interest rate swap	$	(57)	$	—	$	(57)	$	—

XML

Revenue Recognition and Receivables (Tables)

12 Months Ended

Dec. 31, 2020

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table set forth net patient revenues related to our continuing operations by payor source for the periods presented (dollar amounts in thousands):

	Twelve Months Ended December 31,
	2020				2019
Medicaid	$	217,147	45.6	%	$	222,560	46.9	%
Medicare	94,375		19.8	%	80,798		17.0	%
Managed Care	49,708		10.4	%	50,323		10.6	%
Private Pay and other	114,488		24.2	%	121,339		25.5	%
Total	$	475,718	100.0	%	$	475,020	100.0	%

Schedule of Accounts Receivable

Accounts receivable as of December 31, 2020 and 2019 is summarized in the following table:

	December 31,
	2020		2019
Medicaid	$	17,354	$	21,998
Medicare	14,273		11,811
Managed Care	8,021		9,103
Private Pay and other	14,043		17,609
Total accounts receivable	$	53,691	$	60,521

XML

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2020

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment, at Cost

Property and equipment are recorded at cost or at fair value determined on the respective dates of acquisition for assets obtained in a business combination, with depreciation and amortization being provided over the shorter of the remaining lease term (where applicable) or the assets' estimated useful lives on the straight-line basis as follows:

Buildings and improvements	-	5 to 40 years
Leasehold improvements	-	2 to 10 years
Furniture, fixtures and equipment	-	2 to 15 years

Property and equipment, at cost, consists of the following:

	December 31,
	2020		2019
Land	$	5,265	$	5,265
Buildings and leasehold improvements	85,857		84,544
Furniture, fixtures and equipment	44,112		42,966
	135,234		132,775
Less: accumulated depreciation	(91,914)		(85,020)
Net property and equipment	$	43,320	$	47,755

XML

Leases (Tables)

12 Months Ended

Dec. 31, 2020

Leases [Abstract]

Assets and Liabilities, Leases

Leases

	Classification	December 31, 2020		December 31, 2019
Assets
Operating lease assets	Operating lease right-of-use assets	$	290,296	$	310,238
Finance lease assets	Property and equipment, net (a)	508		906
Total leased assets		$	290,804	$	311,144
Liabilities
Current
Operating	Current portion of operating lease liability	$	28,583	$	23,736
Finance	Current portion of long-term debt and finance lease obligations, net	251		231
Noncurrent
Operating	Operating lease liability, less current portion	274,155		295,636
Finance	Long-term debt and finance lease obligations, less current portion and deferred financing costs, net	280		445
Total lease liabilities		$	303,269	$	320,048
(a) Finance lease assets are recorded net of accumulated amortization of $471 and $1,522 as of December 31, 2020 and 2019, respectively.

Lease Cost

Lease Cost

		Year Ended		Year Ended
	Classification	December 31, 2020		December 31, 2019
Operating lease cost (a)	Lease and rent expense	$	54,001	$	52,990
Finance lease cost:
Amortization of finance lease assets	Depreciation and amortization	226		263
Interest on finance lease liabilities	Interest expense, net	36		48
Short term lease cost	Operating expense	581		649
Net lease cost		$	54,844	$	53,950
(a) Includes variable lease costs, which are immaterial

Maturity of Lease Liabilities

Maturity of Lease Liabilities

	As of December 31, 2020
	Operating Leases (a)		Finance Leases (a)		Total
2021	$	51,165	$	282	$	51,447
2022	52,142		209		52,351
2023	53,120		62		53,182
2024	53,064		20		53,084
2025	53,921		—		53,921
After 2025	141,875		—		141,875
Total lease payments	$	405,287	$	573	$	405,860
Less: Interest	(102,549)		(42)		(102,591)
Present value of lease liabilities	$	302,738	$	531	$	303,269
(a) Operating and Finance lease payments exclude options to extend lease terms that are not reasonably certain of being exercised.

Summary of Other Lease Information

Lease Term and Discount Rate

	December 31, 2020	December 31, 2019
Weighted-average remaining lease term (years)
Operating leases	7.91	8.81
Finance leases	2.26	3.00
Weighted-average discount rate
Operating leases	7.9%	8.9%
Finance leases	6.2%	6.1%

Other Information

	Year Ended		Year Ended
	December 31, 2020		December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases	$	50,869	$	55,485
Operating cash flows for finance leases	36		48
Financing cash flows for finance leases	235		471
Acquisition of operating leases though adoption of Topic 842	—		389,403
Lease modification	$	7,051	$	(48,877)

XML

Long-Term Debt, Interest Rate Swap and Finance Lease Obligations (Tables)

12 Months Ended

Dec. 31, 2020

Debt Disclosure [Abstract]

Schedule of Long Term Debt

Long-term debt consists of the following:

	December 31,
	2020		2019
Mortgage loan	$	61,087	$	49,743
Acquisition loan	—		9,400
Revolver	—		14,000
Affiliated revolver	—		1,000
	61,087		74,143
Plus finance lease obligations	531		857
Less current portion	(1,660)		(3,498)
	59,958		71,502
Less deferred financing costs, net	(1,432)		(865)
Long-term debt and finance lease obligation, net	$	58,526	$	70,637

Schedule of Deferred Financing Costs

In connection with the Company's loan agreements, the Company recorded the following amounts related to deferred loan costs:

	2020		2019
Write-off of deferred financing costs	$	247	$	—
Deferred financing costs capitalized	$	1,228	$	333

Scheduled Principal Payments of Long-term Debt

Scheduled principal payments of long-term debt are as follows:

2021	$	1,404
2022	1,368
2023	58,315
Total	$	61,087

Scheduled Payments of Capitalized Lease Obligations

Scheduled payments of the financed lease obligations are as follows:

2021	$	282
2022	209
2023	62
2024	20
Total	573
Amounts related to interest	(42)
Principal payments on finance lease obligation	$	531

XML

Shareholders' Equity, Stock Plans and Preferred Stock (Tables)

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

The table below shows the weighted average assumptions the Company used to develop the fair value estimates under its option valuation model:

	Year Ended December 31,
	2020	2019
Expected volatility (range)	N/A(1)	N/A(1)
Risk free interest rate (range)	N/A(1)	N/A(1)
Expected dividends	N/A(1)	N/A(1)
Weighted average expected term (years)	N/A(1)	N/A(1)

___________

(1)The Company did not issue any options or other equity grants that would require application of the Black-Scholes-Merton equity grant valuation model during the years ended December 31, 2020 and 2019. All equity grants during

these periods were restricted common shares which are valued using an intrinsic valuation method based on market price.

Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

The table below describes the resulting weighted average grant date fair values calculated as well as the intrinsic value of options exercised under the Company's equity awards during each of the following years:

	Year Ended December 31,
	2020(1)		2019(1)
Weighted average grant date fair value	$	—	$	—
Total intrinsic value of exercises	$	—	$	3

___________

(1)The Company did not issue any options or other equity grants that would require application of the Black-Scholes-Merton equity grant valuation model during the years ended December 31, 2020 and 2019. All equity grants during this period were restricted common shares which are valued using an intrinsic valuation method based on market price.

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range

The following table summarizes information regarding stock options and SOSAR grants outstanding as of December 31, 2020:

		Weighted
		Average			Intrinsic			Intrinsic
Range of		Exercise		Grants	Value-Grants		Grants	Value-Grants
Exercise Prices1		Prices		Outstanding	Outstanding		Exercisable	Exercisable
$8.14 to $10.21		$	8.83	45	$	—	45	$	—
$	5.86	$	5.86	20	$	—	20	$	—
				65			65

Schedule of Share-based Compensation Arrangements by Share-based Payment Award

Summarized activity of the equity compensation plans is presented below:

		Weighted
	SOSARs/	Average
	Options	Exercise Price
Outstanding, December 31, 2019	76	$	7.55
Granted	—	—
Exercised	—	—
Expired or cancelled	(11)	5.45
Outstanding, December 31, 2020	65	$	7.92
Exercisable, December 31, 2020	65	$	7.92

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

		Weighted
		Average
	Restricted	Grant Date
	Shares	Fair Value
Outstanding, December 31, 2019	207	$	5.28
Granted	198	2.00
Dividend Equivalents	—	—
Vested	(187)	3.93
Cancelled	(25)	4.55
Outstanding, December 31, 2020	193	$	3.32

Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:

		Weighted
		Average
	Restricted	Grant Date
	Share Units	Fair Value
Outstanding, December 31, 2019	48	$	5.08
Granted	28	2.00
Dividend Equivalents	—	—
Vested	(21)	6.45
Cancelled	—	—
Outstanding December 31, 2020	55	$	2.92

XML

Net Income (Loss) Per Common Share (Tables)

12 Months Ended

Dec. 31, 2020

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Net Income (Loss) Per Common Share

Information with respect to the calculation of basic and diluted net income (loss) per common share is presented below:

	Years Ended December 31,
	2020		2019
Numerator: Income (loss):
Income (loss) from continuing operations	$	6,530	$	(27,474)
Loss from discontinued operations, net of income taxes	(1,371)		(8,589)
Net income (loss)	$	5,159	$	(36,063)
Denominator: Basic Weighted Average Common Shares Outstanding:	6,615		6,459
Dilutive effect of stock options, SOSARs, Restricted Shares and Restricted Share Units	90		—
Adjusted weighted average common shares outstanding	6,705		6,459
Basic net income (loss) per common share
Income (loss) from continuing operations	$	0.99	$	(4.25)
Loss from discontinued operations
Operating loss, net of taxes	(0.21)		(1.33)
Discontinued operations, net of taxes	(0.21)		(1.33)
Basic net income (loss) per common share	$	0.78	$	(5.58)
Diluted net income (loss) per common share
Income (loss) from continuing operations	$	0.97	$	(4.25)
Loss from discontinued operations
Operating loss, net of taxes	(0.20)		(1.33)
Discontinued operations, net of taxes	(0.20)		(1.33)
Diluted net income (loss) per common share	$	0.77	$	(5.58)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table reflects the weighted average outstanding SOSARs and Options that were excluded from the computation of diluted earnings per share, as they would have been anti-dilutive:

	2020	2019
SOSARs/Options Excluded	65	76

XML

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Schedule of Income before Income Tax, Domestic and Foreign

The provision (benefit) for income taxes on continuing operations for the years ended December 31, 2020 and 2019 is summarized as follows:

	Year Ended December 31,
	2020		2019
Current provision (benefit) :
Federal	$	719	$	197
State	(23)		76
	696		273
Deferred provision (benefit):
Federal	(1,227)		12,439
State	—		2,982
	(1,227)		15,421
Provision (benefit) for income taxes of continuing operations	$	(531)	$	15,694

Schedule of Components of Income Tax Expense (Benefit)

A reconciliation of taxes computed at statutory income tax rates on income (loss) from continuing operations is as follows:

	Year Ended December 31,
	2020		2019
Provision (benefit) for federal income taxes at statutory rates	$	1,260	$	(2,469)
Provision (benefit) for state income taxes, net of federal benefit	478		(106)
Valuation allowance changes affecting the provision for income taxes	(2,922)		19,002
Employment tax credits	(355)		(210)
Nondeductible expenses	251		122
Stock based compensation expense	98		80
WOTC Credit and Other	931		(1,349)
Other	(272)		624
Provision (benefit) for income taxes of continuing operations	$	(531)	$	15,694

Schedule of Deferred Tax Assets and Liabilities

The net deferred tax assets and liabilities, at the respective income tax rates, are as follows:

	December 31,
	2020		2019
Deferred tax assets (liabilities):
Net operating loss and other carryforwards	$	67	$	859
Credit carryforwards	1,777		3,118
Accounts receivable	4,652		4,852
Prepaid expenses	(938)		(1,015)
Interest rate limitation	—		971
Right-of-use lease liability	78,674		82,194
Right-of-use lease asset	(75,443)		(79,843)
Depreciation	1,731		1,863
Tax goodwill and intangibles	(1,098)		(1,066)
Stock-based compensation	164		183
Accrued liabilities	124		504
Accrued rent	340		380
Impairment of long-lived assets	177		176
Interest rate swap	—		(4)
Hedge Ineffectiveness	—		(155)
Noncurrent self-insurance liabilities	6,350		6,363
Restitution	2,329		2,445
Other	28		30
	18,934		21,855
Less valuation allowance	(18,934)		(21,855)
	$	—	$	—

XML

Business and Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($) nursing_bed segment nursing_center	Dec. 31, 2019 USD ($)	Oct. 01, 2018 nursing_center
Accounting Policies [Line Items]
Number of operating segments | segment	1
Number of reportable segments | segment	1
Number of nursing centers	61
Number of licensed nursing beds | nursing_bed	7,250
Number of licensed assisted living beds | nursing_bed	397
Number of nursing center facilities leased	46		34
Stock based compensation | $	$ 570	$ 573
Leases, acquired-in-place
Accounting Policies [Line Items]
Number of nursing center facilities leased	7
Amortization of intangible asset | $	$ 534	$ 571
Omega Healthcare Investors, Inc
Accounting Policies [Line Items]
Number of nursing center facilities owned	23
Golden Living
Accounting Policies [Line Items]
Number of nursing center facilities owned	20
Other parties
Accounting Policies [Line Items]
Number of nursing center facilities owned	3
Minimum
Accounting Policies [Line Items]
Number of licensed nursing beds per nursing center | nursing_bed	50
Maximum
Accounting Policies [Line Items]
Number of licensed nursing beds per nursing center | nursing_bed	320

XML

Business and Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2020
Buildings and improvements | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Buildings and improvements | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	40 years
Leasehold improvements | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	2 years
Leasehold improvements | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Furniture, fixtures and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	2 years
Furniture, fixtures and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	15 years

XML

Business and Summary of Significant Accounting Policies - Schedule of Acquired Leasehold Interest Intangible (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Acquired leasehold interest, net	$ 5,202
Leases, acquired-in-place
Finite-Lived Intangible Assets [Line Items]
Acquired leasehold interest, gross	10,652	$ 10,652
Accumulated amortization	(5,450)	(4,916)
Acquired leasehold interest, net	$ 5,202	$ 5,736

XML

Business and Summary of Significant Accounting Policies - Schedule of Expected Amortization Expense for Acquired Leasehold Interest Intangible Asset (Details) $ in Thousands	Dec. 31, 2020 USD ($)
Accounting Policies [Abstract]
2021	$ 534
2022	534
2023	534
2024	534
2025	534
Thereafter	2,532
Acquired leasehold interest, net	$ 5,202

XML

Business and Summary of Significant Accounting Policies - Schedule of Fair Value Measurements - Assets and Liabilities (Details) - Interest rate swap - Fair value, measurements, recurring - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) at fair value	$ 0	$ (57)
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) at fair value	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) at fair value	0	(57)
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets (liabilities) at fair value	$ 0	$ 0

XML

COVID-19 PANDEMIC (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Unusual or Infrequent Items, or Both [Abstract]
COVID-19, PHSSEF funds received	$ 47,158
COVID-19, PHSSEF revenue received	19,762
Proceeds from stimulus funds used to purchase property and equipment	1,496	$ 0
COVID-19, Remaining stimulus funds	25,900
COVID-19, Medicaid revenue from states	4,040
Medicaid and Hospice revenue	16,965
Payroll and employee benefits, less current portion	3,185
COVID-19, Medicaid sequestration amount	1,824
COVID-19, Salaries expense	21,211
COVID-19, Supplies expense	4,661
COVID-19, Employee testing expense	5,978
COVID-19, Travel expense	$ 491

XML

Business Developments and Other Significant Transactions - Narrative (Details)			12 Months Ended
	Aug. 30, 2019 nursing_center	Oct. 01, 2018 nursing_center lease_extension	Dec. 31, 2020 nursing_center	Sep. 30, 2020 nursing_center	Oct. 01, 2019	Sep. 01, 2019 nursing_center	Aug. 30, 2019 facility	Aug. 30, 2019 lease_extension	May 13, 2019 nursing_center	Apr. 30, 2019 nursing_center	Mar. 31, 2019 nursing_center
Business Acquisition [Line Items]
Number of nursing center facilities leased		34	46
Number of skilled nursing centers under lease		23
Number of skilled nursing centers participating in QIPP		11				11			4	11	1
Operating lease, initial term	12 years	12 years
Operating lease, number of lease extensions allowed | lease_extension		2						2
Lease extension period	10 years	10 years
Annual lease fixed escalators, percent		2.15%			2.15%
Number of nursing center facilities terminated				10
Absent termination cause by either party ,contract term			3 years
Kentucky Properties | Discontinued Operations
Business Acquisition [Line Items]
Number of nursing center facilities terminated	10						10

XML

Discontinued Operations - Narrative (Details) $ in Thousands		12 Months Ended
	Dec. 01, 2018 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Sep. 30, 2020 nursing_center	Aug. 30, 2019 facility	Aug. 30, 2019 nursing_center	May 22, 2019 nursing_center nursing_bed
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of nursing center facilities terminated | nursing_center				10
Discontinued operation, revenue			$ 46,019
Income (Loss) from discontinued operations, net of tax, including portion attributable to noncontrolling interest		$ (1,371)	$ (8,589)
Kentucky Properties | Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of nursing center facilities terminated | nursing_center							10
Number of skilled nursing beds terminated | nursing_bed							885
Pretax gain on transaction		$ 733
Kentucky Properties
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets	$ 18,700
Carrying value of centers	13,331
Gain on disposition of assets	$ 4,825
Kentucky Properties | Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of nursing center facilities terminated					10	10

XML

Revenue Recognition and Receivables - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
COVID-19, Medicaid funds received	$ 16,142
COVID-19 ,Hospice funds received	823
Disaggregation of Revenue [Line Items]
Total revenues	$ 475,718	$ 475,020
Total revenues, as a percent	100.00%	100.00%
Medicaid
Disaggregation of Revenue [Line Items]
Total revenues	$ 217,147	$ 222,560
Total revenues, as a percent	45.60%	46.90%
Medicare
Disaggregation of Revenue [Line Items]
Total revenues	$ 94,375	$ 80,798
Total revenues, as a percent	19.80%	17.00%
Managed Care
Disaggregation of Revenue [Line Items]
Total revenues	$ 49,708	$ 50,323
Total revenues, as a percent	10.40%	10.60%
Private Pay and other
Disaggregation of Revenue [Line Items]
Total revenues	$ 114,488	$ 121,339
Total revenues, as a percent	24.20%	25.50%

XML

Revenue Recognition and Receivables - Schedule of Other Receivables and Advances (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	$ 53,691	$ 60,521
Medicaid
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	17,354	21,998
Medicare
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	14,273	11,811
Managed Care
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	8,021	9,103
Private Pay and other
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total accounts receivable	$ 14,043	$ 17,609

XML

Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 135,234	$ 132,775
Less: accumulated depreciation	(91,914)	(85,020)
Property and equipment, net	43,320	47,755
Land
Property, Plant and Equipment [Line Items]
Property and equipment, gross	5,265	5,265
Buildings and leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	85,857	84,544
Furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 44,112	$ 42,966

XML

Leases - Narrative (Details) $ in Thousands			12 Months Ended
	Aug. 30, 2019 lease_extension	Oct. 01, 2018 lease_extension	Dec. 31, 2020 USD ($)	Dec. 01, 2020 USD ($)	Dec. 31, 2019 USD ($)	Oct. 01, 2019
Lessee, Lease, Description [Line Items]
Other leases renewal term			20 years
Other leases termination period			1 year
Operating lease, initial term	12 years	12 years
Operating lease, number of lease extensions allowed | lease_extension	2	2
Operating lease, extension period	10 years	10 years
Annual lease fixed escalators, percent		2.15%				2.15%
Increase in right-of-use asset and lease liabilities | $			$ 7,051	$ 7,051	$ (48,877)
Minimum
Lessee, Lease, Description [Line Items]
Other leases remaining lease term			1 year
Maximum
Lessee, Lease, Description [Line Items]
Other leases remaining lease term			12 years

XML

Leases - Balance Sheet Classification (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Assets
Operating lease assets	$ 290,296	$ 310,238
Finance lease assets	508	906
Total leased assets	290,804	311,144
Liabilities, Current [Abstract]
Current portion of operating lease liabilities	$ 28,583	$ 23,736
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent	us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
Finance lease, current	$ 251	$ 231
Liabilities, Noncurrent [Abstract]
Operating lease liabilities, less current portion	274,155	295,636
Finance lease, non current	280	445
Total lease liabilities	303,269	320,048
Accumulated amortization	$ 471	$ 1,522
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	us-gaap:LongTermDebtAndCapitalLeaseObligations	us-gaap:LongTermDebtAndCapitalLeaseObligations

XML

Leases - Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease cost	$ 54,001	$ 52,990
Amortization of finance lease assets	226	263
Interest on finance lease liabilities	36	48
Short term lease cost	581	649
Net lease cost	$ 54,844	$ 53,950

XML

Leases - Maturities of Operating and Financing Lease Liabilities (Details) $ in Thousands	Dec. 31, 2020 USD ($)
Operating Leases
2021	$ 51,165
2022	52,142
2023	53,120
2024	53,064
2025	53,921
After 2025	141,875
Total lease payments	405,287
Less: Interest	(102,549)
Present value of lease liabilities	302,738
Finance Leases
2021	282
2022	209
2023	62
2024	20
2025	0
After 2025	0
Total lease payments	573
Less: Interest	(42)
Present value of lease liabilities	531
Total
2021	51,447
2022	52,351
2023	53,182
2024	53,084
2025	53,921
After 2025	141,875
Total lease payments	405,860
Less: Interest	(102,591)
Present value of lease liabilities	$ 303,269

XML

Leases - Other Lease Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 01, 2020
Weighted-average remaining lease term (years)
Operating leases	7 years 10 months 28 days	8 years 9 months 21 days
Finance leases	2 years 3 months 3 days	3 years
Weighted-average discount rate
Operating leases	7.90%	8.90%
Finance leases	6.20%	6.10%
Operating cash flows for operating leases	$ 50,869	$ 55,485
Operating cash flows for finance leases	36	48
Financing cash flows for finance leases	235	471
Acquisition of operating leases through adoption of ASC Topic 842	0	389,403
Lease modification	$ 7,051	$ (48,877)	$ 7,051

XML

Long-Term Debt, Interest Rate Swap and Finance Lease Obligations - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Long-term debt	$ 61,087	$ 74,143
Plus finance lease obligations	531
Less current portion	(1,660)	(3,498)
Long-term debt, excluding current maturities	59,958	71,502
Less deferred financing costs, net	(1,432)	(865)
Long-term debt and finance lease obligation, net	58,526	70,637
Equipment
Debt Instrument [Line Items]
Plus finance lease obligations	531	857
Mortgage loan | Loans Payable
Debt Instrument [Line Items]
Long-term debt	61,087	49,743
Acquisition loan | Loans Payable
Debt Instrument [Line Items]
Long-term debt	0	9,400
Revolver | Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt	0	14,000
Affiliated revolver | Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt	$ 0	$ 1,000

XML

Long-Term Debt, Interest Rate Swap and Finance Lease Obligations - Narrative (Details)		12 Months Ended
	Oct. 14, 2020 USD ($)	Dec. 31, 2020 USD ($) nursing_center letter_of_credit	Dec. 31, 2019 USD ($)
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Long-term debt		$ 61,087,000	$ 74,143,000
Weighted average interest rate of long term debt		5.00%
Revolver
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Number of owned nursing centers | nursing_center		15
Number of letters of credit | letter_of_credit		4
Amount available for borrowing under the revolvers		$ 16,446,000
Acquisition loan
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Borrowing capacity			12,500,000
Affiliated revolver
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Borrowing capacity			2,000,000
Mortgage term loan | Revolver
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Debt instrument, floor interest rate	1.00%
Mortgage term loan | Revolver | LIBOR
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Long-term debt basis spread based on LIBOR	4.00%
Loans Payable | Acquisition loan
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Long-term debt		0	9,400,000
Loans Payable | Mortgage loan
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Long-term debt		$ 61,087,000	49,743,000
Mortgages
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Borrowing capacity			67,500,000
Mortgages | Revolver
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Borrowing capacity	$ 62,000,000
Mortgage loan with principal and interest payable monthly based	25 years
Mortgages | Mortgage term loan | Revolver
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Stated interest rate		5.00%
Revolving Credit Facility
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Borrowing capacity			40,250,000
Revolving Credit Facility | Revolver
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Borrowing capacity	$ 2,000,000
Term of loan	3 years
Letters of credit security deposit for a lease		$ 12,387,000
Revolving Credit Facility | Mortgage loan
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Borrowing capacity	$ 36,000,000
Revolving Credit Facility | Line of Credit | Revolver
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Long-term debt		0	14,000,000
Revolving Credit Facility | Line of Credit | Affiliated revolver
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Long-term debt		0	1,000,000
Revolving Credit Facility | Line of Credit | Revolver and Affiliated Revolver
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Long-term debt		$ 0	$ 15,000,000
Letter of credit | Revolver
Long-Term Debt and Interest Rate Swap (Textual) [Abstract]
Annual fee for letters of credit issued under Revolver outstanding		3.00%

XML

Long-Term Debt, Interest Rate Swap and Finance Lease Obligations - Schedule of Deferred Loan Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Write-off of deferred financing costs	$ 247	$ 0
Revolver
Debt Instrument [Line Items]
Write-off of deferred financing costs	247	0
Deferred financing costs capitalized	$ 1,228	$ 333

XML

Long-Term Debt, Interest Rate Swap and Finance Lease Obligations - Schedule of Principal Payments of Long Term Debt Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Debt Disclosure [Abstract]
2021	$ 1,404
2022	1,368
2023	58,315
Total	$ 61,087	$ 74,143

XML

Long-Term Debt, Interest Rate Swap and Finance Lease Obligations - Finance Lease Obligations (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Present value of lease liabilities	$ 531
Equipment
Lessee, Lease, Description [Line Items]
Present value of lease liabilities	$ 531	$ 857
Equipment | Minimum
Lessee, Lease, Description [Line Items]
Lease agreement term	3 years
Equipment | Maximum
Lessee, Lease, Description [Line Items]
Lease agreement term	5 years

XML

Long-Term Debt, Interest Rate Swap and Finance Lease Obligations - Scheduled Payments of Finance Lease Obligations (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
2021	$ 282
2022	209
2023	62
2024	20
Total lease payments	573
Less: Interest	(42)
Principal payments on finance lease obligation	531
Equipment
Lessee, Lease, Description [Line Items]
2021	282
2022	209
2023	62
2024	20
Total lease payments	573
Less: Interest	(42)
Principal payments on finance lease obligation	$ 531	$ 857

XML

Shareholders' Equity, Stock Plans and Preferred Stock - Shareholders' Equity and Stock Plans (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2020	Jun. 30, 2017	May 31, 2017	Jun. 30, 2016	May 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	$ 570	$ 573
Total unrecognized stock-based compensation expense	$ 196
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under the Plan (in shares)			100,000
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants approved by the Board of Directors (in shares)	198,000	151,000
Restricted stock | First anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.33%
Restricted stock | Second anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.33%
Restricted stock | Third anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.33%
SOSAR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining life of outstanding equity grants	5 years 3 months 3 days
Weighted average remaining life of grants that are exercisable	5 years 3 months 3 days
Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)	150,000
Percentage of fair market value at date of grant (percentage)	85.00%
Restriction period	2 years
Shares authorized under the Plan (in shares)						350,000	150,000
2010 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved for future issuance (in shares)				680,000	380,000

XML

Shareholders' Equity, Stock Plans and Preferred Stock - Schedule of Weighted Average Grant Date Fair Value and Total Intrinsic Value of Exercises (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Weighted average grant date fair value (in dollars per share)	$ 0	$ 0
Total intrinsic value of exercises	$ 0	$ 3

XML

Shareholders' Equity, Stock Plans and Preferred Stock - Schedule of Stock Options Outstanding and Exercisable (Details) - SOSAR - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Prices (in dollars per share)	$ 7.92	$ 7.55
Grants Outstanding (in shares)	65
Grants Exercisable (in shares)	65
$8.14 to $10.21
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Prices (in dollars per share)	$ 8.83
Grants Outstanding (in shares)	45
Intrinsic Value - Grants Outstanding	$ 0
Grants Exercisable (in shares)	45
Intrinsic Value - Grants Exercisable	$ 0
Range of Exercise Prices, lower range limit (in dollars per share)	$ 8.14
Range of Exercise Prices, upper range limit (in dollars per share)	10.21
5.86
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Prices (in dollars per share)	$ 5.86
Grants Outstanding (in shares)	20
Intrinsic Value - Grants Outstanding	$ 0
Grants Exercisable (in shares)	20
Intrinsic Value - Grants Exercisable	$ 0
Range of Exercise Prices, lower range limit (in dollars per share)	$ 5.86
Range of Exercise Prices, upper range limit (in dollars per share)	$ 5.86

XML

Shareholders' Equity, Stock Plans and Preferred Stock - Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable (Details) - SOSAR - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)	65	65	76
Granted (in shares)	0
Exercised (in shares)	0
Expired or cancelled (in shares)	(11)
Outstanding at end of period (in shares)	65
Number of Shares, Exercisable (in shares)		65
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted-Average Exercise Price, Outstanding at beginning of period (in dollars per share)	$ 7.55
Weighted-Average Exercise Price, Granted (in dollars per share)	0
Weighted-Average Exercise Price, Exercised (in dollars per share)	0
Weighted-Average Exercise Price, Expired or cancelled (in dollars per share)	5.45
Weighted-Average Exercise Price, Outstanding at end of period (in dollars per share)	$ 7.92
Weighted-Average Exercise Price, Exercisable (in dollars per share)		$ 7.92

XML

Shareholders' Equity, Stock Plans and Preferred Stock - Restricted Stock and Restricted Stock Units Activity (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2020 $ / shares shares
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding at beginning of period (in shares) | shares	207
Granted (in shares) | shares	198
Dividend Equivalents (in shares) | shares	0
Vested (in shares) | shares	(187)
Cancelled (in shares) | shares	(25)
Outstanding at beginning of period (in shares) | shares	193
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted-Average Grant Date Fair Value, Outstanding at beginning of period (in dollars per share) | $ / shares	$ 5.28
Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares	2.00
Weighted Average Grant Date Fair Value, Dividend Equivalents (in dollars per share) | $ / shares	0
Weighted Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares	3.93
Weighted-Average Grant Date Fair Value, Cancelled (in dollars per share) | $ / shares	4.55
Weighted-Average Grant Date Fair Value, Outstanding at end of period (in dollars per share) | $ / shares	$ 3.32
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding at beginning of period (in shares) | shares	48
Granted (in shares) | shares	28
Dividend Equivalents (in shares) | shares	0
Vested (in shares) | shares	(21)
Cancelled (in shares) | shares	0
Outstanding at beginning of period (in shares) | shares	55
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted-Average Grant Date Fair Value, Outstanding at beginning of period (in dollars per share) | $ / shares	$ 5.08
Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares	2.00
Weighted Average Grant Date Fair Value, Dividend Equivalents (in dollars per share) | $ / shares	0
Weighted Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares	6.45
Weighted-Average Grant Date Fair Value, Cancelled (in dollars per share) | $ / shares	0
Weighted-Average Grant Date Fair Value, Outstanding at end of period (in dollars per share) | $ / shares	$ 2.92

XML

Shareholders' Equity, Stock Plans and Preferred Stock - Preferred Stock (Details)	Dec. 31, 2020 shares
Series A Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares authorized	195,000

XML

Net Income (Loss) Per Common Share - Calculation of Net Income (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Numerator: Income (loss):
Income (loss) from continuing operations	$ 6,530	$ (27,474)
Loss from discontinued operations, net of income taxes	(1,371)	(8,589)
Net income (loss)	$ 5,159	$ (36,063)
Denominator: Basic Weighted Average Common Shares Outstanding (in shares)	6,615	6,459
Dilutive effect of stock options, SOSARs, Restricted Shares and Restricted Share Units (in shares)	90	0
Adjusted weighted average common shares outstanding (in shares)	6,705	6,459
Basic net income (loss) per common share
Income (loss) from continuing operations (in dollars per share)	$ 0.99	$ (4.25)
Loss from discontinued operations
Operating loss, net of taxes (in dollars per share)	(0.21)	(1.33)
Discontinued operations (in dollars per share)	(0.21)	(1.33)
Net income (loss) (in dollars per share)	0.78	(5.58)
Diluted net income (loss) per common share
Income (loss) from continuing operations (in dollars per share)	0.97	(4.25)
Operating loss, net of taxes (in dollars per share)	(0.20)	(1.33)
Discontinued operations, net of taxes (in dollars per share)	(0.20)	(1.33)
Diluted net income (loss) per common share (in dollars per share)	$ 0.77	$ (5.58)

XML

Net Income (Loss) Per Common Share - Schedule of Antidilutive Securities Excluded from the Computation of Earnings Per Share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
SOSARs/Options Excluded	65	76

XML

Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Current provision (benefit) :
Federal	$ 719	$ 197
State	(23)	76
Total current	696	273
Deferred provision (benefit):
Federal	(1,227)	12,439
State	0	2,982
Total deferred	(1,227)	15,421
Provision (benefit) for income taxes of continuing operations	$ (531)	$ 15,694

XML

Income Taxes - Income Tax Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]
Provision (benefit) for federal income taxes at statutory rates	$ 1,260	$ (2,469)
Provision (benefit) for state income taxes, net of federal benefit	478	(106)
Valuation allowance changes affecting the provision for income taxes	(2,922)	19,002
Employment tax credits	(355)	(210)
Nondeductible expenses	251	122
Stock based compensation expense	98	80
WOTC Credit and Other	931	(1,349)
Other	(272)	624
Provision (benefit) for income taxes of continuing operations	$ (531)	$ 15,694

XML

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets (liabilities):
Net operating loss and other carryforwards	$ 67	$ 859
Credit carryforwards	1,777	3,118
Accounts receivable	4,652	4,852
Prepaid expenses	(938)	(1,015)
Interest rate limitation	0	971
Right-of-use lease liability	78,674	82,194
Right-of-use lease asset	(75,443)	(79,843)
Depreciation	1,731	1,863
Tax goodwill and intangibles	(1,098)	(1,066)
Stock-based compensation	164	183
Accrued liabilities	124	504
Accrued rent	340	380
Impairment of long-lived assets	177	176
Interest rate swap	0	(4)
Hedge Ineffectiveness	0	(155)
Noncurrent self-insurance liabilities	6,350	6,363
Restitution	2,329	2,445
Other	28	30
Subtotal	18,934	21,855
Less valuation allowance	(18,934)	(21,855)
Total noncurrent deferred tax assets	$ 0	$ 0

XML

Income Taxes - Narrative (Details) $ in Thousands		12 Months Ended		24 Months Ended		36 Months Ended
	Mar. 27, 2020 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)	Jun. 30, 2019	Dec. 31, 2020 USD ($)	Sep. 30, 2020 nursing_center
Income Tax Disclosure [Line Items]
Cumulative pre-tax income (loss) from continuing operations		$ 5,999	$ (11,780)			$ (18,526)
Tax contingency				$ 9,500
Cumulative loss preceding months					36 years
Number of nursing center facilities terminated | nursing_center							10
Deferred tax assets, valuation allowance		18,934	21,855	$ 21,855		18,934
CARES Act, tax refund received	$ 1,227
Net operating losses		5,576				5,576
Work Opportunity Tax Credit
Income Tax Disclosure [Line Items]
Employment tax credit		355	$ 210
IRS
Income Tax Disclosure [Line Items]
Operating loss carryforwards limited by change in ownership provisions		$ 257				$ 257

XML

Commitments and Contingencies - Narrative (Details)					1 Months Ended	12 Months Ended		60 Months Ended	138 Months Ended
	Feb. 14, 2020 USD ($)	Aug. 30, 2019 nursing_center	Oct. 01, 2018 nursing_center lease_extension	Nov. 01, 2016 lease_extension	Feb. 29, 2020 USD ($)	Dec. 31, 2020 USD ($) lawsuit Multiple nursing_center	Dec. 31, 2019 USD ($)	Dec. 31, 2008	Dec. 31, 2019 USD ($)	Sep. 30, 2020 nursing_center	Oct. 01, 2019	Aug. 30, 2019 facility	Aug. 30, 2019 lease_extension	Oct. 01, 2016 nursing_center
Commitments and Contingencies [Line Items]
Operating lease cost						$ 54,001,000	$ 52,990,000
Accrued liability related to straightline rent						$ 12,382,000	9,325,000		$ 9,325,000
Number of nursing center facilities leased | nursing_center			34			46
Number of skilled nursing centers under lease | nursing_center			23
Operating lease, initial term		12 years	12 years
Operating lease, number of lease extensions allowed | lease_extension			2										2
Operating lease, extension period		10 years	10 years
Operating lease, annual lease fixed escalators, percent			2.15%								2.15%
Number of nursing center facilities terminated | nursing_center										10
Estimated insurance recoveries						$ 1,025,000	1,011,000		1,011,000
Cash expenditures for self-insured professional liability costs						5,514,000	4,578,000
Liability for workers compensation claims						1,039,000	921,000		921,000
Workers compensation insurance, non current receivable for excess premiums paid						2,050,000	1,575,000		1,575,000
Health insurance, maximum self-insured annual amount per individual						$ 200,000
Salary multiple | Multiple						2
Renewal period for employee agreements						1 year
Number of professional liability lawsuits | lawsuit						79
Number of professional liability lawsuits, | nursing_center						36
Government settlement expense						$ 0	3,100,000
Government settlement accrual						8,000,000	9,000,000		9,000,000
Duration of alleged breaches of statutory and contractual obligations to patents								5 years
Violations of False Claims Act
Commitments and Contingencies [Line Items]
Government settlement expense					$ 9,500,000
Initial payment requirement, amount	$ 500,000
Settlement, payment period					5 years
Settlement agreement outstanding balance						9,000,000
Settlement agreement ,other current liabilities						1,000,000
Government settlement accrual						$ 8,000,000
Settlement agreement, term					5 years
Scheduled for trial or arbitration over next 12 months
Commitments and Contingencies [Line Items]
Number of professional liability lawsuits | lawsuit						22
Professional malpractice liability insurance
Commitments and Contingencies [Line Items]
Insurance policy coverage limits per claim						$ 1,000,000
Workers compensation insurance, maximum annual aggregate self-insured amount						3,000,000
Maximum claim amount on insurance						5,000,000
Liability for reported and estimated future claims						24,744,000	27,390,000		27,390,000
Prefunded deductible policy
Commitments and Contingencies [Line Items]
Insurance policy coverage limits per claim									500,000
Professional liability insurance, annual coverage limit per facility									3,000,000
Liability for reported claims and estimates for incurred but unreported claims						$ 2,358,000	$ 1,810,000		$ 1,810,000
Minimum
Commitments and Contingencies [Line Items]
Employee termination agreement term						1 year
Maximum
Commitments and Contingencies [Line Items]
Maximum contingent liability						$ 1,500,000
Employee termination agreement term						3 years
Golden Living | Amended lease
Commitments and Contingencies [Line Items]
Term of lease				10 years
Annual rent increase, as a percent				2.00%
Golden Living | Mississippi
Commitments and Contingencies [Line Items]
Number of nursing center facilities leased | nursing_center														8
Golden Living | Alabama
Commitments and Contingencies [Line Items]
Number of nursing center facilities leased | nursing_center														12
Golden Living
Commitments and Contingencies [Line Items]
Operating lease, number of lease extensions allowed | lease_extension				2
Operating lease, extension period				5 years
Number of nursing center facilities owned | nursing_center						20
Omega Healthcare Investors, Inc
Commitments and Contingencies [Line Items]
Number of nursing center facilities leased | nursing_center			11
Annual capital expenditure per licensed bed						$ 403
Total required capital expenditures during remaining lease term						10,118,000
Letters of credit security deposit for a lease						5,447,000
Golden Living Master Lease [Member]
Commitments and Contingencies [Line Items]
Annual capital expenditure per licensed bed						530
Total required capital expenditures during remaining lease term						5,432,000
Golden Living Master Lease [Member] | Letter of credit
Commitments and Contingencies [Line Items]
Letters of credit security deposit for a lease						$ 6,610,000
Kentucky Properties | Discontinued Operations
Commitments and Contingencies [Line Items]
Number of nursing center facilities terminated		10										10

XML

Schedule II - Valuation of Qualifying Accounts of Continuing Operations (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2020	Dec. 31, 2019
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation allowance	$ 20,000
Professional Liability Reserve
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period		$ 27,390	$ 27,201
Charged to Costs and Expenses		6,919	10,435
Other		(1,625)	(3,020)
Payments		(7,940)	(7,226)
Balance at End of Period		24,744	27,390
Workers Compensation Reserve
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period		921	618
Charged to Costs and Expenses		1,352	400
Other		0	0
Payments		(1,234)	(97)
Balance at End of Period		1,039	921
Health Insurance Reserve
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period		1,810	1,396
Charged to Costs and Expenses		14,003	16,733
Other		0	0
Payments		(13,455)	(16,319)
Balance at End of Period		2,358	1,810
Deferred Tax Valuation Allowance
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period		21,855	228
Charged to Other Accounts		0	21,627
Payments		(2,921)	0
Balance at End of Period		$ 18,934	$ 21,855